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General introduction
This general introduction consists of the published study protocol “Physiological and 
neurophysiological determinants of postcancer fatigue: design of a randomized 
controlled trial”1, extended with paragraphs describing two influenza studies. Because 
the study population of one of the influenza studies consisted of a group of chronic 
fatigue syndrome (CFS) patients, in contrast to the rest of this dissertation describing 
postcancer fatigue patients, a paragraph about CFS has been added to the 
Background section. Furthermore, this general introduction includes references to 
the separate chapters of this thesis. 
Background
Postcancer fatigue  
Postcancer fatigue is a frequently occurring, severe, and invalidating problem in 
cancer survivors, impairing quality of life.2, 3 About 70-96% of the cancer patients 
undergoing chemotherapy and/or radiotherapy experience symptoms of fatigue.4, 5 
The prevalence of postcancer fatigue observed in longitudinal follow-up studies 
ranged from 19-39%.2, 6-9 Previous disease and treatment characteristics are unrelated 
to postcancer fatigue.3, 5, 10-13 However, there is some evidence that patients who are 
treated with only a surgery are less at risk for postcancer fatigue9 and survivors who 
are treated with more aggressive treatments are more at risk for postcancer fatigue2, 14. 
Cognitive behavior therapy (CBT), especially designed for postcancer fatigue, seems 
to be an effective treatment option for postcancer fatigue.12, 15 However, although it is 
now possible to effectively treat postcancer fatigue, the nature of the underlying 
physiology of postcancer fatigue remains unclear. 
Chronic fatigue syndrome
Another patient group suffering from severe feelings of fatigue are patients with CFS, 
which is a clinical condition characterized by severe and disabling fatigue that is 
medically unexplained and lasts longer than six months.16 The estimated worldwide 
prevalence of CFS is 0.4-1%.17 The existing evidence suggests that CBT, specifically 
designed for CFS, is an effective treatment option.18-25 However, the nature of the 
underlying pathophysiology of CFS remains unclear. The presence of an underlying 
immunological problem has been suggested as an explanation for CFS.
The term fatigue in the medical literature usually refers to fatigue experienced by the 
patient, but it can also refer to physiological fatigue. Fatigue experienced by the 
patient and its psychological aspects can be quantified using questionnaires. 
Physiological aspects of fatigue include physical deconditioning, resulting from a 
decreased cardiopulmonary function (Chapter 2.1 and 2.2); central fatigue, 
originating in nerves, spinal cord, and brain (Chapter 3 and 4); peripheral fatigue, 
originating in muscle or the neuromuscular junction (Chapter 4); and a disbalance in 
the immune system (Chapter 5.1 and 5.2).
Physical fitness and activity
Despite the fact that current cancer treatments are increasingly efficacious for 
improving survival, they are toxic in numerous ways. Therefore, many cancer patients 
are forced to decrease their physical activity, possibly leading to physical 
deconditioning. Physical activity levels were significantly reduced after diagnosis in a 
study of 812 breast cancer patients.26 It may be hypothesized that compared to 
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to healthy controls.34 As the amount of creatine in the brain is often assumed to be 
constant, an increased choline to creatine ratio suggests an abnormality of 
phospholipid metabolism and/or associated brain morphology. Similarly, in a 1H MRS 
study of the left basal ganglia, a highly significant increase in the signal from choline-
containing compounds was seen in CFS patients compared to age- and sex-matched 
healthy controls.35 In three children with CFS, 1H MRS demonstrated a significantly 
higher choline to creatine ratio in the frontal cortex compared to healthy controls.36 
N-acetylaspartate is considered to be a marker of neuronal density and neuronal 
function. In one study, reduced levels of N-acetylaspartate were observed in the right 
hippocampus of seven CFS patients compared to ten healthy controls.37 Elevated 
lactate in the brain may suggest cerebral energy dysfunction. The presence of 
elevated ventricular lactate was observed in sixteen CFS patients as compared to 
fifteen healthy controls.38
 Especially for CFS, certain characteristics of brain morphology and metabolism 
may serve as objective biomarkers for fatigue. However, since CFS and postcancer 
fatigue differ in some psychological aspects39 it still needs to be shown that these 
characteristics also play a role in postcancer fatigue.  
 Chapter 3 describes whether volumetric and metabolic parameters in the brain 
are different between severely fatigued and non-fatigued cancer survivors. 
Furthermore, the effect of CBT on these volumetric and metabolic markers in severely 
fatigued cancer survivors was examined.
Central and peripheral muscle fatigue
In physiology, fatigue is usually defined as the loss of voluntary force-producing 
capacity during exercise,40 which can have a peripheral and a central origin.41 During 
peripheral muscle fatigue, membrane excitability of muscle tissue is influenced due 
to a decrease in pH, accumulation of lactate, and changes in intra- and extracellular 
ion concentrations.42 Muscle fiber conduction velocity (MFCV), which can be 
determined by surface electromyography (sEMG), reflects the peripheral situation.41 
Alternatively, peripheral fatigue can be quantified by measuring the muscular force 
response to artificial electrical stimulation before and after exercise. Besides 
peripheral factors, a failure of drive from the central nervous system may also 
contribute to fatigue.43 This sub-maximal central activation during exercise, or central 
activation failure (CAF), is named central fatigue41 and can be measured with a twitch 
interpolation technique.44 
 Physiological fatigue has been studied in patients with neuromuscular diseases,45 
in patients with CFS,46 but also in cancer patients to evaluate cancer-related fatigue.47 
In a study of sixteen cancer patients referred to palliative medicine and sixteen 
matched non-cancer controls, neuromuscular testing was applied to determine 
whether cancer-related fatigue is a more centrally or peripherally mediated disorder.47 
non-fatigued cancer survivors, postcancer fatigue patients have an impaired physical 
condition due to decreased physical activity after cancer treatment.
 In a previous study comparing physical condition in a group of 20 CFS patients 
and 20 matched non-fatigued sedentary controls, physical condition did not 
significantly differ between both groups. Although as a clinical syndrome postcancer 
fatigue and CFS show strong similarities, in postcancer fatigue a clear precipitating 
moment can be identified that provoked fatigue, namely the diagnosis of cancer and 
its subsequent treatment. In contrast to postcancer fatigue, not always a precipitating 
factor can be identified in CFS. Therefore, studies on physical condition, specifically 
in cancer survivors, are needed to investigate the physiology of postcancer fatigue.
 The study described in Chapter 2.1 examined whether physical fitness of 
severely fatigued and non-fatigued cancer survivors, as measured by maximal 
exercise performance, is different between both groups and, if so, whether this 
difference can be explained by differences in physical activity, by differences in the 
personal factor self-efficacy (SE) regarding the exercise test, and/or by the 
environmental factor social support (SS).
 The effect of CBT on physical activity and physical fitness in severely fatigued 
cancer survivors is described in Chapter 2.2. In addition, we examined whether the 
effect of CBT on postcancer fatigue was mediated by physical activity and/or physical 
fitness.  
Brain volume and metabolism
Using magnetic resonance imaging (MRI), several studies have reported structural 
abnormalities in the brains of patients with CFS. In a group of 259 fatigued patients, 
specific hyperintense small punctuated subcortical white-matter foci were observed.27 
Similar results have been reported by others.28-30 Different research groups conducted 
voxel-based morphometry (VBM) in CFS patients and matched healthy controls and 
observed gray matter volume reductions in fatigued patients compared to 
non-fatigued controls.31, 32 Interestingly, it has been shown that CFS patients showed 
a significant increase in gray matter volume, localized in the lateral prefrontal cortex, 
after CBT.33
 Magnetic resonance spectroscopy (MRS) provides a non-invasive window on 
metabolism in the brain. Studies with proton (1H) MRS allow the detection and 
quantification of metabolites like choline, creatine, N-acetylaspartate, and lactate. 
Choline is a precursor of membrane phospholipids and an elevated choline level has 
been associated with increased cell membrane turnover, cell density, and gliosis. 
Choline levels vary over the brain and the choline to creatine ratio is higher in white 
matter than in gray matter. In a 1H MRS study of the brain of eight CFS patients and 
eight age- and sex-matched healthy control subjects, the mean ratio of choline to 
creatine in the occipital cortex of fatigued patients was significantly higher compared 
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Methods
Ethical consideration
Both the randomized controlled trial (RCT) and the influenza study have been 
approved by the Medical Ethical Committee of the Radboud University Nijmegen 
Medical Centre (RUNMC). Patients will be informed about the study and informed 
consent will be obtained before randomization.
Study design
RCT
An RCT with six months follow-up will be conducted to identify and measure (neuro)
physiological factors of fatigue in severely fatigued disease-free cancer survivors and 
to determine the role of these factors in the maintaining of fatigue. At baseline, 
fatigued and non-fatigued patients will undergo measurements for central and 
peripheral fatigue, brain volume and metabolism, and physical fitness and activity. 
Fatigued patients will be randomly assigned to either the intervention group, who will 
immediately start CBT, or the control group, who will start CBT after six months. After 
six months follow-up, the measurements will be repeated in both groups of fatigued 
patients.
Influenza study
A case-control study will be performed to compare humoral and cellular immune 
responses upon influenza vaccination in severely fatigued disease-free cancer 
survivors and in CFS patients. Humoral immune responses will be measured at 
baseline and three weeks post-vaccination. Cellular immune responses will be 
measured at baseline and one week post-vaccination.
Study population
RCT
Patients who have been curatively treated for cancer and finished treatment at least 
one year before, will be asked by their physician to fill out the Checklist Individual 
Strength (CIS),53 RAND-36,54 Beck Depression Inventory for Primary Care,55 and 
some additional demographic and medical questions during their control-visits. 
Based on the scores of the fatigue severity subscale of the CIS (CIS-fatigue), patients 
with a cut-off score of ≥35 will be classified as severely fatigued. Severely fatigued 
patients, who are referred to the Expert Centre for Chronic Fatigue of the RUNMC and 
who met the in- and exclusion criteria of the study (Table 1), will be informed by their 
treating psychologist about the study. If the patients agree to be further informed 
about the study, the researcher will inform the patients extensively about the study 
and will ask for participation. Severely fatigued patients will be matched with 
Patients suffering from cancer-related fatigue showed less peripheral muscle fatigue 
and more central muscle fatigue compared to their non-fatigued controls. 
 It should be noted that some psychological aspects of fatigue are different for 
different neuromuscular diseases48 as well as for fatigue in CFS and for cancer-related 
fatigue. Nevertheless, CAF appears to be a shared neurophysiological feature of fatigue 
in all these diseases. Therefore, it is of great interest to know whether postcancer fatigue 
is also characterized by CAF. 
 The aim of the study described in Chapter 4 was to examine whether peripheral 
and central muscle fatigue of severely fatigued and non-fatigued disease-free cancer 
survivors, as measured by respectively MFCV and CAF, are different between both 
groups. In addition, the effect of CBT on peripheral and central muscle fatigue of 
severely fatigued disease-free cancer survivors was examined.
Humoral and cellular immune responses
The presence of an immunological distortion has been suggested as an explanation 
for postcancer fatigue. Activation of the immune system, as a response to the tumor 
or its treatment, leads to the release of cytokines and other immune factors, including 
receptor antagonists, soluble receptors, and products of cellular activation.49 Most of 
these changes in immune parameters resolve following completion of cancer 
treatment, but a disbalance in the immune system might persist, which could explain 
symptoms of fatigue. If so, postcancer fatigue patients might have an altered response 
to vaccination.
 The presence of an underlying immunological problem has also been suggested 
as an explanation for CFS. Cytokine dysregulation, decreased natural killer cell 
functioning, the presence of autoantibodies, and a reduced response of T cells to 
mitogens and other specific antigens have been reported in CFS.50-52 If immunity is 
disturbed in CFS patients, they might have an altered response to vaccination.
 The humoral and cellular immune responses upon vaccination, using seasonal 
influenza vaccination as a representative vaccination, in postcancer fatigue and CFS, 
are described in respectively Chapter 5.1 and Chapter 5.2.
General discussion and summary
Finally, the findings of the studies presented in this manuscript are discussed in 
Chapter 6.1 and summarized in Chapter 6.2.
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non-fatigued patients with respect to age, sex, and previous cancer treatment (Figure 1). 
A total number of 57 severely fatigued and 21 non-fatigued cancer survivors will be 
included (see power calculation).
 As shown in Figure 1, severely fatigued cancer survivors will be randomized to 
either the intervention group (75%) or the control group (25%). Randomization will 
take place per patient. Patients randomized to the intervention group will be treated 
with CBT for postcancer fatigue, as described previously.15 The treatment consists of 
12–14 individual sessions in six months. Patients randomized to the control group will 
be treated with CBT after six months.
Influenza study
Severely fatigued and non-fatigued cancer survivors will be recruited as described 
above for the RCT. CFS patients, who are referred to the Expert Centre for Chronic 
Fatigue of the RUNMC will be informed by their treating psychologist about the study. 
CFS patients will be asked to bring a friend as a control. The in- and exclusion criteria 
of the study are presented in Table 2. Fatigued and non-fatigued patients will be 
matched with respect to age and sex (Figure 2). Given the exploratory nature of the 
influenza study, group sizes will not be based on power calculations. About 20 
patients per group will be included. All participants will be intramuscularly vaccinated 
with single dose of the seasonal influenza vaccine.
Table 1   Inclusion and exclusion criteria of the randomized controlled trial
Inclusion criteria
1) Age between 19 and 65 years
2) Age at disease onset minimal 18 years
3) Treated for a malignant, solid tumor
4)  Completion of treatment for cancer minimal 1 year ago 
(single treatment modality surgery/current hormonal therapy permitted)
5) Disease-free, as defined by the absence of somatic disease activity parameters
Exclusion criteria
1) Physical comorbidity that could explain the fatigue
2) Current psychological or psychiatric treatment
3) Brain tumor in the past
4) Contra-indication for MR examinations (e.g. claustrophobia)
5) Treatment with anti-depressive drugs, anti-epileptic drugs, or benzodiazepines
6) Insufficient command of the Dutch language to fill out questionnaires
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Brain volume and metabolism
Global volumes of gray and white matter, subcortical brain volumes, and brain 
metabolite concentrations will be obtained. Magnetic resonance (MR) measurements 
will be performed on a 3 Tesla MR system using a radiofrequency head coil. High 
resolution (1 mm3), T1 weighted MR images of the whole brain will be acquired using 
a magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence. 
Normalizing, bias-correcting, and segmenting into global volumes of gray and white 
matter will be performed using the VBM method.58 Automatic segmentation of 
subcortical brain structures was performed using the FIRST module of FSL.59
 1H MR spectroscopic imaging (MRSI) will be performed, with special interest for 
the hippocampus, the occipital cortex, the frontal cortex, and the ventricles. The 1H 
MRSI will allow the identification and quantification of metabolites like choline, 
Outcome measures
RCT
Physical fitness and activity
To measure maximal oxygen consumption (VO2max) a maximal exercise test will be 
performed.56 In addition to the determination of VO2max, also carbon dioxide 
production, heart rate, respiratory quotient, and ventilation will be measured. Patients 
will cycle with an increased workload of 10 Watt/min for women and 20 Watt/min for 
men. Patients will be verbally encouraged to perform maximally until exhaustion.
 Daily activity will be measured during two weeks using an actometer.57 The 
actometer used is a motion-sensing device, worn around the ankle, which can 
register and quantify human physical activity. The actometer has a piezoelectric 
sensor that is sensitive in three directions. Accelerations of the built-in sensor larger 
than a predefined threshold are considered as activity and are stored in an internal 
memory every five minutes. A general physical activity score, expressed in the 
average number of accelerations per 5-minute period, will be provided for the whole 
measurement period. Actometer testing is part of the standard care if patients are 
referred for CBT. To assess the effect of the maximal exercise test on the daily activity 
of patients, they will wear an actometer for an additional five days after the maximal 
exercise test.
 Finally, participants will score their physical activity level long before cancer 
diagnosis on a 10-point numeric rating scale.
Table 2   Inclusion and exclusion criteria of the influenza study
Inclusion criteria
1) All participants: age between 18 and 60 years
2)  Fatigued cancer survivors: CIS-fatigue score of ≥ 35 and inclusion criteria 2, 3, 4, and 
5 of Table 1 
3)  Non-fatigued cancer survivors: CIS-fatigue score of <27 and inclusion criteria 2, 3, 4, 
and 5 of Table 1
4)  CFS patients: fulfilled the Centre for Disease Control and prevention criteria for CFS16 
5)  Healthy controls: no cancer in medical history and no CFS 
Exclusion criteria
1)  Treatment with corticosteroids during the previous two weeks
2)  Immune disorder or allergy to chicken eggs
3)  Symptoms of influenza or an influenza-like illness on the day of the vaccination
Abbreviation: CFS: chronic fatigue syndrome
Figure 2   Flow chart of the influenza study
Humoral and Cellular
immune response
20 Fatigued
cancer survivors
Inclusion fatigued and
matched non-fatigued
participants
20 Non-fatigued
cancer survivors 20 CFS patients 20 Healthy controls
Blood collection
Day 1
Influenza vaccination
Day 1
Blood collection
Day 8
Blood collection
Day 22
Cellular immune
response
Humoral immune
response
Screening and recruitment
Abbreviation: CFS: chronic fatigue syndrome
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Social Support Inventory (SSL).64 The SSL is divided into the SSL-I (amount of SS, 
eight questions, score range from 8 to 32), the SSL-D (discrepancy between the 
amount of SS and the desired amount of SS, eight questions, score range from 0 to 
32), and the SSL-N (negative interactions, unsupportive behavior, seven questions, 
score range from 7 to 28). A higher score indicates a higher amount of SS, discrepancy, 
or negative interactions.
Influenza study
Immune system
Peripheral blood mononuclear cells (PBMC) will be collected at baseline (day 1) and 
seven days after vaccination (day 8). Serum will be collected at baseline and 21 days 
after vaccination (day 22). 
 The humoral immune responses on influenza vaccination will be measured in 
serum by the hemagglutination-inhibition (HI) antibody test as described previously.65 
The virus antibody responses will be measured at day 1 and day 22 for the individual 
influenza strains of the vaccine. Seroprotection was defined as an antibody titer of at 
least 1:40.65, 66 Post-vaccination seroresponse was defined as at least a four-fold 
increase in titer.66
 The cellular immune responses will be measured by T lymphocyte proliferation 
and cytokine secretion of PBMC collected at day 1 and 8. In the proliferation assay, 
PBMC will be incubated with the separate virus-strains. After 48 hours of culture, 
supernatant will be harvested to analyze cytokine production. After four days of 
culture, T lymphocyte proliferation will be measured.
Statistical analysis
RCT
Independent samples t tests will be performed for testing baseline differences in 
primary and secondary outcome measures between fatigued and non-fatigued 
cancer survivors. Baseline differences between the therapy and waiting list condition 
are entered as covariates in further analyses. A paired t test will be performed to test 
whether differences can be observed within the therapy or waiting list condition from 
baseline to follow-up. Differences between the therapy and waiting list group on the 
change in outcome measures from baseline to 6 months later will be calculated with 
analyses of covariance (ANCOVA).
Influenza study
Independent samples t tests will be performed to assess differences in numerical 
variables at day 1, 8, and 22. Paired t tests were used to assess changes in numerical 
variables from pre- to post-vaccination. Chi-square tests were performed to compare 
groups on categorical variables. 
creatine, N-acetylaspartate, and lactate. Volume selection will be performed with a 
semi-localized by adiabatic selective refocusing (semi-LASER) pulse sequence60 
with a repetition time of 1500 ms, an echo time of 30 or 136 ms, and a voxel size of 10 
mm3. The data will be analyzed using LCModel software.
Central and peripheral muscle fatigue
To obtain maximal voluntary contraction (MVC) of the biceps brachii muscle, 
participants will make MVCs, with 1 min intervals, until no further force increase is 
observed. After a rest period of 10 min, peripheral and central fatigue will be measured 
during a 2 min sustained MVC of the biceps brachii muscle.43 During these 2 min, 
electrical endplate stimulation over the motor points of the medial and lateral head of 
the biceps brachii muscle will be applied every 15 s, leading to superimposed force 
responses. Patients will be verbally encouraged to perform maximally throughout the 
2 min. An indicator of peripheral muscle fatigue is MFCV, which will be measured 
using sEMG.41 Peripheral muscle fatigue will also be quantified by measuring the 
muscular force response to electrical endplate stimulation before and after the test. 
An indicator of central muscle fatigue is additional force production upon electrical 
endplate stimulation during exercise.43 Submaximal central activation during exercise, 
or CAF, will be measured using a twitch interpolation technique.44
Fatigue and psychosocial measures
Fatigued severity will be measured using the CIS-fatigue (8 items, 7-point Likert Scale, 
severity range from 8 to 56).53 High scores indicate a high level of fatigue. The CIS-fatigue 
has excellent psychometric properties, including good reliability and discriminative 
validity.61 Simultaneously to the actometer measurements, daily observed fatigue 
(DOF) will be measured with the Self-Observation List (4 times a day, 4-point scale)62 
two weeks prior and five days subsequent to the maximal exercise test. This instrument 
gives the actual level of daily fatigue. In this way, the relation between actual fatigue 
levels and the (neuro)physiological measures can be accessed directly.
 To examine whether SE regarding the maximal exercise test could be an 
explanation for possible discrepancies in VO2max between fatigued and non-fatigued 
participants, SE regarding the maximal exercise test will be measured using a 
task-specific SE questionnaire. This questionnaire consists of nine questions 
concerning sense of control (each item scored on a 4-point numeric scale, total score 
range from 9 to 36) and was adapted from the SE scale (SES).63 The SES measures 
the perceived level of control over fatigue, whereas the task-specific SE questionnaire 
used in this study measures the sense of control regarding the test. A higher score 
indicates a higher sense of control regarding the maximal exercise test.
 To assess whether environmental factors, like SS for exercise, may influence 
physical activity behavior, SS will be investigated using the shortened van Sonderen 
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physiological feature of fatigue. CFS patients showed a significant reduced gray 
matter volume compared to healthy controls and even showed a significant increase 
in gray matter volume after CBT. Altered levels of specific metabolites in the brains of 
patients with CFS, measured with 1H MRS, have been reported. CFS patients showed 
a significant reduced physical activity, measured by actigraphy, compared to healthy 
controls. Furthermore, the presence of an immunological distortion has been 
suggested as an explanation for postcancer fatigue and CFS. Therefore, further 
studies on (neuro)physiological aspects of fatigue in cancer survivors and CFS 
patients are essential not only for a theoretical understanding of these invalidating 
conditions, but also for providing an objective biological marker that could support 
the diagnosis of fatigue and follow-up of the treatment of fatigue. 
 In conclusion, the aims of these studies are to identify and measure physiological, 
structural, metabolic, and immunological factors of fatigue in disease-free cancer 
survivors and to identify and measure immunological factors of fatigue in CFS. The 
identification of (neuro)physiological factors of persistent fatigue can help to improve 
the diagnostics of fatigue, predict therapy outcome, and facilitate other treatment 
options. Finally, if (neuro)physiological characteristics of fatigue can be influenced by 
CBT, it will enhance our understanding of the mechanism causing fatigue.
Power calculation 
RCT
From previous studies in patients with CFS compared to healthy controls we know 
that groups of at least 10, preferably 20 patients per condition are sufficient to detect 
significant differences in (neuro)physiological parameters measured with sEMG, 
MRI, and exercise testing.31, 46, 67, 68 To identify (neuro)physiological characteristics of 
fatigue, a comparison of baseline measurements with an age, sex, and previous 
cancer treatment matched group of 20 non-fatigued patients is sufficient. Fifty-seven 
severely fatigued patients are needed to measure a change in (neuro)physiological 
factors due to CBT. As depicted in Figure 1, we assume that 5% of the measurements 
will yield technically insufficient data and 20% of the fatigued patients will drop-out 
from the study (14% drop-out due to failure to complete CBT or the follow-up 
measurements and 6% due to cancer recurrence during or after CBT or waiting list). 
Assuming that about two third of the patients who complete CBT will have a clinically 
significant response to CBT, defined as a CIS-fatigue score of less than 35 points, 
there will be 20 responding patients, 10 non-responding patients, and 10 untreated 
patients. Based on 30 patients in the CBT condition and 10 patients in the waiting list 
condition and assuming that the success rate of CBT is about 67% and the chance 
to recover spontaneously in the waiting list condition is maximally 10%, the power of 
the study to demonstrate a significantly greater decrease in CIS-fatigue score in 
patients in the intervention condition than in patients in the waiting list condition will 
be at least 80%.
Influenza study
Given the exploratory nature of the influenza study, group sizes will not be based on 
power calculations. About 20 patients per group will be included. 
Discussion
To the best of our knowledge, this study will be the first that characterizes (neuro)
physiological factors of fatigue in disease-free cancer survivors and the changes of 
these factors in a randomized controlled way. In addition, we are the first to explore 
immune responses in both fatigued disease-free cancer survivors and in patients 
suffering from CFS.
 Studies on physiological aspects of postcancer fatigue mainly concentrate on 
(cardiopulmonary) deconditioning. Other aspects of fatigue, like central and 
peripheral fatigue and brain morphology and function, have been studied for patients 
with fatigue in the context of CFS and neuromuscular diseases and show several 
characteristic differences with healthy controls. CAF appears to be a shared neuro-
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Abstract
The aim of this study is to examine whether physical fitness of severely fatigued and 
non-fatigued cancer survivors, as measured by maximal exercise performance, is 
different between both groups and, if so, whether this difference can be explained by 
differences in physical activity, self-efficacy regarding the exercise test, and/or social 
support.
Severely fatigued (n=20) and sex- and age-matched non-fatigued (n=20) disease-free 
cancer survivors, who completed treatment for a malignant, solid tumor at least one 
year earlier, participated in this case-control study. Maximal oxygen consumption 
was measured during an incremental cycling exercise test. Physical activity was 
assessed via actigraphy. Self-efficacy regarding the test and social support were 
assessed via questionnaires to study its relationship with physical fitness.
Maximal oxygen consumption was significantly lower in fatigued compared to 
non-fatigued participants. Actual physical activity, self-efficacy regarding the test, 
and negative interactions of social support were significantly different between both 
groups. However, after inclusion of these three variables in linear regression analyses, 
the difference in physical fitness between fatigued and non-fatigued cancer survivors 
persisted. 
Maximal oxygen consumption, a measure for physical fitness, was reduced in 
severely fatigued compared to non-fatigued cancer survivors. The inferior maximal 
exercise performance cannot fully be explained by differences in physical activity, 
self-efficacy, or social support between both groups. Other currently still unknown 
factors, such as a disturbance in the cardiopulmonary circuit, may play a role.
Introduction
Fatigue during -but also long after- curative treatment of cancer is a frequently 
occurring, severe, and invalidating problem, impairing quality of life.1, 2 The prevalence 
of fatigue in cancer patients undergoing chemotherapy and/or radiotherapy has 
been estimated to range from 70-96%.3, 4 The percentage of fatigued cancer survivors 
found in longitudinal studies ranges from 19-39%.5-9 The majority of the studies 
observed no association between postcancer fatigue and previous disease or 
treatment characteristics.10-15 However, there is some evidence that patients who are 
treated with surgery only are less at risk for postcancer fatigue,9 while survivors who 
are treated with more aggressive treatments are more at risk for postcancer fatigue.5, 
16 The existing evidence suggests that cognitive behavior therapy (CBT), specifically 
designed for postcancer fatigue, is an effective treatment option for severely fatigued 
cancer survivors.17 However, although it is possible to effectively treat postcancer 
fatigue, the nature of the underlying physiology of postcancer fatigue remains unclear.
 Although current cancer treatments are increasingly efficacious for improving 
survival, they are toxic in numerous ways and may force patients to decrease their 
physical activity, leading to physical deconditioning. In a study of 812 patients with 
breast cancer, physical activity levels were significantly reduced after diagnosis.18 
When physical activity is lacking and deconditioning occurs, the workload of normal 
physical activities demands a relatively higher percentage of physical capacity, 
resulting in the experience of fatigue.19, 20 Therefore, it may be hypothesized that 
compared to non-fatigued patients, fatigued patients have a reduced physical fitness 
due to a decreased level of physical activity after cancer diagnosis and treatment. 
 The social cognitive theory provides a framework to explain how people develop 
and maintain physical activity behavior.21 One of the most important aspects of this 
framework is self-efficacy (SE), which is a person’s belief in his or her ability to perform 
specific tasks in specific circumstances.21 Physiological sensations during exercise 
can be positive or negative, thereby increasing or decreasing SE.21 In patients 
suffering from chronic fatigue syndrome (CFS), extensive exercise can trigger an 
increase in symptoms.22, 23 Expected symptoms after physical activity might influence 
the performance of that task or might even lead to avoidance of the task. In breast 
cancer patients receiving adjuvant cancer treatment, barrier SE for exercise was 
lowest when patients felt nauseated and tired.24 
 Next to personal factors, such as SE, also environmental factors, such as social 
support (SS) for exercise may influence physical activity behavior.25 In a sample of breast 
cancer survivors it was recently shown that SS was positively associated with exercise.25 
Family support was an important facilitator of exercise behavior. Although severely fatigued 
breast cancer survivors may have the same amount of SS compared to non-fatigued 
breast cancer survivors, severely fatigued patients experience more negative interactions.26 
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and height. A full blood cell count was performed and hemoglobin, glucose, and 
cholesterol levels, iron status, electrolyte balance, erythrocyte sedimentation rate, 
and thyroid, kidney, and liver function were checked. Blood lactate concentration was 
measured using BM-lactate Accutrend Plus (Roche Diagnostics, ref 0 3012654016, 
Mannheim, Germany).
Also, a higher discrepancy between the received amount of SS and the amount of 
desired SS was observed for fatigued compared to non-fatigued patients.26 
 Physical fitness in postcancer fatigue, in relation to physical activity and 
psychosocial factors, has not been studied yet. Therefore, the aim of this study was 
to examine whether physical fitness of severely fatigued and non-fatigued disease-free 
cancer survivors, as measured by a maximal exercise test (max test),27 is different 
between the two groups and, if so, whether this difference can be explained by 
differences in physical activity, self-efficacy regarding the max test, and/or social 
support (Figure 1).
Methods
Participants
Severely fatigued (n=20) and sex- and age-matched non-fatigued (n=20) cancer 
survivors were included. Fatigue severity was measured by the fatigue severity 
subscale of the Checklist Individual Strength (CIS-fatigue).28, 29 The CIS-fatigue was 
used in previous research investigating fatigue in cancer patients and was showed 
to be sensitive to detect changes.9, 17, 26, 30 A cut-off score of ≥35 points on this subscale 
is an indicator for severe fatigue. Severely fatigued patients who were referred for CBT 
for postcancer fatigue to the Expert Centre for Chronic Fatigue of the Radboud 
University Nijmegen Medical Centre (RUNMC) were asked for participation. 
Non-fatigued patients (score of <27 points on the CIS-fatigue) were recruited from 
the outpatient clinics of Medical Oncology and Radiation Oncology of the RUNMC. 
All participants had completed curative treatment of a malignant, solid tumor or of a 
(non-)Hodgkin’s lymphoma at least 1 year earlier. Participants had no evidence of 
disease recurrence at the time of the test. The minimum age at disease onset was 18 
years, patients were no older than 65 years, had no current psychological/psychiatric 
treatment when participating in the study, and used no anti-depressive drugs, 
anti-epileptic drugs, or benzodiazepines. 
 All subjects underwent a physical examination before the max test to exclude 
co-morbidity, which would preclude a safe max test, and an electrocardiogram (ECG) 
was approved by a physician. The local ethics committee of the RUNMC approved 
the study and all patients provided written informed consent. 
Measurements
Baseline characteristics
For each patient the oncological treatment history was retrieved from the medical 
chart. Anthropometric measures, including weight, height, and blood pressure, were 
measured before the max test. Body mass index (BMI) was calculated from weight 
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regarding the test was completed just before start of the test. This task-specific SE 
questionnaire consists of nine questions concerning sense of control and each item 
is scored on a 4-point numeric rating scale (Appendix 1, total score ranges from 
9-36). A higher total score indicates a higher sense of control regarding the max test. 
Cronbach’s alpha is 0.78.
Social support
SS was investigated by a short version of the van Sonderen Social Support Inventory 
(SSL).33 The SSL was divided into the SSL-I (amount of SS), the SSL-D (the discrepancy 
between the amount of SS and the desired amount of SS), and the SSL-N (negative 
interactions, unsupportive behavior). The SSL-I consists of eight questions (score 
ranges from 8-32), the SSL-D consists of eight questions (score ranges from 0-32), 
and the SSL-N consists of seven questions (score ranges from 7-28). A higher score 
indicates a higher amount of SS, discrepancy, or negative interactions. 
Statistics
Statistical analyses were performed using SPSS for Windows®, version 16.0 (Chicago, 
Illinois). Descriptive statistics were used to verify if the data are normal distributed. 
Results are presented as mean ± standard deviation (SD) or as frequencies with 
percentages. Two-tailed unpaired Student’s t tests were performed to compare 
differences between groups. Correlation coefficients were calculated using Pearson 
correlations. To analyze possible effects of independent factors, viz. fatigue status 
(severely fatigued or non-fatigued), sex, age, actual physical activity, SE regarding 
the test, and SSL negative interactions on the dependent variable physical fitness 
(VO2max/kg), linear regression analyses (enter-method) were carried out. Differences 
were considered statistically significant at p<0.05.
Results
Baseline characteristics
Baseline characteristics of the participants are presented in Table 1. The group 
suffering from fatigue did not significantly differ from the non-fatigued group in sex, 
age, weight, height, BMI, blood pressure, blood lactate concentration, and 
hemoglobin levels. Breast cancer was the most common tumor type. Eighty-five 
percent and 90% of the fatigued and the non-fatigued participants, respectively, 
underwent surgery and 90% of both groups received adjuvant therapy. The average 
length of time since cancer treatment was 61.6±70.3 months in the fatigued and 
60.5±43.5 months in the non-fatigued group.
Maximal exercise test
To assess participants’ physical fitness, max tests were performed. Patients cycled on an 
ergometer (Lode, Excalibur, Groningen, the Netherlands) with an increased workload of 10 
Watt/min for women and 20 Watt/min for men, starting at a workload of respectively 10 and 
20 Watt. Patients were instructed to cycle at a speed of 60-80 rpm and were verbally 
encouraged to perform maximally until exhaustion. Starting during rest, at least one and a 
half minute before applying the workload and continuing until finishing the max test, 
oxygen consumption (VO2), carbon dioxide production (VCO2), heart rate (HR), respiratory 
quotient (RQ, defined as VCO2/VO2), and ventilation (Ve, defined as the amount of air 
moved in and out the lungs per minute) were measured, breath by breath. Resting values 
were averaged over the 1.5 minute period prior to the test. Maximal values were represented 
as the mean of the last half a minute of maximal exercise. Maximal VO2 (VO2 max) is a 
measure of physical fitness and is the main outcome parameter of the test.27 For safety 
reasons, a continuous 4-lead ECG was obtained during the max test and subsequently 
during recovery. Blood lactate concentration was measured again within two minutes after 
finishing the max test, to examine the acidification of the muscles.
 The max test was considered maximal (i.e. subjects attained physiological 
limitations) if at least three of the following criteria were met: a) a difference of <150ml 
in VO2 between the last minute of the test and the preceding minute b) a maximal HR 
<10 beats below the predicted maximal HR (220-age of the patient) c) an RQ of ≥1.0 
d) a blood lactate concentration after the test of ≥8.0 mmol/l. 
Physical activity
In order to assess whether differences in physical fitness between severely fatigued 
and non-fatigued cancer survivors could be explained by differences in physical 
activity between both groups, actual physical activity levels were assessed by 
actigraphy31, 32 during two weeks prior to the test. An actometer is a motion-sensing 
device, worn around the ankle, which can register and quantify human physical activity. 
The actometer has a piezoelectric sensor that is sensitive in three directions. 
Accelerations of this built-in sensor larger than a predefined threshold are considered 
as activity and are stored in an internal memory every five minutes. For the registration 
period of two weeks, twelve daily physical activity scores were calculated, expressed in 
the average number of accelerations per 5-minute period. A general physical activity 
score reflected the mean physical activity level over the total 12-day time period.
 Also, participants scored their physical activity level long before cancer diagnosis 
on a 10-point numeric rating scale. 
Self-efficacy questionnaire
To examine whether SE regarding the max test could be an explanation for discrepancies 
in physical fitness between fatigued and non-fatigued participants, a SE questionnaire 
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Maximal exercise test
Eighty-five percent of the fatigued (17/20) and 95% of the non-fatigued participants 
(19/20) performed up to physiological limitations during the max test. Test outcomes 
did not significantly change when only those patients who reached physiological 
limitations were included in the analyses. All 40 tests were included in the analyses. 
VO2max during the test was significantly lower for fatigued (26.0±6.0 ml/min/kg) 
compared to non-fatigued patients (34.3±7.2 ml/min/kg, Table 2). In addition, the 
duration of the test, blood lactate concentration, maximal VCO2, and Ve were 
significantly lower in fatigued compared to non-fatigued cancer survivors (Table 2). 
Maximal HR and RQ were not significantly different between fatigued and non-fatigued 
participants (Table 2). 
VO2max and physical activity
Actual physical activity was significantly lower (p=0.001) in fatigued (66.8±17.6) 
compared to non-fatigued patients (91.0±23.5). Actual physical activity correlated 
with VO2max (r=0.694; p<0.001). In the regression analysis including independent 
variables actual physical activity, fatigue status, sex, and age, actual physical activity 
was a significant predictor of dependent variable physical fitness (VO2max), but 
fatigue status also remained a significant predictor of physical fitness (p<0.003).
 Self-reported physical activity long before cancer diagnosis did not significantly 
(p>0.05) differ between fatigued (7.40±1.76) and non-fatigued patients (7.70±2.08). 
No correlation between self-reported physical activity long before cancer diagnoses 
and actual physical activity or VO2max was observed (p>0.05). 
Table 1   Baseline and medical characteristics
Fatigued 
(n=20)
Non-fatigued 
(n=20)
p-value
Sex
 Female 10 (50) 10 (50)
 Male 10 (50) 10 (50)
Age (years) 48.6 ± 10.3 49.0 ± 10.4 0.892
Weight (kg) 81.4 ± 15.1 76.9 ± 9.7 0.274
Height (m) 1.76 ± 0.10 1.76 ± 0.08 0.757
Body Mass Index (kg/m2) 26.4 ± 3.9 24.7 ± 1.9 0.090
Systolic blood pressure (mmHg) 140.1 ± 26.4 135.3 ± 22.1 0.532
Diastolic blood pressure (mmHg) 80.1 ± 9.7 82.1 ± 11.3 0.553
Blood lactate concentration (mmol/l) 1.86 ± 0.96 2.29 ± 1.18 0.225
Hemoglobin levels (mmol/l) 8.6 ± 0.7 8.6 ± 0.6 0.921
Time since cancer treatment (months) 61.6±70.3 60.5±43.5 0.951
Cancer diagnosis
 Breast cancer 6 (30) 9 (45)
 Head and neck cancer 3 (15) 2 (10)
 Testicular cancer 2 (10) 3 (15)
 (Non)Hodgkin 2 (10) 3 (15)
 Prostate cancer 2 (10) 0
 Thyroid cancer 2 (10) 0
 Melanoma 1 (5) 2 (10)
 Other solid cancers 2 (10) 1 (5)
Surgery 17 (85) 18 (90)
Adjuvant therapy
 No adjuvant therapy 2 (10) 2 (10)
 Radiotherapy only 3 (15) 3 (15)
 Chemotherapy only 6 (30) 4 (20)
 Radiotherapy and chemotherapy 5 (25) 5 (25)
 Radiotherapy and hormonal therapy 1 (5) 0
 Chemotherapy and hormonal therapy 1 (5) 2 (10)
  Radiotherapy, chemotherapy, and hormonal 
therapy 
2 (10) 4 (20)
Data are presented as mean ± SD or as frequencies with percentages in brackets.
Table 2   Maximal exercise test results
Fatigued 
(n=20)
Non-fatigued 
(n=20)
p-value
Duration of test (min) 12.9 ± 4.2 16.6 ± 4.3 0.008
Blood lactate concentration (mmol/l) 8.4 ± 2.8 10.5 ± 2.3 0.013
VO2 (ml/min/kg) 26.0 ± 6.0 34.3 ± 7.2 <0.001
VCO2 (ml/min) 2565.8 ± 734.0 3187.2 ± 897.6 0.022
Ventilation (l/min) 91.9 ± 28.5 116.3 ± 35.9 0.022
Heart rate (beats/minute) 166.4 ± 20.0 176.4 ± 12.7 0.067
Respiratory quotient 1.21 ± 0.05 1.20 ± 0.08 0.585
Data are presented as mean ± SD. 
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VO2max and self-efficacy
SE regarding the max test was significantly lower in fatigued compared to non-fatigued 
cancer survivors (Table 4). SE regarding the test correlated with VO2max (r=0.476, 
p=0.002). However, SE regarding the test was not significant (p=0.092) in the 
regression analysis (also including independent variables fatigue status, sex, and 
age), while fatigue status remained a significant predictor of dependent variable 
physical fitness (VO2max, Table 3). 
VO2max and social support
Amount of SS and discrepancy between the received amount of SS and the desired 
amount of SS was not significantly different between fatigued and non-fatigued 
patients (Table 4). Negative interactions regarding SS were significantly higher in 
fatigued (11.8±2.9) compared to non-fatigued (9.4±1.8) participants (Table 4). In the 
regression analysis (also including independent variables fatigue status, sex, and 
age) negative interactions regarding SS was not a significant predictor for independent 
variable physical fitness (p=0.467) and fatigue status remained a significant of 
physical fitness (VO2max, Table 3). 
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Table 4   Results with respect to self-efficacy regarding the exercise test and 
results on social support
Fatigued 
(n=20)
Non-fatigued
(n=20)
p-value
Self-efficacy regarding the exercise test 
(range 9-36)
26.2 ± 2.2 31.6 ± 3.1 <0.001
SSL-I amount of social support 
(range 8-32)
19.3 ± 4.4 20.6 ± 3.6 0.298
SSL-D discrepancy received and desired 
social support 
(range 0-32)
11.2 ± 3.9 9.4 ± 2.0 0.074
SSL-N negative interactions 
(range 7-28)
11.8 ± 2.9 9.4 ± 1.8 0.003
Data are presented as mean ± SD. 
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 In the present study, Ve has been examined, which was not significantly different 
between fatigued and non-fatigued cancer survivors. However, additional parameters 
reflecting pulmonary function such as vital capacity, in- and expiratory reserve 
volume, functional residue capacity, residual volume, and diffusion capacity have not 
been examined in this study, and could possibly explain the observed differences in 
physical fitness. 
 With respect to the cardiovascular system, blood pressure was measured at 
baseline and directly after the test. No significant differences between fatigued and 
non-fatigued participants were found (blood pressure after the test not shown). 
Important indices to assess cardiac function next to blood pressure, which could 
explain our findings, are oxygen (O2) pulse, end-diastolic ventricular volume, ejection 
fraction, and cardiac output. 
 Energy for the exercising skeletal muscle comes from three different sources, 
subsequently from energy stored in the muscle in the form of creatine phosphate and 
from aerobic and anaerobic metabolism of glucose.36 Adenosine triphosphate 
synthesis can be restricted when mitochondria are insufficiently active or by a limited 
O2 supply.
37 
 Of the hematopoietic system, hemoglobin levels are most relevant for max test 
results.36 Hemoglobin is the iron-containing oxygen-transport protein in red blood 
cells and determines O2 saturation. O2 saturation has not been directly measured in 
this study, but O2 saturation is hemoglobin dependent, and hemoglobin levels in 
venous blood of the participants were not significantly different between fatigued and 
non-fatigued cancer survivors. 
 Regarding the neuropsychological system, SE regarding the test and negative 
interactions of SS were significantly different between fatigued and non-fatigued 
cancer survivors, but these differences could not explain the discrepancy in physical 
fitness between both groups. Other neuropsychological factors of relevance would 
be SE regarding fatigue,8 exercise outcome expectancy,25 and mental health status.25 
In a previous study comparing physical condition of a group of 20 CFS patients with 
20 matched controls, physical condition did not significantly differ between both 
groups.38 Although as a clinical syndrome CFS and postcancer fatigue show strong 
resemblances, in postcancer fatigue a clear precipitating moment can be identified 
that elicited fatigue, namely the diagnosis of cancer and its subsequent treatment. In 
contrast, in CFS often no clear precipitating factor can be identified. The difference in 
physical condition, together with the difference in the presence of a precipitating 
factor, suggests that the underlying pathophysiology of postcancer fatigue and CFS 
may be different. 
Discussion
To the best of our knowledge, we are the first to report that patients suffering from 
postcancer fatigue had an inferior physical fitness compared to their sex- and 
age-matched non-fatigued controls. The inferior maximal exercise performance 
could not be explained by differences in pre-cancer physical activity or current 
physical activity, SE regarding the exercise test, or by differences in SS between 
severely fatigued and non-fatigued cancer survivors. 
An obvious explanation for the difference in physical fitness between fatigued and 
non-fatigued patients would be a difference in physical activity levels. Although in our 
study actual physical activity was significantly lower in the fatigued compared to the 
non-fatigued group and did significantly contribute to the actual physical fitness, the 
linear regression analysis showed that fatigue status remained a significant, negative 
predictor of physical fitness. This suggests that, besides reduced actual physical 
activity, other factors underlying fatigue after cancer play a role in explaining the 
impaired physical fitness. It should be noted that the effect of CBT, an effective 
intervention to reduce fatigue given during curative cancer treatment, was not 
mediated by physical activity.34 Similarly, the effect of CBT especially designed for 
severely fatigued patients after cancer treatment is not mediated by a persistent 
increase in objective physical activity.35 
 In this study, fatigued cancer survivors showed a reduced SE regarding the 
exercise test compared to non-fatigued survivors. Expected symptoms after physical 
activity might influence the SE and the performance of the test. However, SE did not 
significantly explain the difference in VO2 max between fatigued and non-fatigued 
cancer survivors. Similarly, SS, and more specifically negative interactions with the 
environment, was worse in the postcancer fatigue group compared to non-fatigued 
cancer survivors, but did not significantly explain the difference in VO2 max between 
fatigued and non-fatigued participants.
Although the sample size is relatively small, based on the data of the present study, 
we can conclude that maximal exercise performance was reduced in severely 
fatigued compared to non-fatigued cancer survivors, but could not fully be explained 
by differences in physical activity or by differences in the psychosocial factors, i.e. SE 
regarding the exercise test and SS. Therefore, another explanation for the difference 
in physical fitness between fatigued and non-fatigued cancer survivors must be 
sought, which may not have been taken into account in our study. Max test results 
follow from the integrated response of the pulmonary, cardiovascular, skeletal muscle, 
hematopoietic, and neuropsychological systems.36 
248 49
Chapter 2.1 Maximal exercise performance in patients with postcancer fatigue
References
1. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer 
survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18(4):743-53.
2. Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, 
correlates and interventions. Eur J Cancer 2002;38(1):27-43.
3. Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L. The prevalence and correlates of fatigue in 
patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue 
experienced by healthy individuals. Cancer Nurs 1994;17(5):367-78.
4. Smets EM, Garssen B, Schuster-Uitterhoeve AL, de Haes JC. Fatigue in cancer patients. Br J Cancer 
1993;68(2):220-4.
5. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal 
investigation. Cancer 2006;106(4):751-8.
6. Hjermstad MJ, Fossa SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH. Fatigue in long-term Hodgkin’s 
Disease survivors: a follow-up study. J Clin Oncol 2005;23(27):6587-95.
7. Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating factors in high-risk breast cancer patients 
treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol 
2005;23(33):8296-304.
8. Servaes P, Gielissen MF, Verhagen S, Bleijenberg G. The course of severe fatigue in disease-free breast 
cancer patients: a longitudinal study. Psychooncology 2007;16(9):787-95.
9. Servaes P, Verhagen S, Schreuder HW, Veth RP, Bleijenberg G. Fatigue after treatment for malignant and 
benign bone and soft tissue tumors. J Pain Symptom Manage 2003;26(6):1113-22.
10. Bartsch HH, Weis J, Moser MT. Cancer-related fatigue in patients attending oncological rehabilitation 
programs: prevalence, patterns and predictors. Onkologie 2003;26(1):51-7.
11. Dimeo F, Schmittel A, Fietz T, et al. Physical performance, depression, immune status and fatigue in 
patients with hematological malignancies after treatment. Ann Oncol 2004;15(8):1237-42.
12. Gielissen MF, Schattenberg AV, Verhagen CA, Rinkes MJ, Bremmers ME, Bleijenberg G. Experience of 
severe fatigue in long-term survivors of stem cell transplantation. Bone Marrow Transplant 
2007;39(10):595-603.
13. Okuyama T, Akechi T, Kugaya A, et al. Development and validation of the cancer fatigue scale: a brief, 
three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom 
Manage 2000;19(1):5-14.
14. Servaes P, van der Werf S, Prins J, Verhagen S, Bleijenberg G. Fatigue in disease-free cancer patients 
compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer 2001;9(1):11-7.
15. Smets EM, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes JC. Fatigue and 
radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 1998;78(7):907-12.
16. Woo B, Dibble SL, Piper BF, Keating SB, Weiss MC. Differences in fatigue by treatment methods in 
women with breast cancer. Oncol Nurs Forum 1998;25(5):915-20.
17. Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Effects of cognitive behavior therapy in severely 
fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a 
randomized controlled trial. J Clin Oncol 2006;24(30):4882-7.
18. Irwin ML, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast 
carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer 2003;97(7):1746-57.
19. Davis MP, Khoshknabi D, Yue GH. Management of fatigue in cancer patients. Curr Pain Headache Rep 
2006;10(4):260-9.
20. Velthuis MJ, Agasi-Idenburg SC, Aufdemkampe G, Wittink HM. The effect of physical exercise on 
cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. Clin 
Oncol (R Coll Radiol) 2010;22(3):208-21.
21. Perkins HY, Baum GP, Taylor CL, Basen-Engquist KM. Effects of treatment factors, comorbidities and 
health-related quality of life on self-efficacy for physical activity in cancer survivors. Psychooncology 
2009;18(4):405-11.
The patient group was rather heterogeneous and participants were not perfectly 
matched by cancer type, cancer treatment, and time since cancer treatment. 
However, previous disease and treatment characteristics seem to be unrelated to 
postcancer fatigue.10-15 
 In addition, there might be a selection bias in the group of severely fatigued 
cancer survivors, as these patients were referred for CBT and therefore had to visit 
the Expert Centre for Chronic Fatigue. Willingness to participate in CBT, journey 
distance, and physical state could have caused a bias.
 Also, patients and controls were not matched by actual physical activity. The 
actometer scores used as a reference in our centre are 90.6±24.8 for healthy controls, 
79.1±20.8 for non-fatigued cancer survivors, and 68.6±21.0 for patients suffering 
from postcancer fatigue. In the present study, the non-fatigued cancer survivors had 
an actometer score in the range of the healthy control reference (91.0±23.5) and the 
severely fatigued cancer survivors had an actometer score in the range of the 
postcancer fatigue reference (66.8±17.6). This would imply that the non-fatigued 
sample of this study had a relatively high actual physical activity. Nevertheless, linear 
regression analysis showed that actual physical activity could not fully account for 
the difference in physical fitness between fatigued and non-fatigued participants. 
 Finally, as we used a cross-sectional design, it is not possible to make any claims 
for causality between fatigue and physical fitness. 
Identification of characteristic physiological factors of fatigue in disease-free cancer 
survivors may not only serve as a theoretical understanding of this invalidating 
condition, but may also provide an objective biological marker that could support the 
diagnosis and follow-up of treatment.
It would enhance the understanding of the mechanism causing fatigue to study if 
physiological characteristics of fatigue, like physical fitness, can be influenced by 
CBT in a randomized controlled trial. 
Acknowledgements
We thank all patients who participated in this study; all physicians for referring 
patients; Lianne Vermeeren for assistance with data collection; Bregina Hijmans-
Kersten and Linda Pardoel for technical support and helpful advice. 
 This work was supported by the Dutch Cancer Society [KUN 2008-4002].
250 51
Chapter 2.1 Maximal exercise performance in patients with postcancer fatigue
Appendix 1
Translation self-efficacy questionnaire, Dutch → English
1. Dit onderzoek zal me wel lukken
→  I will be able to do this test
2. Ik heb me goed voorbereid op deze dag
→ I prepared well for this day
3. Ik zie tegen het onderzoek op
→  I am reluctant to do this test
4. Het zal een grote inspanning voor mij zijn
→ This will be an intensive exercise for me
5. Ik denk dat ik moeite zal hebben om dit onderzoek te voltooien
→ I think I will find it difficult to complete this test
6. Ik weet niet of ik me volledig kan inspannen tijdens dit onderzoek
→ I don’t know if I can fully exert myself during this test
7. Ik verwacht dat ik de opdrachten goed kan uitvoeren
→ I expect that I can fulfill these assignments well
8. Ik heb de afgelopen dagen extra veel rust genomen voor dit onderzoek
→ I have taken extra rest over the last few days for this test
9. Ik ga me volledig inzetten
→ I will apply myself fully
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Abstract
Patients suffering from postcancer fatigue have both an inferior physical activity and 
physical fitness compared to non-fatigued cancer survivors. The aims of this study 
were 1) to examine the effect of cognitive behavior therapy, an effective treatment 
for postcancer fatigue, on physical activity and physical fitness and 2) to examine 
whether the effect of cognitive behavior therapy on postcancer fatigue is mediated 
by a change in physical activity and/or physical fitness.
Severely fatigued cancer survivors were randomly assigned to either the intervention 
condition (cognitive behavior therapy) or the waiting list condition. After assigning 23 
patients in the intervention condition and fourteen patients in the waiting list condition, 
they were assessed both at baseline and six months later. Physical activity was 
assessed via actigraphy and physical fitness was assessed by a maximal exercise 
test. A nonparametric bootstrap approach was used to test the statistical significance 
of the mediation effects.
A significant increase in physical activity was observed in the intervention group 
from baseline to follow-up, whereas physical activity did not change from baseline 
to follow-up in the waiting list group. Physical fitness did not significantly change 
after cognitive behavior therapy or after six months of waiting for therapy. Fatigue 
decreased significantly more in the intervention group than in the waiting list group. 
The mediation hypotheses were rejected.
Cognitive behavior therapy effectively reduced postcancer fatigue and increased 
physical activity, but did not change physical fitness. The effect of cognitive behavior 
therapy on postcancer fatigue is not mediated by a change in physical activity or 
physical fitness. 
Introduction
One of the long-term side effects of cancer treatment is postcancer fatigue, which is a 
severe and invalidating problem, impairing quality of life.1, 2 According to longitudinal 
studies, about 20-40% of cancer survivors suffer from postcancer fatigue.3-7 Previous 
disease or treatment characteristics seem to be unrelated to postcancer fatigue.8-13 
However, there is some evidence that cancer survivors who underwent surgery only 
are less at risk for postcancer fatigue,7 while survivors who were treated with more 
aggressive cancer treatments are more at risk for postcancer fatigue.3, 14 Cognitive 
behavior therapy (CBT), especially designed for postcancer fatigue, is effective in 
treating fatigue in severely fatigued cancer survivors.15 
 It has been hypothesized that postcancer fatigue is related to physical deconditioning 
and/or decreased physical fitness. Today’s cancer treatments are increasingly 
efficacious for improving survival, but they are toxic in numerous ways and may 
compel patients to decrease physical activity, consequently leading to physical 
deconditioning. In a previous study, we demonstrated that severely fatigued disease-
free cancer survivors had a reduced physical activity and an inferior physical fitness 
compared to non-fatigued disease-free cancer survivors.16 However, the role of 
physical activity and physical fitness in reduction of fatigue is unknown. If there is 
a direct relationship between fatigue and physical fitness, one would expect that 
exercise interventions would lead to fatigue reduction. However, the literature on 
the effects of exercise interventions on postcancer fatigue is inconsistent. Some of 
the conducted systematic reviews concluded that exercise is beneficial for patients 
suffering from postcancer fatigue,17-19 while others showed that exercise had no 
mitigating effects on fatigue.20-22. A meta-analysis of randomized controlled trials 
that assessed the effects of physical activity in cancer survivors reported that, 
based on studies in breast cancer survivors, physical activity was associated with 
improvements in fatigue, but not in physical fitness.23 When studies on different types 
of cancer were combined, physical activity was associated with improvements in 
physical fitness, but not in fatigue.23 Thus, the role of physical activity and physical 
fitness in the reduction of postcancer fatigue is unclear. 
 An evidence-based method to reduce fatigue in cancer survivors is CBT.15 
CBT offers an approach to address several elements, including insufficient coping 
with the experience of cancer, fear of disease recurrence, dysfunctional cognitions 
concerning fatigue, dysregulation of sleep, low social support and negative social 
interactions, and dysregulation of activity.15 Within the last mentioned module, 
postcancer fatigue patients select a simple physical activity (walking or cycling) 
and are stimulated to gradually and systematically increase their level of physical 
activity.24 When patients are active for about 45-60 minutes, twice per day, walking or 
cycling is gradually replaced by other, not necessarily physical activities.24 The aim 
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cancer treatment initiated the fatigue (precipitating factors), but other factors are 
responsible for the persistence of the fatigue (perpetuating factors). In six modules, 
CBT focused on six perpetuating factors of postcancer fatigue, including insufficient 
coping with the experience of cancer, fear of disease recurrence, dysfunctional 
cognitions concerning fatigue, dysregulation of sleep, dysregulation of activity, and 
low social support and negative social interactions. Because of the existence of large 
differences within the group of postcancer fatigue patients, therapy was adapted to the 
individual patient.15, 24 However, for all patients, the module focusing on dysregulation 
of activity was part of their tailored treatment, which started with setting a base level 
of physical activity. Once this base level was set, a physical activity program was 
started, usually twice a day, starting with 5-10 minutes of walking or cycling. The 
activity was increased by one minute per day each time the activity was performed, 
ending at a maximum of 120 minutes per day. Gradually, physical activities were 
replaced by other activities. One might choose to systematically expand mental and 
social activities, preparing the patient for a return to work or other personal goals. 
The mean number of (50 minute) sessions of CBT for postcancer fatigue is twelve. 
Patients randomized to the control group waited six months for CBT and received 
this treatment outside the study. CBT focused on six modules, including insufficient 
coping with the experience of cancer, fear of disease recurrence, dysfunctional 
cognitions concerning fatigue, dysregulation of sleep, dysregulation of activity, low 
social support and negative social interactions, and was tailored to the individual 
patient.15 
Physical fitness 
To assess the participants’ physical fitness at baseline and at six months follow-up, 
max tests were performed as described previously.16 
 Anthropometric measures were taken before the max tests. Patients cycled on 
an ergometer with an increased workload and were instructed to perform maximally. 
Starting during rest and continuing until finishing the max test, oxygen consumption 
(VO2), ventilation (Ve), respiratory quotient (RQ), and heart rate (HR) were measured, 
breath by breath. Maximal VO2 (VO2 max) is a measure of physical fitness and is the 
primary outcome parameter of the max test.32 Within two minutes after finishing the 
max test, blood lactate concentration was measured.
 Max tests were considered maximal if at least three of the following four criteria 
were met: a) a difference of <150ml in VO2 between the last minute of the test and 
the preceding minute b) a maximal HR of <10 beats below the predicted maximal HR 
(220-age of the patient) c) an RQ of ≥1.0 d) a blood lactate concentration after the test 
of ≥8.0 mmol/l. 
of this (temporary) increase in physical activity during CBT is to raise the patient’s 
capabilities in other areas and to reach the patient’s individual treatment goals set 
at the start of the therapy. A recent mediation analysis showed that the effect of CBT 
on postcancer fatigue is not mediated by a persistent increase in physical activity.24 
The role of physical fitness in the effect of CBT on postcancer fatigue has not been 
studied before. The aims of this study are 1) to examine the effect of CBT on physical 
activity and physical fitness of severely fatigued disease-free cancer survivors, as 
measured by respectively actigraphy25, 26 and maximal exercise test (max test)27 and 
2) to examine whether the effect of CBT on postcancer fatigue is mediated by an 
increase in physical activity and/or physical fitness. 
Methods
Participants
Severely fatigued cancer survivors who were referred for CBT to the Expert Centre 
for Chronic Fatigue of the Radboud University Nijmegen Medical Centre (RUNMC), 
were asked to participate in this parallel-group randomized controlled trial. The local 
ethics committee of the RUNMC approved the study and all participants provided 
written informed consent. 
 Fatigue severity was measured by the fatigue severity subscale of the Checklist 
Individual Strength (CIS-fatigue).28, 29 The CIS-fatigue has been used in previous 
research investigating fatigue in cancer patients and was shown to be sensitive to 
detect changes. Severe fatigue was defined by a cut-off score of ≥35 points.7, 15, 30, 31
 All patients had completed curative treatment of a malignant, solid tumor or of a 
(non-)Hodgkin’s lymphoma a minimum of one year earlier, and had no evidence of 
disease recurrence at the time of the study. The minimum age of disease onset was 
eighteen years and patients were no older than 65 years of age when entering the 
study. Patients had no current psychological or psychiatric treatment and used no 
anti-depressive drugs, anti-epileptic drugs, or benzodiazepines when participating 
in the study. Patients had no physical comorbidity (e.g. anemia, poor kidney function, 
etc.) that could explain the fatigue. 
 Patients were randomly assigned 3:1 to either the intervention condition (n=50) 
or the waiting list condition (n=14). Random assignment was done by means of a 
sequence of labeled cards contained in sealed, numbered envelopes prepared 
by a statistical adviser. The envelopes were opened by the psychologists in the 
presence of the patient. Randomization took place per patient. Patients randomized 
to the intervention group were treated with CBT for postcancer fatigue, as described 
previously.15 In postcancer fatigue, a distinction can be made between precipitating 
factors and perpetuating factors. The assumption is that the cancer itself and/or the 
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account, we assumed that a number of 57 randomized severely fatigued cancer 
survivors would be sufficiently high to answer the research questions. In the 
waiting list condition, the percentage drop-out was zero, resulting in more follow-
up measurements in this condition than initially calculated in the study protocol. 
Because the percentage of patients completing both the baseline and the follow-up 
measurements in the CBT condition was lower than expected, more patients were 
included and randomized (n=64) than initially calculated. The 3:1 randomization ratio 
was maintained. However, as the randomization took place in blocks, and since the 
inclusion stopped in the middle of a block, the ratio is not exactly 3:1. Therefore, a 
few more patients were allocated to the intervention condition than to the waiting list 
condition than would be expected based on the 3:1 randomization. Unfortunately, as 
a result of financial and logistic reasons, it was not possible to perform the follow-up 
measurements of the patients still undergoing CBT.
 The first objective of this study is to examine the effect of CBT on physical activity 
and physical fitness (Figure 1, part a). In part b of Figure 2, physical activity and 
physical fitness are depicted as hypothesized mediators of the treatment effect of 
CBT on fatigue. The mediation hypotheses were tested separately using a non-
parametric bootstrap approach. A macro expansion, consisting of a syntax file for 
PASW, was introduced by Preacher and Hayes35 to test the mediation hypothesis 
according to the guidelines of Baron and Kenney36. Paths a, b, and c of Figure 1 were 
analyzed using regression analysis. To examine path a, changes in physical activity 
were regressed on CBT. Path b was examined by regressing changes in fatigue on 
changes in physical activity, correcting for CBT. Path c was examined by regressing 
changes in fatigue on CBT, this time correcting for the mediator changes in physical 
activity. The size of the mediation effect was computed by multiplying path a with path 
b. The observed dataset was randomly resampled in 5,000 samples with mediation 
effect. The mediation hypothesis was accepted when the 95% confidence interval did 
not include zero.35 The same regression analysis was applied to paths d, e, and f of 
Figure 1, according to physical fitness. 
Results
Flow chart
The flow chart of the study is presented in Figure 2. Participants were assessed two 
times at the RUNMC, at baseline and at six months follow-up. In thirteen patients, 
CBT is still ongoing and baseline data are available only. Unfortunately, post-CBT 
measurements cannot be performed in these patients due to limitations in the study 
budget. Data are presented of patients who completed both the baseline and follow-
up measurements (n=23 in the intervention group and n=14 in the waiting list group).
Physical activity
Physical activity was measured by actigraphy25, 26 during two weeks prior to the test, 
both at baseline and at follow-up, as described previously.16 The actometer used is 
a motion-sensing device, worn around the ankle, which can register and quantify 
human physical activity. The actometer has a piezoelectric sensor that is sensitive 
in three directions. Accelerations of this in-built sensor larger than a predefined 
threshold are considered as activity and are stored in an internal memory every five 
minutes. For the registration period of two weeks, twelve daily physical activity scores 
were calculated, expressed in the average number of accelerations per 5-minute 
period. A general physical activity score reflected the mean physical activity level 
over the total 12-day period.
Functional impairment
Functional impairment was measured using the Sickness Impact Profile-8 (SIP-8), although 
not mentioned in the original study protocol.27 The SIP-8 measures the influence of 
symptoms on daily functioning, using eight subscales (home management, mobility, 
alertness behavior, sleep/rest, ambulation, social interactions, work, and recreation 
and pastimes).33 A total score was calculated by addition of the weights of items. The 
SIP-8 has good reliability and validity.34 
Statistics
Statistical analyses were performed using PASW for Windows®, version 18.0.2 
(Armonk, New York, USA). Results are presented as mean ± standard deviation (SD), 
as frequencies with percentages of total, or as change scores (percentage change 
from baseline to follow-up). Independent samples t tests and χ2 tests were performed 
to test differences between the therapy and the waiting list condition at baseline and 
at follow-up and to test differences in change scores between both groups. Paired 
t tests were performed to test differences within the therapy and waiting list condition 
from baseline to follow-up. Differences were considered statistically significant at 
p<0.05. Physical activity at baseline was used as a covariate in the baseline and 
the change score analyses of the max test results and in the analysis of the physical 
activity change score. 
 The power calculation is described in the study protocol.27 The number of groups 
was based on previous studies, using the same (neuro)physiological parameters 
and the same methods to measure these parameters. In these studies, at least ten, 
preferably 20 patients per condition were needed to detect significant differences. We 
assumed that 5% of the measurements would yield technically insufficient data and 
that 20% of the fatigued patients would drop-out from the study (14% due to failure 
to complete CBT or the follow-up measurements and 6% due to cancer recurrence 
during or after CBT or waiting list). Taking these numbers and percentages into 
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 At baseline, no significant differences were detected in age, time since cancer 
treatment, fatigue severity, physical activity, and max test outcome parameters (duration 
of the test, VO2max, maximal Ve, RQ, and HR, and blood lactate concentration) between 
the 23 patients in the intervention group, who completed both the baseline and follow-
up measurements, and the patients in the intervention group, for whom baseline 
measurements were available only (n=23, data not shown). 
Figure 2   Flow chart of the study
Referred for CBT and
eligible to enter study n=66
Refused participation n=2
Randomization
n=64
Intervention
condition n=50
Waitinglist
condition n=14
Excluded from study n=2
Disease recurrence n=1
Incorrectly included n=1
Did not start CBT n=1
CBT drop-out n=3
CBT still ongoing n=13
-------------------------------------------------------------
No baseline measurements n=4
Not able to perform maximal exercise test n=4
Complete
CBT n=31
No follow-up measurements n=8
Refused follow-up measurements n=4
Not able to perform maximal exercise test n=4
Follow-up
measurements
n=23
Follow-up
measurements
n=14
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Study population
Anthropometric and medical characteristics
Anthropometric and medical characteristics at baseline and follow-up are presented 
in Table 1. Sex, age, weight, height, and BMI were similar in the intervention and the 
waiting list group, both at baseline and at follow-up. The average length of time since 
completion of cancer treatment did not significantly differ between both groups. 
Breast cancer, head and neck cancer, and (non-)Hodgkin were the most common 
cancer types. 
Fatigue severity
Fatigue severity at baseline was similar in the intervention and the waiting list group 
(Table 1). After six months of follow-up, patients who underwent CBT, with a mean 
of 12.0±5.0 individual sessions, showed a significantly larger change in fatigue 
scores than patients in the waiting list group (p<0.001, respectively -49.0±23.0% 
and -16.4±25.0%). 
Functional impairment
Functional impairment was not significantly different between the intervention and 
the waiting list group at baseline (Table 1). The change score in functional impairment 
(SIP-8) was significantly different between the CBT and the waiting list group 
(respectively -73.0±28.1% and -9.5±47.1%).
Physical activity
Baseline
At baseline, physical activity was significantly lower in the intervention group compared 
to physical activity in the waiting list group (Table 2). 
Follow-up
Physical activity at follow-up was not significantly different between the intervention 
and the waiting list group (Table 2). A significant increase in physical activity was 
observed in the intervention group from baseline to follow-up (p=0.012), whereas 
physical activity did not change from baseline to post-waiting list. The change score 
of physical activity from baseline to follow-up was not significantly different between 
both groups (Table 2).
Table 1   Anthropometric and medical characteristics at baseline and follow-up
CBT
(n=23)
Waiting list 
(n=14)
p-value
Male / Female (n) 13 / 10 5 / 9 0.219
Age (years) 
   Baseline
   Follow-up
48.5 ± 9.2
49.3 ± 9.3
50.7 ± 10.9
51.1 ± 10.9
0.510
0.602
Weight (kg)
   Baseline
   Follow-up
81.3 ± 12.9
81.0 ± 14.2 
76.9 ± 17.1
76.3 ± 16.5
0.387
0.366
Height (m)
   Baseline and follow-up 1.77 ± 0.12 1.74 ± 0.10 0.464
Body Mass Index (kg/m2)
   Baseline
   Follow-up
25.9 ± 3.3
25.8 ± 3.6
25.1 ± 3.3
24.9 ± 3.3
0.442
0.444
Time since cancer treatment (months)
   Baseline
   Follow-up
52.2 ± 63.8
63.4 ± 65.0
45.3 ± 36.8
51.4 ± 36.3
0.714
0.529
Cancer diagnosis (n) 
   Breast cancer 7 (30) 6 (43)
   Head and neck cancer 6 (26) 3 (21)
   (Non)Hodgkin 2 (9) 3 (21)
   Prostate cancer 2 (9) 1 (7)
   Testicular cancer 3 (13) 0
   Thyroid cancer 2 (9) 0
   Other solid cancers 1 (4) 1 (7)
Cancer treatment (n)
   Surgery only 3 (13) 1 (7)
   Surgery and RT 3 (13) 2 (14)
   Surgery and CT 5 (22) 0
   Surgery and RI 1 (4) 0
   Surgery and IT 0 1 (7)
   Surgery, RT and CT 3 (13) 1 (7)
   Surgery, RT, and HT 1 (4) 0
   Surgery, RT, and RI 1 (4) 0
   Surgery, CT, and HT 2 (9) 2 (14)
   Surgery, CT, and IT 1 (4) 0
   Surgery, RT, CT, and HT 2 (9) 3 (21)
   CT only 0 1 (7)
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Physical fitness
Baseline
At baseline, VO2max was not significantly different between patients in the intervention 
group and patients in the waiting list group (Table 2). In addition, the duration of the 
test, maximal Ve, RQ, and HR, and blood lactate concentration were not significantly 
different between both groups at baseline (Table 2). 
 Of the patients, 91% (21/23) who underwent CBT and 86% (12/14) on the waiting 
list for CBT performed up to physiological limitations during the max test at baseline. 
Max test results did not significantly differ when only those tests that were considered 
maximal were included in the analyses. Therefore, results are reported for all tests. 
Follow-up
At follow-up, VO2max was not significantly different between the intervention and the 
waiting list group (Table 2). Also, the duration of the test, maximal Ve, RQ, and HR, and 
blood lactate concentration were not significantly different between the intervention 
and the waiting list group at follow-up (Table 2).
 Of the patients, 87% (20/23) in the intervention group and 79% (11/14) in the 
waiting list group performed tests that met the criteria of a max test at follow-up. 
Table 1   Continued
CBT
(n=23)
Waiting list 
(n=14)
p-value
Cancer treatment (n)
   CT and RT 1 (4) 1 (7)
   CT and IT 0 1 (7)
   RT only 0 1 (7)
Fatigue severity
   Baseline
   Follow-up
44.4 ± 6.2
22.5 ± 10.2
46.1 ± 4.8
38.6 ± 11.8
0.403
<0.001
   Baseline to follow-up (within group) p<0.001 p=0.022
Functional impairment
   Baseline 1072.5 ± 574.3 990.2 ± 584.2 0.684
   Follow-up 289.4 ± 321.6 852.4 ± 667.8 0.009
Data are presented as mean ± SD or as frequencies with percentages in brackets. 
Abbreviations: CBT: cognitive behavior therapy; CT: chemotherapy; HT: hormonal therapy; 
IT: immunotherapy; RI: radioactive iodine; RT, radiotherapy.
Table 2   Baseline, follow-up, and change scores on max test results and  
physical activity
CBT 
(n=23)
Waiting list
(n=14)
p-value
(uncorrected)
p-value
(corrected)
Duration of test 
   Baseline (min) 12.7 ± 3.1 14.3 ± 3.6 0.141 0.333
   Follow-up (min) 12.6 ± 3.2 14.2 ± 4.4 0.195
   Change score (%) 0.0 ± 11.6 -1.6 ± 8.3 0.666 0.753
VO2 max
   Baseline (ml/min/kg) 27.0 ± 6.7 28.0 ± 5.7 0.633 0.521
   Follow-up (ml/min/kg) 27.1 ± 7.3 28.4 ± 6.0 0.580
   Change score (%) 0.6 ± 12.9 1.5 ± 7.9 0.809 0.254
Maximal Ve 
   Baseline (l/min) 98.1 ± 32.0 96.7 ± 41.7 0.914 0.580
   Follow-up (l/min) 94.5 ± 33.0 94.8 ± 37.1 0.980
   Change score (%) -2.9 ± 18.5 -0.3 ± 12.5 0.654 0.493
Maximal RQ 
   Baseline 1.23 ± 0.06 1.19 ± 0.04 0.034 0.061
   Follow-up 1.32 ± 0.34 1.17 ± 0.07 0.114
   Change score (%) 7.2 ± 25.7 -1.5 ± 4.8 0.220 0.734
Maximal HR
   Baseline (beats/min) 172.0 ± 14.4 164.9 ± 19.6 0.218 0.164
   Follow-up (beats/min) 169.4 ± 17.1 163.6 ± 18.1 0.352
   Change score -1.5 ± 5.8 -2.2 ± 3.2 0.683 0.365
Blood lactate concentration
   Baseline (mmol/l)
   Follow-up (mmol/l)
   Change score (%)
9.4 ± 2.7
9.4 ± 2.3
8.6 ± 39.0
9.3 ± 3.2
8.1 ± 2.5
-5.4 ± 33.4
0.856
0.120
0.281
0.961
0.437
Physical activity
   Baseline 65.1 ± 15.7 77.5 ± 17.7 0.037
   Follow-up 73.0 ± 18.8 80.0 ± 23.6 0.336
   Change score (%) 14.6 ± 34.2 5.6 ± 29.1 0.440 0.926
Baseline and follow-up data are presented as mean ± SD and change scores are presented as a 
percentage change from baseline to follow-up. P -values are presented with and without correction for 
covariate physical activity at baseline. Abbreviations: CBT: cognitive behavior therapy; HR: heart rate; 
RQ: respiratory quotient; VCO2: carbon dioxide production; Ve: ventilation; VO2: oxygen consumption.
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bootstrap analysis showed that the positive effect of CBT on postcancer fatigue was 
neither mediated by a change in physical activity, nor by a change in physical fitness.
Physical activity increased significantly from baseline to follow-up in the CBT 
condition. However, the change in physical activity was not significantly different 
between the two conditions. At baseline, the physical activity in the waiting list group 
was already higher than in the intervention group, but we corrected the max test 
outcome parameters and the change in physical activity for this baseline difference. 
One would also expect an increase in physical activity as a result of CBT, as 
gradually increasing physical activity (walking or cycling) to 90-120 minutes per day 
is an important part of the treatment protocol. However, this increase in physical 
activity could be temporary, as walking or cycling is gradually replaced by other, 
not necessarily physical activities. Physical fitness did not significantly increase from 
baseline to follow-up, neither in the CBT group, nor in the waiting list group. Probably, 
the intensity of the additional physical activities that patients perform at the end of 
CBT compared to the start of the therapy is high enough to establish a significant 
increase in physical activity (actometer score) from baseline to follow-up, but is too 
low to result in an increase in physical fitness (maximal VO2) from baseline to follow-
up. In line with the results of a previous study examining the role of physical activity 
in reducing postcancer fatigue,24 in the present study the increase in physical activity 
did not mediate the effect of CBT on postcancer fatigue.
In a previous study, we demonstrated that severely fatigued disease-free cancer 
survivors had a reduced physical fitness compared to non-fatigued disease-free 
cancer survivors.16 Physical fitness of the larger group of fatigued patients included in 
the present analysis was again significantly lower at baseline compared to physical 
fitness of the non-fatigued patients reported in the previous study (respectively 
27.4±6.3 ml/min/kg and 34.3±7.2 ml/min/kg). From baseline to follow-up, physical 
fitness did not increase, neither in the CBT group, nor in the waiting list group. At 
follow-up, physical fitness was still significantly lower in both groups of the present 
study compared to physical fitness of the non-fatigued patients of the previous study. 
Consequently, the absence of a mediating effect of physical fitness on CBT efficacy 
cannot be based on a lack of room for improvement of physical fitness. 
As we observed an improvement in fatigue without an improvement in physical 
fitness, the conclusion seems to be that physical fitness is not the factor, or at least 
not the only factor, related to postcancer fatigue. This lack of relation between fatigue 
and physical fitness in the present study could explain the inconsistent literature on 
the effects of exercise interventions on postcancer fatigue. Probably, other factors 
than physical activity and physical fitness mediate the effect of exercise interventions 
Test outcomes did not significantly change when only those patients who reached 
physiological limitations were included in the analyses. Therefore, all follow-up 
measurements were included in the analyses. 
VO2max did not significantly change (in absolute numbers) from baseline to post-CBT 
or from baseline to post-waiting list, nor did we observe any significant differences in 
change scores (percentage change from baseline to follow-up) between patients in 
the intervention and patients in the waiting list group (Table 2). 
 Except for a significant decrease in maximal HR in the waiting list group from 
baseline to follow-up (p=0.022, within group analysis), the duration of the test, 
maximal Ve, RQ, HR, and blood lactate concentration did not significantly change 
from baseline to post-CBT or from baseline to post-waiting list (within group analysis). 
In addition, change scores of the duration of the test, maximal Ve, RQ, HR, and blood 
lactate concentration were not significantly different between the intervention and the 
waiting list group (Table 2).
Mediation analysis
Physical activity
The bootstrap approach showed that the mean mediation effect was -0.7125. The 
95% confidence interval of the mean mediation effect included zero (-4.4124–2.0381), 
thus rejecting the mediation hypothesis. 
Physical fitness
The bootstrap approach showed that the mean mediation effect was 0.0929. The 
95% confidence interval of the mean mediation effect included zero (-2.9206–2.0377), 
thus rejecting the mediation hypothesis. 
 
Discussion
To the best of our knowledge, this is the first randomized controlled trial examining 
the effect of CBT on both physical activity and physical fitness of severely fatigued 
disease-free cancer survivors. As has been shown before,15 CBT resulted in a 
significantly larger decrease in fatigue severity compared to a period of waiting for 
therapy. In addition, patients in the CBT group showed a significantly larger decrease 
in functional impairment from baseline to follow-up, compared to patients in the 
waiting list group. Physical activity increased significantly from pre- to post-CBT 
and remained unchanged from pre- to post-WL. Physical fitness did not significantly 
change after CBT or after six months of waiting for CBT, nor did we observe significant 
differences in physical fitness between both groups at baseline or follow-up. A 
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available only (50 fatigued patients allocated to the intervention condition minus two 
patients who were excluded from the study, minus four patients who did not complete 
the baseline measurements, and minus 23 patients who completed the follow-up 
measurements) CBT did not significantly differ from the 23 patients in the intervention 
condition, who completed both the baseline and the follow-up measurements, in 
terms of age, time since cancer treatment, baseline fatigue severity, physical activity, 
and max test outcome parameters. Also the thirteen patients still undergoing CBT did 
not significantly differ from these 23 completers on these parameters.
In conclusion, CBT resulted in a significantly larger decrease in fatigue severity 
compared to a period of waiting for therapy, but did not change physical fitness. 
The positive effect of CBT on postcancer fatigue was neither mediated by a change 
in physical activity, nor by a change in physical fitness. Thus, physical activity 
and physical fitness are not the factors, or at least not the only factors, related to 
postcancer fatigue. 
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or CBT on postcancer fatigue. Next to dysregulation of activity, CBT for postcancer 
fatigue also focused on five other perpetuating factors of severe fatigue. Additional 
investigations are needed to establish the essential elements of CBT. It may be 
hypothesized that a decrease in focusing on symptoms mediated the effect of CBT on 
postcancer fatigue. A randomized controlled trial investigating potential mechanisms 
underlying the efficacy of graded exercise therapy for chronic fatigue syndrome 
demonstrated that a decrease in symptom focusing rather than an increase in fitness 
mediated the effect of treatment.37 
Our study has several limitations. One limitation is that our patient group was rather 
heterogeneous in terms of tumor types and treatment. There is some evidence that 
cancer survivors who underwent surgery only are less at risk for postcancer fatigue,7 
while survivors who were treated with more aggressive cancer treatments are more at 
risk for postcancer fatigue.3, 14 However, the intensity of treatment (surgery only versus 
surgery+(neo)adjuvant therapy) was more or less equally distributed in both groups. 
In addition, it has been shown several times that previous disease or treatment 
characteristics are unrelated to postcancer fatigue.8-13
 Other limitations are the small sample size and the fact that only half of the 
patients in the intervention condition were followed up. The sample size of our study 
was relatively small, partly due to incomplete data. In the waiting list condition, the 
dropout rate was zero, as all participants waited six months to start CBT and all 
participants were willing to perform both the baseline and follow-up measurements. 
In the intervention condition, nearly half of the randomized patients completed 
both the baseline and follow-up measurements. Three patients allocated to the 
intervention condition dropped out of the study, because they stopped following 
CBT. Unfortunately, as a result of financial and logistic reasons, it was not possible to 
perform the follow-up measurements of the patients still undergoing CBT (n=13). Of 
the patients who completed CBT, follow-up measurements of a total of eight patients 
were lacking, because four patients were not able to perform a maximal exercise test 
and four patients refused to do the follow-up measurements. This means that the 
strength of a randomized trial could not be fully realized. However, the sample size 
of the present study seems sufficient based on previous studies, using the same 
methods to measure these (neuro)physiological parameters. At least ten, preferably 
20 patients per condition are sufficient to detect significant differences in (neuro)
physiological parameters between patients and controls.27 Importantly, the power of 
the study was sufficiently high to demonstrate a significantly larger decrease in CIS-
fatigue score in patients in the intervention condition than in patients in the waiting list 
condition. In addition, in the mediation analysis, the bootstrap approach gives more 
power to detect significant differences in small samples. Furthermore, the 21 patients 
randomized in the intervention group, for whom baseline measurements were 
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Abstract
Postcancer fatigue is a frequently occurring problem, impairing quality of life. Until 
now, little is known about (neuro)physiological factors determining postcancer 
fatigue. For non-cancer patients with chronic fatigue syndrome, certain characteris-
tics of brain morphology and metabolism have been identified in previous studies. 
We investigated whether these volumetric and metabolic traits are a reflection of 
fatigue in general and thus also of importance for postcancer fatigue.
Fatigued patients were randomly assigned to either the intervention condition 
(cognitive behavior therapy) or the waiting list condition. Twenty-five patients in the 
intervention condition and fourteen patients in the waiting list condition were assessed 
twice, at baseline and six months later. Baseline measurements of 20 fatigued 
patients were compared with 20 matched non-fatigued controls. All participants had 
completed treatment of a malignant, solid tumor minimal one year earlier. Global 
brain volumes, subcortical brain volumes, metabolite tissue concentrations, and 
metabolite ratios were primary outcome measures. 
Volumetric and metabolic parameters were not significantly different between 
fatigued and non-fatigued patients. Change scores of volumetric and metabolic 
parameters from baseline to follow-up were not significantly different between 
patients in the therapy and the waiting list group. Patients in the therapy group 
reported a significant larger decrease in fatigue scores than patients in the waiting list 
group. 
No relation was found between postcancer fatigue and the studied volumetric and 
metabolic markers. This may suggest that, although postcancer fatigue and chronic 
fatigue syndrome show strong resemblances as a clinical syndrome, the underlying 
physiology is different.
Introduction 
One of the well-known problems of patients undergoing cancer treatment is fatigue.1, 2 
According to longitudinal studies, about 20-40% of the cancer survivors suffer from 
persistent fatigue, sometimes even years after successful completion of cancer 
treatment.3-7 Postcancer fatigue is a severe and invalidating problem, impairing 
quality of life.8, 9 Cognitive behavior therapy (CBT) addresses the perpetuating factors 
of postcancer fatigue and has a clinically relevant effect on reducing fatigue in 
severely fatigued cancer survivors.10 However, until now, little is known about (neuro)
physiological factors determining postcancer fatigue. 
 For non-cancer patients with chronic fatigue syndrome (CFS), certain character-
istics of brain morphology and metabolism have been identified in previous studies. 
Using magnetic resonance imaging (MRI) and voxel-based morphometry (VBM), in a 
study of 16 CFS patients and 49 healthy controls and in another study of 28 CFS 
patients and 28 healthy controls, significantly reduced gray matter volumes were 
observed in CFS patients compared to controls.11, 12 Interestingly, it has been shown 
that CBT led to a significant increase in gray matter volume in CFS patients.13 These 
findings indicate that the cerebral atrophy associated with CFS can be partially 
reversed after effective CBT.13 
 In addition, altered levels of specific metabolites have been reported in the brains 
of CFS patients, measured with magnetic resonance spectroscopy (MRS). In a study 
of seven CFS patients and ten healthy controls, a significantly reduced level of N-
acetylaspartate (NAA) was observed in the hippocampus of CFS patients compared 
to controls.14 This result has been attributed to a reduction in neuronal and/or glial cell 
density or metabolism, as NAA is a marker of neuronal and axonal integrity.15 The 
hippocampus plays a pivotal role both in working memory and in long-term memory 
storage and retrieval, which could be related to the reduced ability of CFS patients to 
perform memory tasks.16 
 In another MRS study of eight CFS patients and eight healthy controls, the mean 
ratio of choline (Cho) to creatine (Cr) in the occipital cortex was demonstrated to be 
significantly higher in CFS patients compared to controls.17 As creatine tends to be 
relatively stable, this result suggests that choline is increased in the occipital cortex of 
CFS patients. Increased choline levels are associated with abnormal cell membrane 
metabolism.15 It has been hypothesized that brain metabolites in the frontal and 
occipital cortex are altered in CFS patients, because simple reaction times are longer 
in CFS patients than in controls,18 and simple reaction times might reflect the 
functioning of both the frontal and occipital lobes.19 
 It may be hypothesized that these metabolic and volumetric traits found in CFS 
patients are a reflection of fatigue in general and thus may also be of importance for 
patients suffering from postcancer fatigue. In this study we extended the survey of 
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metabolites in the hippocampus with the gliosis-associated marker myoinositol (mI) 
and the excitatory neurotransmitter glutamate (Glu) and the metabolite ratios mI:NAA 
and Glu:mI.20, 21 Next to global volumes of gray and white matter, as has been studied 
in CFS patients, we examined subcortical brain volumes. 
 The aims of this study were A) to examine if volumetric and metabolic parameters 
are different between severely fatigued and non-fatigued cancer survivors and B) to 
examine the effect of CBT on these volumetric and metabolic markers in severely 
fatigued cancer survivors.
Methods
Participants
The local ethics committee of the Radboud University Nijmegen Medical Centre (RUNMC) 
approved the study and all participants provided written informed consent. In part A of 
the study, severely fatigued and non-fatigued cancer survivors were compared (Figure 1). 
In part B of the study, severely fatigued cancer survivors were randomly assigned to 
either the intervention condition or the waiting list condition (Figure 1). Fatigue severity 
was measured by the fatigue severity subscale of the Checklist Individual Strength 
(CIS-fatigue).22, 23 Severe fatigue was defined by a cut-off score of ≥35points.7, 10, 24, 25 
The CIS-fatigue has been used in previous research investigating fatigue in cancer 
patients and was shown to be sensitive to detect changes. 
 All participants had completed curative treatment of a malignant, solid tumor or 
of a (non-)Hodgkin’s lymphoma a minimum of one year earlier, and had no evidence 
of disease recurrence at the time of the study. The minimum age of disease onset 
was eighteen years and patients were no older than 65 years of age when entering 
the study. Patients had no current psychological or psychiatric treatment and used no 
anti-depressive drugs, anti-epileptic drugs, or benzodiazepines when participating in 
the study. Patients had no brain tumor in the past and had no physical comorbidity 
(e.g. anemia, poor kidney function, etc.) that could explain fatigue. 
 For the evaluation of severely fatigued cancer survivors, referred for CBT to the 
Expert Centre for Chronic Fatigue of the RUNMC, versus non-fatigued cancer survivors 
(part A of the study), patients were included from March 2009 onwards. Enrollment of 
severely fatigued cancer survivors for the parallel-group randomized controlled trial 
(part B of the study) continued in March 2010 until April 2012. Sixty-four fatigued patients 
consented and were randomly assigned at a ratio of 3:1 to either the intervention condition 
(n=50) or the waiting list condition (n=14). Random assignment was done by means of 
a sequence of labeled cards contained in sealed, numbered envelopes prepared by a 
statistical adviser. The envelopes were opened by the psychologists in the presence of 
the patient. Patients randomized to the intervention group were immediately treated 
Figure 1   Flow chart of the study
Severely fatigued patients
referred for CBT and
eligible to enter study n=66
Refused participation n=2
Randomization
n=64
Part b
Intervention
condition n=50
Waiting list
condition n=14
Excluded from study n=2
Disease recurrence n=1
Incorrectly included n=1
Did not start CBT n=1
CBT drop-out n=3
CBT still ongoing n=14
Complete CBT
n=30
No follow-up measurements n=5
Refused follow-up measurements n=4
Contraindication n=1
Follow-up
measurements
n=25
Follow-up
measurements
n=14
Complete
Waiting list
n=14
Non-fatigued
patients n=20
Severely
fatigued
patients n=20
Measurements
MRI n=22
MRS n=20
Technical failure
MRI n=3
MRS n=5
Technical failure
MRI n=0
MRS n=2
Measurements
MRI n=14
MRS n=12
Technical failure
MRI n=0
MRS n=3
Measurements
MRI n=20
MRS n=17
Part a
Matched
Abbreviations: CBT: cognitive behavior therapy; MRI: magnetic resonance imaging; 
MRS: magnetic resonance spectroscopy.
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and a second 2D MRSI slice in the plane including the occipital cortex. Volume 
selection was done by using the semi-LASER pulse sequence31, 32 with 12x16 phase 
encoding steps for MRSI in the hippocampus and 16x20 phase encoding steps for 
MRSI in the occipital cortex (nominal voxel size 10.0x10.0x10.0 mm, TR=1500 ms, 
TE=30 ms for the hippocampus, TE=136 ms for the occipital cortex, 6 acquisition-
weighted averages). MRSI data of the hippocampus were acquired with and without 
water signal suppression for referencing purposes.32 Metabolite tissue concentrations 
were obtained from two voxels selected in the hippocampus (one voxel in the right 
and one voxel in the left hippocampus) and from two voxels selected in the occipital 
cortex adjacent to each other, close to the parieto-occipital sulcus. LCModel was 
used to obtain absolute tissue concentrations (water referenced, corrected for T1 and 
T2 relaxation, but not for cerebrospinal fluid contribution) of NAA, mI, and Glu, and 
the concentration ratios of mI:NAA, and Glu:mI in the hippocampus. Signal ratios of 
Cho:Cr in the occipital cortex were also obtained using LCModel. Per subject, the 
metabolite tissue concentrations, metabolite concentration ratios, and metabolite 
signal ratios were calculated for the two voxels per location and subsequently 
averaged.
Statistics
Statistical analyses were performed using PASW for Windows®, version 18.0.2 
(Armonk, New York, USA). Results are presented as absolute numbers, as mean ± 
standard deviation (SD), as frequencies with percentages of total, or as change 
scores (the percentage change from baseline to follow-up). Normality of the data was 
tested using a Shapiro-Wilk test. Chi square tests, independent samples t tests, and 
Mann-Whitney U tests were performed to compare differences in baseline character-
istics between fatigued and non-fatigued patients and between the therapy and the 
waiting list condition (Table 1). To compare differences in MR results between fatigued 
and sex- and age-matched non-fatigued cancer survivors, independent samples 
t tests were performed (Table 2). Given the differences in brain size and morphology 
between men and women33 and the age-related changes in GM,11, 27 the normally 
distributed data of Table 3 are corrected for sex and age by analyses of covariance. 
Differences in the non-normally distributed parameters between the therapy and the 
waiting list condition were tested by Mann-Whitney U tests (Table 3). To evaluate the 
uncontrolled within group effects of CGT and WL from baseline to follow-up, paired 
t tests were performed for the normally distributed parameters and the Wilcoxon 
matched-pairs tests for the non-normally distributed parameters (Table 4). Differences 
were considered statistically significant at p<0.05. The power calculation is described 
in the study protocol as published previously.34 As a result of financial and logistic 
reasons, it was not possible to perform the follow-up measurements of the patients 
still undergoing CBT.
with CBT for postcancer fatigue, as described previously,10 whereas patients randomized 
to the control group waited six months for CBT and received CBT outside the study. 
Both the intervention and the waiting list group were assessed twice, at baseline and at 
six months follow-up, at the RUNMC. Data are presented of patients who completed 
both the baseline and follow-up measurements. 
 Baseline measurements of 20 of the 64 randomized severely fatigued cancer 
survivors were compared with 20 age- and sex-matched non-fatigued patients, recruited 
from the outpatient clinics of Medical Oncology and Radiation Oncology of the RUNMC 
(part A of the study). Non-fatigued patients were assessed only once, at the RUNMC. 
Measurements
MRI and MRS measurements were performed on a 3 Tesla MR system (Tim TRIO, 
Siemens, Erlangen, Germany) using the standard circularly polarized birdcage head 
coil. Fatigue scores, global brain volumes, subcortical brain volumes, metabolite 
tissue concentrations, and metabolite ratios were the primary outcome measures.
Volumetric measurements
High-resolution 3D T1-weighted anatomical images of the whole brain (voxel size 
1x1x1mm3) were acquired using a magnetization prepared rapid acquisition gradient 
echo sequence (TR=2300 ms, TE=3.16 ms). Raw MRI data in DICOM format were 
converted to NIFTI format using the conversion as implemented in the SPM5 package 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm5/). 
 Normalizing, bias-correcting, and segmentation of gray matter (GM) and white 
matter (WM) was performed using the VBM toolbox (VBM5.1 Toolbox version 1.19) in 
SPM5 using priors (default settings). This method uses an optimized VBM protocol26, 27 
as well as a model based on Hidden Markov Random Fields (HMRF) developed to 
increase signal-to-noise ratio.28 Total GM volume (GMV) and WM volume (WMV) 
were calculated by adding the resulting tissue probabilities. Total brain volume (TBV) 
was defined as the sum of WMV and GMV.
 Automatic segmentation of subcortical brain structures was performed using the 
FIRST module (version 1.1) of FSL (version 4.1.4) (http://www.fmrib.ox.ac.uk/fsl).29, 30 
Volumetry was applied to segment brainstem (defined as medulla, pons, and 
midbrain, bordering the ventral diencephalon, the fourth ventricle, and the cerebellum) 
and bilateral accumbens, amygdala, caudate nucleus, hippocampus, globus 
pallidus, putamen, and thalamus. Volumes of bilateral structures were added-up. 
Subcortical brain volumes were expressed as a percentage of TBV. 
1H Magnetic Resonance Spectroscopic Imaging 
The T1-weighted images were used to position one 2D MR spectroscopic image 
(MRSI) slice in the plane perpendicular to the longitudinal axis of the hippocampus 
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Table 2   MR results of fatigued and non-fatigued patients
Fatigued
(n=20)
Non-fatigued
(n=20)
p-value
Global brain volumes (n=20) (n=20)
   Gray matter volume (ml) 689.1 ± 76.8 661.6 ±60.4 0.449
   White matter volume (ml) 530.8 ± 94.3 501.3 ± 62.4 0.703
   Total brain volume (ml) 1219.9 ±153.3 1162.9 ±111.7 0.703
Subcortical brain volumes (n=20) (n=20)
   Accumbens (% of TBV) 0.090 ± 0.013 0.097 ± 0.018 0.150
   Amygdala  (% of TBV) 0.280 ± 0.043 0.299 ± 0.040 0.155
   Caudate nucleus (% of TBV) 0.606 ± 0.054 0.596 ± 0.053 0.578
   Hippocampus (% of TBV) 0.647 ± 0.063 0.679 ± 0.065 0.113
   Globus pallidus (% of TBV) 0.321 ± 0.024 0.319 ± 0.031 0.783
   Putamen (% of TBV) 0.873 ± 0.062 0.891 ± 0.065 0.360
   Thalamus (% of TBV) 1.318 ± 0.077 1.357 ± 0.073 0.108
   Brainstem (% of TBV) 1.911 ± 0.130 1.957 ± 0.139 0.291
Metabolite signal ratios occipital cortex (n=17) (n=17)
   Choline:Creatine 0.34 ± 0.07 0.37 ± 0.06 0.245
Metabolite tissue levels and concentration 
ratios hippocampus
(n=17) (n=17)
   N-acetylaspartate (mmol/l) 8.63 ± 0.72 8.80 ± 0.90 0.539
   Myoinositol (mmol/l) 8.25 ± 1.56 7.64 ± 2.21 0.362
   Glutamate (mmol/l) 7.31 ± 0.97 6.69 ± 1.32 0.128
   Myoinositol:N-acetylaspartate 0.97 ± 0.23 0.87 ± 0.26 0.275
   Glutamate:Myoinositol 0.92 ± 0.23 0.95 ± 0.32 0.742
Data are presented as mean ± standard deviation. Independent samples t tests were performed. 
Fatigued and non-fatigued patients were matched by sex and age. Abbreviation: TBV: total brain volume.
Table 3   MR results of fatigued patients in the therapy and waiting list condition, 
presented as change scores
CBT
(n=25)
WL
(n=14)
p-value
Global brain volumes (%) 
   Gray matter volume 
(n=22)
-0.66 ± 1.39
(n=14)
-0.41 ± 1.10 0.860
   White matter volume -0.20 ± 0.76 -0.21 ± 0.86 0.713
   Total brain volume -0.47 ± 1.04 -0.32 ± 0.66 0.987
Subcortical brain volumes (%) (n=22) (n=14)
   Accumbens -1.50 ± 8.18 0.23 ± 6.21 0.404
   Amygdala 1.60 ± 6.28 2.47 ± 3.35 0.841
   Caudate nucleus 0.26 ± 1.78 0.50 ± 2.00 0.688
   Hippocampus -0.25 ± 2.45 -0.22 ± 2.63 0.680
   Globus pallidus 0.28 ± 2.71 -0.89 ± 2.23 0.140
   Putamen 0.24 ± 1.93 -0.91 ± 2.07 0.114
   Thalamus 0.10 ± 1.79 0.79 ± 1.33 0.254
   Brainstem 0.37 ± 3.00 -0.97 ± 2.45 0.289
Metabolite signal ratios occipital cortex (%) (n=20) (n=12)
   Choline:Creatine 1.45 ± 40.54 3.60 ± 25.77 0.732
Metabolite tissue levels and concentration 
ratios hippocampus (%)
(n=20) (n=12)
   N-acetylaspartate 2.24 ± 10.60 0.32 ± 7.72 0.620
   Myoinositol 7.32 ± 30.55 -2.97 ± 23.86 0.305
   Glutamate 8.86 ± 28.61 -3.90 ± 21.02 0.233
   Myoinositol:N-acetylaspartate 4.89 ± 27.22 -2.71 ± 25.58 0.413
   Glutamate:Myoinositol 5.93 ± 32.60 2.02 ± 23.43 0.793
Data are presented as change scores (the percentage change from baseline to follow-up). Analyses of 
covariance were performed for the normally distributed parameters, correcting for age and sex, and 
Mann Whitney-U tests were performed for the non-normally distributed parameters. Abbreviations: CBT: 
cognitive behavior therapy; WL: waiting list.
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Part A. Fatigued versus non-fatigued patients
Subcortical brain volumes (accumbens, amygdala, caudate nucleus, hippocampus, 
globus pallidus, putamen, thalamus, and brainstem, Figure 2A-C) and global brain 
volumes (GMW, WMV, and TBV, Figure 2D-F) were not significantly different between 
fatigued and non-fatigued patients (Table 2). In the hippocampus, metabolite tissue 
concentrations (NAA, mI, and Glu) and metabolite concentration ratios (mI:NAA and 
Glu:mI) did not significantly differ between fatigued and non-fatigued patients (Table 
2 and Figure 3). Finally, metabolite signal ratios in the occipital cortex (Cho:Cr) were 
not significantly different between fatigued and non-fatigued patients (Table 2 and 
Figure 3).
Results
Patient inclusion
The flow chart of the study is presented in Figure 1. Both severely fatigued and 
non-fatigued cancer survivors were enrolled in this study between March 2009 and 
April 2012 and the last follow-up measurements were performed in September 2012. 
Of the 66 severely fatigued patients who were referred for CBT to the Expert Centre 
for Chronic Fatigue and who met the criteria of the study, baseline data of 20 patients 
were compared with data of 20 age- and sex-matched non-fatigued patients (part A 
of the study). Two severely fatigued patients refused CBT and, therefore, did not 
participate in the randomized controlled trial (part B of the study). Of the 64 patients 
who were randomized, 50 patients were allocated to the intervention condition and 14 
patients were allocated to the waiting list condition. After randomization, one patient 
had disease recurrence, one patient was incorrectly included according to the 
inclusion criteria, one patient did not want to start CBT, and three patients dropped 
out during CBT. As a result of financial and logistic reasons, it was not possible to 
perform the follow-up measurements of the fourteen patients still undergoing CBT. 
The patients still undergoing CBT were not included in the analyses. 
 Twenty-five patients completed both the baseline and follow-up measurements 
in the intervention condition and fourteen patients in the waiting list condition. Due to 
technical failure, three MRI and five MRS measurements in the intervention condition 
could not be analyzed and two MRS measurements in the waiting list condition failed.
Study population
Part A) Baseline characteristics of the 20 fatigued and the 20 sex- and age-matched 
non-fatigued cancer survivors are presented in Table 1. Time since cancer treatment did 
not significantly differ between the patients suffering from fatigue and the non-fatigued 
group. Breast cancer was the most common cancer type. Ninety percent and 85% of the 
fatigued and non-fatigued participants, respectively, underwent surgery. 
 Part B) Baseline characteristics of the 25 fatigued patients in the therapy condition 
and the 14 patients in the waiting list condition are presented in Table 1. Sex, age, 
time since cancer treatment, and fatigue severity were similar in the intervention and 
the waiting list group. Breast cancer was the most common cancer type. Ninety-six 
percent and 79% of the patients in the therapy and the waiting list condition, 
respectively, underwent surgery.
 At baseline, no significant differences were present in age, sex, time since cancer 
treatment, and fatigue severity between the 25 patients in the intervention condition, 
who completed both the baseline and follow-up measurements, and the 25 patients 
in the intervention condition, for whom baseline measurements were available only 
(data not shown). 
Figure 2   Examples of subcortical and global brain segmentation
An example of subcortical brain segmentation of the thalamus in coronal (A), sagittal  
(B), and transversal plane (C), and an example of voxel-based segmentation of an anatomical image 
(D) in a gray matter image (E) and a white matter image (F).
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and brainstem) were not significantly different between patients in the therapy group 
and patients in the waiting list group (Table 3). In the hippocampus, metabolite tissue 
concentrations (NAA, mI, and Glu) and metabolite concentration ratios (mI:NAA and 
Glu:mI) were not significantly different between patients in the therapy group and 
patients in the waiting list group (Table 3). Also, metabolite signal ratios in the occipital 
cortex (Cho:Cr) did not significantly differ between patients in the therapy and patients 
in the waiting list group (Table 3).
 Uncontrolled within group analyses showed no significant effect of CBT from 
baseline to follow-up on global brain volumes, subcortical brain volumes, metabolite 
tissue concentrations, metabolite concentration ratios, and metabolite signal ratios 
(Table 4). The WL condition showed also no effect from baseline to follow-up on these 
volumetric and metabolic parameters, except for a significant increase in the volume 
of the amygdala and the thalamus (Table 4).
Discussion
To the best of our knowledge, this is the first study to report on volumetric and 
metabolic parameters in the brain of severely fatigued and non-fatigued disease-free 
cancer survivors. In contrast to findings in CFS, no volumetric and metabolic 
differences between fatigued and non-fatigued cancer survivors were observed. In 
addition, this is the first randomized controlled trial examining the effect of CBT on 
volumetric and metabolic markers in severely fatigued disease-free cancer survivors. 
CBT for fatigue in cancer survivors is an effective therapy, as has been shown before.10 
In our study CBT also resulted in a significantly larger decrease in fatigue severity 
compared to a period of waiting for therapy. However, we did not observe significant 
effects of CBT on volumetric or metabolic markers in the brain. 
In the study of de Lange et al,13 gray matter volume was significantly smaller in CFS 
patients (669.4 ± 14.4 ml) compared to healthy controls (708.2 ± 12.0 ml) and CFS 
patients showed a significant increase in gray matter volume from pre-CBT to 
post-CBT (674.1 ± 15.1 ml). Although not significantly different between fatigued and 
non-fatigued cancer survivors, the gray matter volumes were comparable to the CFS 
study. In fatigued patients, gray matter volume did not significantly change from pre- 
to post-CBT or from pre- to post-waiting list. In both studies, anatomical images were 
acquired using a magnetization prepared rapid acquisition gradient echo sequence 
and images were analyzed using VBM. The duration of fatigue complaints was 
comparable in the CFS study (CFS duration in years in CFS patients 5.8 ± 0.79) and 
the present study (time since cancer treatment in years in fatigued cancer survivors 
5.4 ± 5.8). The CFS study was performed at a 1.5 Tesla scanner, whereas the present 
Part B. Cognitive behavior therapy versus waiting list
After six months follow-up, patients who underwent CBT, with a mean of 11.8±5.1 
individual sessions, reported a significantly larger change in fatigue scores than 
patients who waited six months for CBT (p<0.001, respectively -45.5±22.7% and 
-16.4±25.0%).
 Change scores (percentage change from baseline to follow-up) of global brain 
volumes (GMW, WMV, and TBV) and subcortical brain volumes (accumbens, 
amygdala, caudate nucleus, hippocampus, globus pallidus, putamen, thalamus, 
Figure 3   Examples of spectra, background images, and 1H magnetic 
resonance spectroscopic imaging grid
An example of a Hanning filtered spectrum in the occipital cortex (A) and in the hippocampus 
(B) and the accompanying background image plus 1H magnetic resonance spectroscopic imaging 
grid (respectively C and D). 
392 93
Chapter 3 MRI and MRS of the brain in postcancer fatigue: a randomized controlled trial
technical arena, in particular because of the much smaller group sizes and more 
favorable measurement conditions (e.g. lower magnetic fields) in the CFS studies. 
However, a direct comparison of the data of the present postcancer fatigue study 
with the data of a CFS study with the same technical parameters and the same 
sample size is needed.
Postcancer fatigue appears to be unrelated to abnormalities in brain structure or 
brain metabolite concentrations, but our results do not imply that alterations in the 
pathophysiology of the brain can be excluded as underlying mechanism of postcancer 
fatigue. In particular, alterations in the dynamics of brain physiology, which are not 
reflected in the static levels of the brain metabolites or in the brain volumes as 
investigated in this study, may be involved. To address if these aspects of brain 
physiology contribute to the experience of fatigue, it is needed to perform more 
functional studies such as, for example, resting state functional MRI.40 
Limitations of the study
We could have investigated more areas in the brain for metabolic differences and the 
number of patients might still have been relatively small, although the group size was 
much larger than in comparable studies. Also, the power of the study was sufficiently 
high to demonstrate a significantly larger decrease in CIS-fatigue score in patients in 
the therapy group compared to patients in the waiting list group. 
In conclusion, no relation was observed between postcancer fatigue and a set of 
volumetric and metabolic markers in the brain in the present study. Therefore, based 
on the VBM method to calculate global brain volumes, the FIRST module of FSL to 
calculate subcortical brain volumes, and 1H MRSI to calculate metabolite 
concentrations and ratios in the hippocampus and the occipital cortex, postcancer 
fatigue does not appear to be associated with abnormalities in brain structures or 
brain metabolism. Additional investigations, including functional brain studies, may 
be needed to identify neurophysiological factors that may explain postcancer fatigue.
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study was performed on a 3.0 Tesla system with a better signal-to-noise ratio. 
Although we did not find significant differences in global brain volumes in the present 
study, the VBM method is able to demonstrate significant differences between 
groups, as has been shown before.11-13 
 We extended the survey of global brain volumes and examined subcortical brain 
volumes, but found no associations with postcancer fatigue. This analysis method 
has shown the potential to detect small differences in subcortical brain volumes, 
however, in larger groups of subjects.29, 35
 The absolute and relative tissue levels of the metabolites determined in this study 
for non-fatigued patients are comparable with values commonly found for the 
hippocampus and occipital cortex in normal persons.32, 36-38 However, the decreased 
levels of NAA in the hippocampus, as found in CFS patients,14 was not observed in 
our patients with postcancer fatigue. This CFS study concerned far less patients than 
in our study. It was performed on a 1.5 Tesla MR system and the spectra were 
acquired using a STEAM sequence, whereas the present study was performed on a 
3.0 Tesla MR system and used a semi-LASER sequence, which results in a much 
better signal-to-noise ratio. Moreover, the T2 relaxation times of the individual 
metabolites measured at three different echo times in the CFS study are susceptible 
to small noise contributions, a rather high absolute NAA concentration was reported 
for healthy controls, and the levels of all main metabolites seemed to decrease for 
CFS patients compared to healthy controls.
 We also could not observe a difference in the Cho:Cr ratio for postcancer fatigue 
patients as seen in the occipital cortex in another study of CFS patients.14 This CSF 
study also concerned a much smaller patient group and was performed at 1.5 Tesla, 
but further described settings were comparable to the current investigation. An 
increased ratio of Cho:Cr was also observed in the basal ganglia of another small 
group of CFS patients.39 
 Furthermore, no significant differences could be found between fatigued and 
non-fatigued cancer survivors for any other investigated metabolite level, such as the 
Glu tissue concentrations in the hippocampus.    
Altogether, the results of our study could not confirm the hypothesis that metabolic 
and volumetric traits observed in CFS patients are a reflection of fatigue in general 
and are, therefore, also of importance for patients suffering from postcancer fatigue. 
This suggests either that, although postcancer fatigue and CFS show strong 
resemblances as a clinical syndrome, the underlying physiology is different, or that 
technical differences between the present study in postcancer fatigue and the 
previous studies in CFS patients explain the differences in study outcomes between 
both fatigue syndromes. The more likely reason for the observed differences between 
postcancer fatigue and CFS in metabolite concentrations and ratios may lie in the 
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Abstract
The aim of this study was to examine whether postcancer fatigue is characterized by 
high central and low peripheral muscle fatigue, a shared feature of fatigue in patients 
with chronic fatigue syndrome and neuromuscular diseases.
Central activation failure (indicator of central muscle fatigue) and muscle fiber 
conduction velocity (indicator of peripheral muscle fatigue) were measured in fatigued 
patients in the intervention and waiting list condition at baseline and six months later. 
Baseline measurements of fatigued patients were compared with non-fatigued 
patients.
Central activation failure and muscle fiber conduction velocity were not significantly 
different between fatigued and non-fatigued patients and change scores were not 
significantly different between patients in the therapy and the waiting list condition.
Postcancer fatigue is neither characterized by high central nor by low peripheral 
muscle fatigue, which suggest a difference in the underlying physiological mechanism 
of postcancer fatigue versus other fatigue syndromes.
Introduction 
An estimated 19-39% of the cancer survivors suffer from persistent fatigue, long after 
finishing treatment.1-3 Postcancer fatigue is an invalidating problem, with profound 
effects on quality of life.4, 5 Previous studies have shown that cognitive behavior 
therapy (CBT), specifically designed for postcancer fatigue, is an effective treatment 
for severely fatigued cancer survivors.6 However, although it is now possible to 
effectively treat postcancer fatigue, the etiology remains unknown.
In medical literature, the term fatigue usually refers to fatigue experienced by the 
patient, but it can also refer to physiological fatigue. In physiology, fatigue is generally 
defined as the loss of voluntary force-producing capacity during exercise.7 Loss of 
force-producing capacity can have a peripheral and a central origin, because 
muscles do not function autonomically, but are activated by the nervous system.8 
 During peripheral muscle fatigue, a decrease in pH, accumulation of lactate, and 
changes in intra- and extracellular ion concentrations influence membrane excitability 
of muscle tissue.9 Multichannel surface electromyography (sEMG) can reveal the 
propagation velocity of an action potential over the muscle fiber, denoted as muscle 
fiber conduction velocity (MFCV). Under isometric conditions, MFCV is an indicator 
of peripheral fatigue.8 Another measure of peripheral fatigue is the decrease in 
muscular force response to artificial electrical stimulation from pre- to post-exercise. 
 Besides peripheral factors, a failure of drive from the central nervous system may 
also contribute to the loss of voluntary force-producing capacity during exercise.10 
Sub-maximal central activation during exercise, or central activation failure (CAF), is 
an indicator of central muscle fatigue8 and can be determined with a twitch interpolation 
technique.11 
Low peripheral muscle fatigue and high central muscle fatigue appear to be a shared 
neurophysiological feature of fatigue in patients with chronic fatigue syndrome (CFS)12 
and neuromuscular diseases13. It may be hypothesized that postcancer fatigue is 
also characterized by low peripheral muscle fatigue and high central muscle fatigue. 
The aims of this study were A) to examine whether peripheral and central muscle 
fatigue of severely fatigued and non-fatigued cancer survivors are different between 
both groups and B) to examine the effect of CBT on peripheral and central muscle 
fatigue of severely fatigued cancer survivors in a randomized controlled trial.
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Methods
Data collection
The local ethics committee of the Radboud University Nijmegen Medical Centre 
(RUNMC) approved the study and all participants provided written informed consent. 
In part A of the study severely fatigued and non-fatigued cancer survivors were 
compared (Figure 1). In part B of the study, severely fatigued cancer survivors were 
randomly assigned to either the intervention condition (CBT) or the waiting list 
condition (Figure 1). Fatigue severity was measured by the fatigue severity subscale 
of the Checklist Individual Strength (CIS-fatigue).14, 15 Severe fatigue was defined by a 
cut-off score of ≥35points.6, 16-18 Central activation failure, an indicator of central 
muscle fatigue, was measured using a twitch interpolation technique. MFCV, an 
indicator of peripheral muscle fatigue, was measured using sEMG. Both the twitch 
interpolation technique and sEMG were applied during a sustained contraction of the 
biceps brachii muscle. 
Participants
All participants had completed curative treatment of a malignant, solid tumor minimal 
one year earlier and had no evidence of disease recurrence. Patients with a 
co-morbidity that could explain fatigue, patients suffering from severe lymph edema, 
and patients that could not use their left arm extensively were excluded. The minimum 
age at disease onset was eighteen years and patients were no older than 65 years 
when entering the study. 
 Severely fatigued cancer survivors (n=66), who were referred for CBT to the 
Expert Centre for Chronic Fatigue of the RUNMC were asked for participation in the 
parallel-group randomized controlled trial (part B). Baseline measurements of 20 of 
the 66 fatigued cancer survivors were compared with 20 age- and sex-matched 
non-fatigued cancer survivors, recruited from the outpatient clinics of Medical 
Oncology and Radiation Oncology of the RUNMC (part A). Non-fatigued patients 
were assessed only once, at the RUNMC. Fatigued patients (n=64, 2 patients refused 
participation) were randomly 3:1 assigned to either the intervention condition (n=50) 
or the waiting list condition (n=14). Random assignment was done by means of a 
sequence of labeled cards contained in sealed, numbered envelopes prepared by a 
statistical adviser. The envelopes were opened by the psychologists in the presence 
of the patient. Patients randomized to the intervention condition were immediately 
treated with CBT as described previously.6 In six modules, CBT focused on six 
perpetuating factors of postcancer fatigue, including insufficient coping with the 
experience of cancer, fear of disease recurrence, dysfunctional cognitions concerning 
fatigue, dysregulation of sleep, dysregulation of activity, and low social support and 
negative social interactions. The therapy was tailored to the individual patient and the 
Figure 1   Flow chart of the study
Severely fatigued patients
referred for CBT and
eligible to enter study n=66
Refused participation n=2
Randomization
n=64
Part b
Intervention
condition n=50
Waiting list
condition n=14
Excluded from study n=2
Disease recurrence n=1
Incorrectly included n=1
Did not start CBT n=1
CBT drop-out n=3
CBT still ongoing n=14
-------------------------------------------------------
Contraindication n=1
Complete CBT
n=30
No follow-up measurements n=5
Refused follow-up measurements n=4
Contraindication n=1
Follow-up
measurements
n=25
Follow-up
measurements
n=13
Complete
Waiting list
n=14
Non-fatigued
patients n=20
Severely
fatigued
patients n=20
Useful follow-up
measurements
n=16
Technical failure at baseline and/or
follow-up n=9
CAF n=20
MFCV n=15
Part aMatched
CAF n=20
MFCV n=18
No follow-up measurements n=1
Contraindication n=1
Contraindication n=1
CAF n=16
MFCV n=11
Technical failure at baseline and/or
follow-up n=5
Useful follow-up
measurements
n=8
CAF n=8
MFCV n=6
Abbreviations: CAF: central activation failure; CBT: cognitive behavior therapy; 
MFCV: muscle fiber conduction velocity
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physiological limits.10 MFCV was expressed as a percentage of MFCV at the start of 
the sustained contraction.10 
Statistics
Statistical analyses were performed using PASW Statistics for Windows® (Armonk, 
New York, USA). Results are presented as absolute numbers, as mean ± standard 
deviation, as mean ± standard error of the mean, or as frequencies with percentages 
of total. Independent samples t tests were performed to compare differences between 
fatigued and non-fatigued patients and between the therapy and the waiting list 
condition. Change scores represent the percentage change from baseline to 
follow-up. Differences were considered statistically significant at p<0.05. The power 
calculation is described in the study protocol as published previously.19 
Results
Patient inclusion
The flow chart of the study is presented in Figure 1. Patients were recruited between 
March 2009 and October 2011. Of the 66 fatigued patients who were referred for CBT 
and who met the criteria of the study, baseline data of 20 patients were compared 
with data of 20 non-fatigued controls (part A). Seven patients of part A of the study 
(five fatigued and two non-fatigued patients) and seven patients of part B of the study 
(five patients in the therapy group and two patients in the waiting list group) were 
excluded from MFCV analysis, because their MFCVs exceeded the physiological limit 
of 8 m/s at least three times or at the first time point. In 14 patients, CBT is still ongoing 
and these patients are not included in the analyses of the randomized controlled trial 
(part B). Twenty-five patients completed both the baseline and follow-up measurements 
in the therapy group and thirteen patients in the waiting list group. Due to technical 
failure, nine measurements in the intervention condition could not be analyzed and 
five measurements in the waiting list condition failed. 
Study population
Baseline characteristics of 20 fatigued and 20 non-fatigued cancer survivors (part A) 
and of sixteen fatigued patients in the therapy condition and eight patients in the 
waiting list condition (part B) are presented in Table 1. 
Part A: Fatigued versus non-fatigued
There were no significant differences in central or peripheral muscle fatigue between 
fatigued and non-fatigued cancer survivors.
number of 50 minute sessions with the psychologist was determined by the number 
of modules used and whether the goal of the therapy was reached. Patients 
randomized to the waiting list condition waited six months for CBT. Both the 
intervention and the waiting list group were assessed twice, at baseline and after six 
months follow-up, at the RUNMC. 
Experimental design
The experimental design was previously set-up and applied by Schillings et al.10, 12 
Participants sat in a chair with their left arm fixed in a dynamometer in a horizontal 
position, the shoulder in abduction, the elbow in a right angle, and the forearm 
supinated. The force of elbow flexion was measured at the wrist. 
 A multi electrode array of five in line placed electrodes was used for sEMG 
measurements. The array was placed parallel to the fiber direction of the biceps 
brachii muscle, distal to the motor points. Force- and sEMG-data were synchronized 
by a custom-made time code generator.
 Electrical stimulation over the motor points of the biceps brachii muscle was 
applied with help of a bio-stimulator and using self-adhesive surface electrodes. The 
basic unit of stimulation was a stimulus train of five rectangular pulses. Five stimulus 
trains were combined to form a stimulus event (SE). 
Protocol
To obtain the maximal voluntary contraction (MVC) of the biceps brachii muscle, the 
subject performed MVCs, with one minute intervals, until no further increase in force 
was observed. After a rest period, initial force response to a SE was measured while 
the biceps brachii muscle was relaxed. Subsequent to this initial SE, participants 
performed a two minute sustained MVC of the biceps brachii muscle. During these 
two minutes, SEs were given every fifteen seconds, leading to superimposed force 
responses. Immediately after the sustained contraction, final force response to a SE 
was evoked while the biceps brachii muscle was relaxed. 
Data analysis
MVC values are the maximum force values before the two minute sustained 
contraction. Voluntary force was averaged over the two seconds prior to stimulation. 
Force responses upon stimulation during sustained contraction were corrected for 
changes of voluntary force via linear interpolation between the moment of stimulation 
and 325 ms thereafter. Subsequently, a correction was made for the influence of 
peripheral fatigue on the size of the superimposed force responses during sustained 
contraction, as described by Schillings et al. 
 sEMG values were averaged over the two seconds prior to stimulation. MFCV 
was determined from four out of five electrodes, unless MFCV was ≥8 m/s, based on 
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Central muscle fatigue 
Mean CAF values during the sustained contraction are presented in Figure 2C. CAF 
at the beginning and at the end of the sustained contraction and the slope of CAF 
during the sustained contraction did not significantly differ between fatigued and 
non-fatigued patients (Table 2). 
Force 
MVC before exercise and the initial force response to the SE in rest did not significantly 
differ between fatigued and non-fatigued patients (Table 2). Mean voluntary force 
values during the sustained contraction are presented in Figure 2A. Voluntary force 
at the beginning and at the end of the sustained contraction and the slope of voluntary 
force during the sustained contraction were not significantly different between 
fatigued and non-fatigued patients (Table 2). Final force response to the SE in rest did 
not significantly differ between fatigued and non-fatigued patients (Table 2). The 
force response to the SE in rest from pre- to post-exercise decreased significantly 
less in the fatigued compared to the non-fatigued patients (Table 2). 
Peripheral muscle fatigue 
Mean MFCV values during the sustained contraction are presented in Figure 2B. The 
initial absolute MFCV and the slope of MFCV during the sustained contraction were 
not significantly different between fatigued and non-fatigued patients (Table 2). 
Table 2   Results of fatigued and non-fatigued patients
Fatigued
(n=20)
Non-fatigued
(n=20)
p-value
Force (n=20) (n=20)
   MVC before exercise (N) 201.0 ± 115.1 241.7 ± 128.7 0.298
   Initial rest twitch force (N) 9.4 ± 3.1 10.7 ± 3.7 0.242
   Force t=0 (N) 158.1 ± 99.1 192.6 ± 103.4 0.288
   Force t=120 (N) 94.2 ± 43.1 117.9 ± 52.0 0.125
   Slope voluntary force (N/s) -0.50 ± 0.54 -0.60 ± 0.53 0.554
   Final rest twitch force (N) 6.4 ± 2.8 5.8 ± 2.4 0.496
   Change in rest twitch force (%) -30.7 ± 24.0 -44.5 ± 14.8 0.036
MFCV (n=15) (n=18)
   MFCV t=0 absolute (m/s) 4.7 ± 1.0 4.4 ± 0.8 0.303
   Slope MFCV (%/s) -0.16 ± 0.24 -0.20 ± 0.24 0.620
CAF (n=20) (n=20)
   CAF t=0 19.1 ± 15.3 18.5 ± 16.0 0.913
   CAF t=120 39.0 ± 19.2 40.0 ± 32.9 0.905
   Slope CAF (%/s) 0.14 ± 0.14 0.15 ± 0.26 0.857
Data are presented as mean ± standard deviation. Abbreviations: CAF: central activation failure; 
MFCV: muscle fiber conduction velocity; MVC: maximal voluntary contraction.
Figure 2   Voluntary force (A), muscle fiber conduction velocity (MFCV, B), and 
central activation failure (CAF, C) during a 2-minute sustained maximal 
voluntary contraction of the biceps brachii muscle of severely fatigued 
and non-fatigued disease-free cancer survivors. 
Data are presented as mean ± standard error of the mean.
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Part B: Cognitive behavior therapy versus waiting list
Patients who underwent CBT, with a mean of 12.2 ± 6.1 individual sessions, reported 
a significantly larger change in fatigue scores than patients who waited six months for 
CBT (p=0.014, respectively -47.6 ± 27.5% and -16.1 ± 27.0%), but neither CBT nor six 
months of waiting for CBT had a significant effect on peripheral or central muscle 
fatigue.
Force
The change score of MVC before exercise and of the initial force response to the SE 
in rest were not significantly different between patients in the therapy and the waiting 
list group (Table 3). Mean voluntary force values during the sustained contraction of 
patients in the therapy and the waiting list condition, both at baseline and follow-up, 
are presented in Figure 3A and 3B. The change score of voluntary force at the 
beginning and at the end of the sustained contraction and the change score of the 
slope of voluntary force during the sustained contraction did not significantly differ 
between the therapy and the waiting list group (Table 3). The change score of the final 
force response to the SE in rest and the change in force response to the SE in rest 
from pre- to post-exercise were not significantly different between the therapy and the 
waiting list group (Table 3). 
Peripheral muscle fatigue
Mean MFCV values during the sustained contraction of patients in the therapy and 
the waiting list condition, both at baseline and follow-up, are presented in Figure 3C 
and 3D. The change score of the initial absolute MFCV and the change in slope of 
MFCV during the sustained contraction did not significantly differ between patients in 
the therapy and the waiting list condition (Table 3). 
Central muscle fatigue 
Mean CAF values during the sustained contraction of patients in the therapy and the 
waiting list condition, both at baseline and follow-up, are presented in Figure 3E and 
3F. The change score of CAF directly at the beginning and at the end of the sustained 
contraction and the change in slope of CAF during the sustained contraction were 
not significantly different between the therapy and the waiting list group (Table 3). 
Figure 3   Voluntary force (A-B), muscle fiber conduction velocity (MFCV, C-D), 
and central activation failure (CAF, E-F) during a 2-minute sustained 
maximal voluntary contraction of the biceps brachii muscle of severely 
fatigued disease-free cancer survivors, in the therapy (A, C, and E) 
and the waiting list condition (B, D, and F), both at baseline and 
follow-up
Data are presented as mean ± standard error of the mean. Abbreviations: CBT: cognitive behavior 
therapy; WL: waiting list.
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Possibly, muscle fatigue is not the physiological factor explaining the difference 
between fatigued and non-fatigued cancer survivors, but is different between cancer 
patients (during and after treatment) and healthy controls. Both studies investigated 
the force of elbow flexion, but in the present study the shoulder was in abduction and 
in the palliative cancer patient study the shoulder was in adduction during sustained 
contraction. As mentioned by Schillings et al, our method does not distinguish 
between force produced by the biceps brachii muscle and force produced by other 
elbow flexors. Although the forearm was supinated, which favors the use of the biceps 
brachii muscle, additional activity of other muscles cannot be excluded. Possibly, the 
force production in the present study and in the study of palliative cancer patients 
was not exactly the same. However, both studies stimulated only the biceps brachii 
muscle for the determination of central muscle fatigue. Patients in the present study 
made a 2-minute sustained maximal voluntary contraction, whereas patients in the 
palliative study performed a voluntary sustained contraction until exhaustion at 30% 
of maximal elbow flexion force. Both studies used the twitch interpolation technique 
as a valid technique to estimate voluntary force production. However, this technique 
should be applied with care. At near maximum contraction intensities, the sensitivity 
is relatively low.21 Probably, the sensitivity of the twitch interpolation technique was 
higher in the study in patients during palliative cancer treatment compared to the 
present study in cancer survivors. 
Of note, the (non-significant) difference in voluntary force production between 
fatigued and non-fatigued patients could not be explained by a difference in CAF. 
Possibly, disuse of the biceps brachii muscle could play a role in fatigued patients. It 
may be hypothesized that during cancer treatment, patients used their muscles less 
intensively, resulting in decreased voluntary force due to muscle atrophy. Muscle 
ultrasound, a non-invasive and real-time technique to visualize normal and 
pathological muscle tissue,22 might be used in additional investigations to measure 
possible differences in muscle diameter between fatigued and non-fatigued cancer 
survivors.
The number of patients might have been relatively small, although the power of the 
study was sufficiently high to demonstrate a significantly larger decrease in fatigue 
severity in patients in the therapy group compared to patients in the waiting list group. 
The patient groups included in this study was rather heterogeneous in terms of tumor 
types and treatment. There is some evidence that cancer survivors who underwent 
surgery only are less at risk for postcancer fatigue,18 while survivors who were treated 
with more aggressive cancer treatments are more at risk for postcancer fatigue.1, 23 
However, the intensity of treatment (surgery only versus surgery+(neo)adjuvant 
therapy) was more or less equally distributed in both groups. Of note, previous 
Discussion
To the best of our knowledge, this is the first study to report on central and peripheral 
muscle fatigue in severely fatigued and non-fatigued disease-free cancer survivors. 
The hypothesized high central muscle fatigue and low peripheral muscle fatigue, a 
shared neurophysiological feature of fatigue in diseases such as CFS and neuro -
muscular disorders, could not be demonstrated in patients with postcancer fatigue. 
 Central muscle fatigue was comparable in fatigued and non-fatigued cancer 
survivors. Force response to the SE in rest from pre- to post-exercise decreased 
significantly less in the fatigued compared to the non-fatigued patients, indicating 
lower peripheral muscle fatigue in postcancer fatigue. However, the (absolute) MFCV 
at the start of the test and the line describing MFCV over time (slope), do not point to 
lower peripheral muscle fatigue in fatigued compared to non-fatigued cancer 
survivors.
 In addition, this is the first randomized controlled trial examining the effect of 
fatigue reduction by CBT on central and peripheral muscle fatigue in severely fatigued 
cancer survivors. As has been shown before,6 CBT resulted in a significantly larger 
decrease in fatigue severity compared to a period of waiting for therapy. However, the 
change scores of peripheral and central muscle fatigue from baseline to follow-up 
were not significantly different between the therapy and the waiting list condition.
 
Neurophysiological fatigue has been studied in patients with CFS,12 in patients with 
neuromuscular diseases,13 and in cancer patients referred to palliative care20 In a 
study of fourteen CFS patients and fourteen healthy controls, MFCV and CAF were 
investigated in the course of a sustained MVC of the biceps brachii muscle.12 CFS 
patients showed significantly less peripheral muscle fatigue and significantly more 
central muscle fatigue than controls. These results are in line with the results of a 
study in 217 patients with a neuromuscular disorder.13 Peripheral fatigue was smaller 
in patients compared to controls and patients showed a large CAF. In a study of 
sixteen cancer patients referred to palliative care and sixteen non-cancer controls, 
neuromuscular testing was applied to determine whether cancer-related fatigue is a 
more centrally or peripherally mediated disorder.20 Patients suffering from 
cancer-related fatigue showed less peripheral muscle fatigue and more central 
muscle fatigue compared to their non-fatigued controls. 
 Differences between the study investigating palliative cancer patients and the 
present study include the patient and control group, the kind of contraction and the 
intensity of the contraction. The present study consisted of cancer survivors, both in 
the patient and the control group, and found no differences in primary outcome 
measures between both groups. Palliative cancer patients showed more central 
muscle fatigue and less peripheral muscle fatigue compared to healthy controls. 
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disease or treatment characteristics are supposed to be unrelated to postcancer 
fatigue.24-29
Conclusion
Postcancer fatigue is neither characterized by abnormally high central muscle fatigue 
nor by low peripheral muscle fatigue. These findings suggest different underlying 
physiological mechanisms for postcancer fatigue versus other fatigue syndromes. 
Fatigue reduction by CBT had no effect on peripheral or central muscle fatigue. 
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Abstract
The aim of this study was to compare humoral and cellular immune responses upon 
influenza vaccination in fatigued and non-fatigued cancer survivors. 
Comparable humoral immune responses were observed in fatigued and non-fatigued 
patients, both pre- and post-vaccination. At baseline, fatigued patients showed a 
significantly diminished cellular proliferation upon stimulation with virus-strain H3N2, 
and a trend in the same direction with virus-strain H1N1, compared to non-fatigued 
patients. The percentage of regulatory T lymphocytes was significantly increased 
and significantly lower amounts of interleukin-2 were detected prior to vaccination in 
fatigued compared to non-fatigued patients. Pre-vaccination heat-shock protein 90 
concentrations, post-vaccination cellular proliferation, and post-vaccination cytokine 
concentrations did not differ between both groups. 
Fatigued cancer survivors mount a protective antibody response and a sufficient 
cellular immune response upon a single shot of influenza vaccine, which is 
comparable to non-fatigued cancer survivors. However, compared to non-fatigued 
cancer survivors, fatigued cancer survivors showed several significant differences in 
immunological reactivity at baseline, which warrants further investigation.
Background
One of the long-term problems cancer survivors are facing is postcancer fatigue. 
Postcancer fatigue is a frequently occurring, severe, and invalidating problem, impairing 
quality of life.1, 2 During cancer treatment, an estimated 70-96% of the patients 
experience symptoms of fatigue.3, 4 The prevalence of postcancer fatigue observed in 
longitudinal studies ranged from 19-39%.5-9 Previous disease and treatment character-
istics are unrelated to postcancer fatigue.4, 10-14 However, there is some evidence that 
patients who are treated with surgery only have a decreased risk for postcancer fatigue9 
and patients who are treated with more aggressive treatments are more at risk for 
postcancer fatigue.5, 15 Cognitive behaviour therapy (CBT), specifically designed for 
postcancer fatigue, is an effective treatment option for postcancer fatigue.12, 16 However, 
the nature of the underlying physiology of postcancer fatigue remains unclear.
 Hypotheses explaining the pathophysiological mechanism of cancer-related fatigue 
include dysregulation of brain serotonin, dysregulation of the hypothalamic-pituitary- 
adrenal axis responsiveness, disruption of the circadian rhythm, alterations in muscle and 
ATP metabolism, activation of the vagal afferent nerve, and dysregulation of cytokines 
(for a review, see Ryan et al 200717, and for a meta-analysis, see Schubert et al 200718). 
 Furthermore, the presence of an immunological distortion has been suggested as 
an explanation for postcancer fatigue. Activation of the immune system, as a response 
to the tumour or its treatment, leads to the release of cytokines and other immune 
factors, including receptor antagonists, soluble receptors, and products of cellular 
activation.19 Cytokines are steering both the innate and adaptive immune response, but 
also mediate neural symptoms such as fatigue.20 Alterations in pro-inflammatory 
cytokines have been observed in fatigue-related disorders, such as depression and 
chronic fatigue syndrome.21, 22 Most of these changes in immune parameters resolve 
following completion of cancer treatment, but a disbalance in the immune system 
might persist, which could explain symptoms of fatigue. 
 If so, postcancer fatigue patients might have an altered response to vaccination. 
Therefore, the aim of this study was to compare the humoral and cellular immune 
responses upon vaccination, using seasonal influenza vaccination as a representative 
vaccination, in severely fatigued and non-fatigued disease-free cancer survivors.
Methods
Participants
The study population consisted of a group of severely fatigued (n=15) and a group of 
non-fatigued cancer survivors (n=12). Fatigue severity was measured using the 
fatigue severity subscale of the Checklist Individual Strength (CIS-fatigue).23, 24 The 
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virus-strains reached the criteria for seroprotection, partially protected when having 
protective titres to only one or two virus-strains, and non-protected when titres to all 
three virus-strains were below 1:40. Post-vaccination seroresponse was defined as at 
least a four-fold increase in titre.29 
Cellular immune response
The cellular immune responses were measured by T lymphocyte proliferation and 
cytokine secretion of PBMC collected at day 1 and 8, the presence of regulatory T 
lymphocytes (Treg) at day 1, and the concentration of human heat shock protein 90 
alpha (HSP90α) at baseline. 
 Cells were simultaneously thawed. For analysis of lymphocyte proliferation and 
cytokine secretion, 1.5x105 PBMC were added per well of a 96-wells plate in culture 
medium (RPMI 1640 (Cambrex Bio Science, Verviers, Belgium) supplemented with 
4% human serum albumin). In the proliferation assay, PBMC were incubated with 1μg/
ml phytohemagglutinin (PHA) and with a 1:10 dilution of the separate virus-strains (A/
H3N2/Perth/25/11/2008, A/H1N1/California/01/2010, and B/Florida/05/11/2008). After 
48 hours of culture, supernatant was harvested to analyze cytokine production. Part 
of the Th1/Th2 11plex kit (eBioscience, San Diego, CA) was used according to the 
manufacturer’s protocol in order to measure interleukin-2 (IL-2) and interleukin-10 
(IL-10) at day 1 and interferon gamma (IFN-γ), interleukin-4 (IL-4), and interleukin-5 
(IL-5) at day 8. After four days of culture, 1 μCi 3[H]-thymidine (MP Biomedicals, Santa 
Ana, California, USA) was added to each well for 8 hours of incubation to measure T 
lymphocyte proliferation. 
 Multi-colour flow cytometric analyses were performed on unstimulated PBMC 
collected at day 1 according to the manufacturer’s protocol. Cells were stained for 
surface antigens anti-CD4/FITC (Beckman Coulter, Woerden, the Netherlands), 
anti-CD25/PE-Cy7 (BD Biosciences, Breda, the Netherlands), and anti-CD127/PE 
(BD Bioscience), fixed and permeabilized prior to staining with anti-FOXP3/APC 
(clone PCH101, eBioscience). Treg were defined as CD4+CD25+CD127-FOXP3+ 
cells and calculated as a percentage of all CD4+ cells. Data were analyzed using 
FlowJo software (Treestar). 
 HSP90α concentrations were detected in serum collected at baseline, using a 
colorimetric, immunometric enzyme immunoassay kit according to the manufacturer’s 
protocol (Enzo Life Sciences, Antwerpen, Belgium).
Statistics
Statistical analyses were performed using PASW for Windows®, version 18.0.2 
(Armonk, New York, USA) and Prism, version 4.0 (San Diego, California, USA). 
Independent samples t tests were performed to assess differences in numerical 
variables at day 1, 8, and 22. Paired t tests were used to assess changes in numerical 
CIS-fatigue was used in previous research investigating fatigue in cancer patients 
and was shown to be a sensitive parameter to detect changes.9, 16, 25, 26 A cut-off score 
of ≥35 points on this subscale is an indicator for severe fatigue. Severely fatigued 
patients who were referred for CBT for postcancer fatigue to the Expert Centre for 
Chronic Fatigue of the Radboud University Nijmegen Medical Centre (RUNMC) were 
asked for participation. Non-fatigued patients (score of <27 points on the CIS-fatigue 
scale) were recruited from the outpatient clinics of Medical Oncology and Radiation 
Oncology of the RUNMC. All participants were between 18 and 60 years old, used no 
corticosteroids during the previous two weeks, did not have an immune disorder or 
allergy to chicken eggs, and had no symptoms of influenza or an influenza-like illness 
on the day of the vaccination. For each patient, the oncological treatment history was 
retrieved from the medical chart. The local ethics committee of the RUNMC approved 
the study and all participants provided written informed consent.
Vaccination and blood collection
Between September 2010 and January 2011, all participants visited the outpatient 
ward of Medical Oncology of the RUNMC and were intramuscularly vaccinated with 
a single dose of the inactivated trivalent split influenza vaccine (VaxigripR, Sanofi 
Pasteur MSD, Hoofddorp, the Netherlands), which contained inactivated, split virion 
of the three influenza strains (A/H3N2/Perth/16/2009, A/H1N1/California/7/2009, and 
B/Brisbane/60/2008). 
 Peripheral blood mononuclear cells (PBMC) were collected at baseline (day 1) 
and seven days after vaccination (day 8). PBMC were isolated from heparinized 
venous blood by density-gradient centrifugation on lymphoprepTM (Axis-Shield PoC 
AS, Oslo, Norway) and cells were frozen using a cryo 1oC freezing container (Nalgene, 
Rochester, New York, USA) in freezing medium (49% X-VIVO15 (Lonza, Verviers, 
Belgium), 1% human serum (Sanquin blood bank, Nijmegen, the Netherlands), 40% 
human serum albumin (Albuman; Sanquin blood bank), and 10% DMSO (Cryo Sure; 
Wak Chemie Medical GMBH, Steinbach, Germany)). After 24h in a freezing container 
at -80oC, PBMC were stored in liquid nitrogen until analysis.
 Serum was collected at baseline and 21 days after vaccination (day 22).27 Serum 
samples were stored at -80oC until analysis. 
Humoral immune response
The humoral immune responses on influenza vaccination were measured in serum 
by the hemagglutination-inhibition (HI) antibody test as described previously.28 The 
virus antibody responses were measured at day 1 and day 22 for the three individual 
influenza strains of the vaccine (A/H3N2/Perth/16/2009, A/H1N1/California/01/2010, 
and B/Florida/004/2006). Seroprotection was defined as an antibody titre of at least 
1:40.28, 29 Participants were considered fully protected if the titres to all three 
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cancer survivors in terms of sex, age, average time since cancer treatment, and 
history of influenza vaccination. 
Humoral immune responses in postcancer fatigue upon influenza 
vaccination 
Participants were vaccinated against seasonal influenza. Pre- and post-vaccination, 
humoral immune responses were measured in serum by the HI antibody test. 
Comparable HI antibody titres were observed in fatigued and non-fatigued patients, 
variables from pre- to post-vaccination. Chi-square tests were performed to compare 
groups on categorical variables. Differences were considered statistically significant 
at p<0.05.
Results
Baseline characteristics of the participants
Baseline characteristics of the participants are presented in Table 1. The group 
suffering from postcancer fatigue did not significantly differ from the non-fatigued 
Table 1   Baseline characteristics
Postcancer
fatigue (n=15)
No postcancer
fatigue (n=12)
p-value
Sex
   Male
   Female 
7 (47)
8 (53)
5 (42)
7 (58)
0.795
Age (years)
   Mean 
 
49.6±11.9 48.8±9.1 0.856
Cancer diagnosis
   Breast cancer
   Testicular cancer
   Melanoma
   (Non)Hodgkin
   Other
7 (47)
1 (7)
2 (13)
2 (13)
3 (20)
7 (58)
3 (25)
1 (8)
1 (8)
0
Cancer treatment
   Surgery only
   Surgery and chemotherapy
   Surgery and radiotherapy
   Surgery, chemotherapy, and radiotherapy
   Surgery, chemotherapy, radiotherapy, 
   and hormonal therapy
   Chemotherapy only
   Chemotherapy and radiotherapy
   Chemotherapy and immunotherapy
3 (20)
2 (13)
2 (13)
2 (13)
3 (20)
1 (7)
1 (7)
1 (7)
1 (8)
3 (25)
2 (17)
3 (25)
2 (17)
0
1 (8)
0
Time since cancer treatment (months) 66.8±84.9 64.4±32.2 0.928
Influenza vaccination prior to 2010
   Yes
   No
5 (33)
10 (67)
2 (17)
10 (83)
0.326
Data are presented as mean ± standard deviation or as frequencies with percentages in brackets.
Figure 1   Hemagglutination inhibition (HI) antibody responses before (day 1) 
and after (day 22) influenza vaccination, and cellular proliferation 
before (day 1) and after (day 8) influenza vaccination. Both immune 
responses are presented for the three influenza strains of the vaccine 
(H3N2, H1N1, and B), in fatigued (A and C) and non-fatigued (B and 
D) cancer survivors
Antibody titres are presented as absolute numbers and mean (horizontal lines) on a linear scale, the 
dotted line indicates the protective titre cut-off value. Proliferation counts are presented as absolute 
numbers and mean (horizontal lines) on a logarithmic scale.
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both pre- and post-vaccination. Vaccination induced a significant increase in HI 
antibody titres for influenza strains H3N2 and H1N1 in patients suffering from 
postcancer fatigue as well as in non-fatigued patients (Figure 1A and 1B). Fatigued 
and non-fatigued patients demonstrated similar seroprotection rates (both pre- and 
post-vaccination) and similar seroresponse rates against all three virus-strains (Table 2). 
The number of fatigued and non-fatigued patients without a humoral response to the 
influenza vaccination was not significantly different (Table 2). 
Cellular immune responses in postcancer fatigue upon influenza 
vaccination
Prior to vaccination
T cells proliferated upon PHA and influenza virus stimulation in both patient groups, 
indicating the presence of functional T cells (Figure 1C and 1D and Table 2). At 
baseline, postcancer fatigue patients showed a significantly diminished cellular 
proliferation upon stimulation with virus-strain H3N2, and a trend in the same direction 
upon stimulation with virus-strain H1N1, compared to non-fatigued controls (Table 2). 
 To investigate the cytokine secretion of PBMC at baseline, IL-2 and IL-10 
concentrations were measured. We detected significantly less IL-2 in patients suffering 
from postcancer fatigue compared to non-fatigued patients upon stimulation with 
virus-strains H3N2 and H1N1, whereas detected IL-10 concentrations did not 
significantly differ between both groups (Table 2). 
 Treg, which are known to negatively modify T cell responses, were measured at 
baseline. Compared to non-fatigued controls, the percentage of Treg was significantly 
increased at baseline in postcancer fatigue patients (Table 2). 
 To test our hypothesis that impaired HSP90α functioning resulted in Treg 
accumulation, HSP90α concentrations were measured in serum at baseline. Human 
HPS90α concentrations were not significantly different between patients suffering 
from postcancer fatigue and non-fatigued patients (Table 2).
 In postcancer fatigue patients, the percentage of Treg correlated significantly 
with cellular proliferation upon stimulation with virus-strain H3N2 (p=0.015), H1N1 
(p=0.031), and B (p=0.005). Also, the percentage of Treg correlated significantly with 
IL-2 concentrations upon stimulation with virus-strain H3N2 (p=0.017) and H1N1 
(p=0.001) in fatigued patients, but not upon stimulation with virus-strain B (p>0.05). 
Non-fatigued patients showed no significant correlation between the percentage of 
Treg and cellular proliferation or between Treg and IL-2 concentrations (p>0.05).
Post-vaccination
The cellular immune responses upon influenza vaccination were measured at day 8 
by T lymphocyte proliferation and cytokine secretion of PBMC. Post-vaccination 
cellular proliferation did not significantly differ between fatigued and non-fatigued 
Table 2   Humoral and cellular immune responses
Postcancer 
fatigue (n=15)
No postcancer
fatigue (n=12)
p-value
Seroprotection rate baseline 
(day 1)
 H3N2
 H1N1
 B
 H3N2, H1N1, and B 
Seroprotection rate post-vaccination 
(day 22)
 H3N2
 H1N1
 B
 H3N2, H1N1, and B 
Seroresponse rate post-vaccination 
(day 1 to 22)
 H3N2
 H1N1
 B
 H3N2, H1N1, and B
11 (55)
2 (13)
10 (67)
1 (7) 
12 (80)
12 (80)
13 (87)
11 (55) 
8 (53)
10 (67)
3 (20)
2 (13)
6 (50)
4 (33)
5 (42)
2 (17) 
12 (100)
10 (83)
8 (67)
7 (58) 
6 (50)
8 (67)
3 (25)
0 (0)
0.212
0.214
0.194
0.411
0.100
0.825
0.214
0.411
0.863
1.000
0.756
0.189
Proliferation upon stimulation PHA 
(counts)
 Baseline (day 1)
 Post-vaccination (day 8) 
Proliferation upon stimulation H3N2 
(counts)
 Baseline (day 1)
 Post-vaccination (day 8) 
Proliferation upon stimulation H1N1 
(counts)
 Baseline (day 1)
 Post-vaccination (day 8) 
Proliferation upon B (counts)
 Baseline (day 1)
 Post-vaccination (day 8) 
24736±22830
22286±15944
1414±1201
2852±3241
3025±2339
4560±5004
2311±1622
3253±3336
22007±9415
28733±18939
3099±2401
3755±4742
5877±4604
5944±6458
3551±2389
4685±5809
0.702
0.356
0.042
0.569
0.069
0.561
0.121
0.434
IL-2 production at baseline 
(day 1, pg/ml)
 H3N2
 H1N1
 B
IL-10 production at baseline 
(day 1, pg/ml)
 H3N2
 H1N1
 B 
Treg at baseline (day 1, %)
 Unstimulated
36.3±44.3
28.4±44.0
37.0±50.9
2.7±5.0
50.0±43.2
34.6±80.3
4.4±2.1
94.0±45.4
74.5±56.1
53.1±55.3
6.3±10.6
55.2±35.5
20.6±14.0
2.4±0.8
0.003
0.030
0.439
0.286
0.736
0.560
0.033
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Postcancer fatigue patients are able to mount a protective antibody response and a 
sufficient cellular immune response upon a single shot of influenza vaccine, which is 
comparable to non-fatigued controls. However, interestingly, compared to 
non-fatigued patients, patients suffering from postcancer fatigue showed significant 
differences in pre-vaccination cellular immune responses.
 We observed that, in comparison to non-fatigued patients, the T cell capacity to 
proliferate was significantly diminished at baseline in fatigued patients upon 
stimulation with virus-strain H3N2, and a trend in the same direction for virus-strain 
H1N1. To investigate this finding in more detail, we studied two immunological 
mechanisms commonly known to suppress T cell immunity. First, the baseline 
production of the immunosuppressive cytokine IL-10, which is able to inhibit T cell 
proliferation30, was assessed. However, baseline IL-10 production was similar in 
fatigued and non-fatigued patients. Secondly, since Treg are known to negatively 
modify T cell responses, we examined pre-vaccination Treg percentages.31 Indeed, 
the percentage of Treg was significantly increased at baseline in postcancer fatigue 
patients, compared to non-fatigued controls, and could not be explained by a 
difference in the number of lymphocytes between both patient groups (data not 
shown). This finding could explain the diminished cellular proliferation in fatigued 
patients compared to non-fatigued patients at baseline. 
 Consistent with the increase in Treg, the baseline production of IL-2, which drives 
T cell growth32, is decreased in fatigued compared to non-fatigued patients. The 
reduction in IL-2 levels is likely the result of IL-2 consumption by Treg33, thereby driving 
their expansion.
 We hypothesized that impaired HSP90α functioning in patients suffering from 
postcancer fatigue resulted in Treg accumulation. Treg accumulation might lead to 
the development of functional somatic syndromes, like chronic fatigue syndrome.34 
HSP90 is highly up regulated during cell stress,35 which occurs as a result of cancer 
or its subsequent treatment modalities, and HSP90 is involved in controlling the 
functions of FoxP3+ Treg.36 Unfortunately, this hypothesis could not be confirmed by 
our data, as fatigued and non-fatigued patients did not significantly differ in baseline 
HSP90α concentrations in serum. 
 Probably, as the influenza virus slightly changes every season, both patient 
groups lacked Treg directed against the new epitopes of the influenza virus strains, 
since both groups showed a normal level of proliferation when stimulated with the 
new viral strains. It was observed that post-vaccination T cell proliferation and IL-2 
production did not significantly differ between fatigued and non-fatigued patients 
(data not shown). We hypothesize that in particular patients suffering from postcancer 
fatigue will expand the percentage of Treg directed to the new epitopes of the 
influenza virus after vaccination. Upon rechallenge with the new virus strains after 
vaccination the proliferation in the fatigued patients should be lower compared to 
patients (Table 2). IFN-γ, IL-4, and IL-5 production were not significantly different 
between both patient groups after stimulation with any of the three influenza 
virus-strains (Table 2). 
 There is no significant correlation (p>0.05) between pre-existing strain-specific 
antibody titres or cellular proliferation and post-vaccination strain-specific antibody 
titres or cellular proliferation, neither in fatigued, nor in non-fatigued patients (data not 
shown).
Discussion
To the best of our knowledge, we are the first to explore both the humoral and cellular 
immune responses after influenza vaccination in patients suffering from postcancer 
fatigue. The hypothesized immunological aberrancy claimed to be operative in 
postcancer fatigue could be confirmed by our data, as patients suffering from 
postcancer fatigue show several significant differences in immunological reactivity at 
baseline, compared to non-fatigued patients.
Table 2  Continued
Postcancer 
fatigue (n=15)
No postcancer
fatigue (n=12)
p-value
IFN-γ production post-vaccination 
(day 8, pg/ml)
 H3N2
 H1N1
 B
IL-4 production post-vaccination 
(day 8, pg/ml)
 H3N2
 H1N1
 B 
IL-5 production post-vaccination 
(day 8, pg/ml)
 H3N2
 H1N1
 B
167.9±216.8
288.7±343.6
326.4±450.4
< detection limit
2.2±8.5
2.8±10.8
5.5±9.9
4.9±8.7
0.7±2.6
142.6±253.0
256.6±308.4
142.4±252.1
3.0±9.9
< detection limit
< detection limit
3.9±8.7
1.0±2.5
< detection limit
0.787
0.808
0.199
0.341
0.403
0.403
0.672
0.121
0.384
HSP90α expression at baseline 
(day 1, ng/ml)
37±17 41±12 0.530
Data are presented as absolute numbers with percentages in brackets or as mean ± standard error of 
the mean.
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non-fatigued patients, since we observed this also before vaccination. Such a 
mechanism should be operative to explain the increased baseline percentage of Treg 
in fatigued compared to non-fatigued patients. This would imply that patients suffering 
from postcancer fatigue have to invest more energy in handling common assaults 
exerted on the organism, leading to less energy available for other tasks of the 
organism, possibly explaining their fatigue. In contrast, cancer survivors who are able 
to handle the immune response to recurrent immunological challenges more 
efficiently may suffer less from fatigue. In fact, this hypothesized difference in Treg 
expansion in response to influenza vaccination between fatigued and non-fatigued 
patients could be based on detected polymorphisms in the FoxP3 gene that affect 
the expression level of FoxP3+ Treg. Polymorphims found in the FOXP3 gene in 
human can cause immune dysregulation, polyendocrinopathy, enteropathy, and 
X-linked syndrome.37 FoxP3 polymorphisms that occur with a high frequency in the 
general population have been studied in common multifactorial human diseases,37 
but not in postcancer fatigue, which warrants further investigation. 
In conclusion, putative aberrations in immune responses in postcancer fatigue 
patients were evident for immunological reactivity at baseline. We show comparable 
humoral and cellular immune responses upon a single shot of influenza vaccine in 
fatigued and non-fatigued patients. Therefore, seasonal influenza vaccination is 
justified and should be recommended for patients suffering from postcancer fatigue, 
when indicated. However, compared to non-fatigued cancer survivors, postcancer 
fatigue patients showed several significant differences in immunological reactivity at 
baseline, which are subject to further investigation.
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Abstract
Chronic fatigue syndrome (CFS) is a clinical condition characterized by severe and 
disabling fatigue that is medically unexplained and lasts longer than six months. 
Although it is possible to effectively treat CFS, the nature of the underlying physiology 
remains unclear. Various studies have sought evidence for an underlying disturbance 
in immunity. The aim of this study was to compare the humoral and cellular immune 
responses upon influenza vaccination in CFS patients and healthy controls.
Identical antibody titers were observed in CFS patients and healthy controls. Patients 
and controls demonstrated similar seroprotection rates against all three virus-strains 
of the influenza vaccine, both pre- and post-vaccination. Functional T cell reactivity 
was observed in both CFS patients and healthy controls. CFS patients showed a 
non-significant, numerically lower cellular proliferation at baseline compared to 
controls. Vaccination induced a significant increase in cellular proliferation in CFS 
patients, but not in healthy controls. Cytokine production and the number of regulatory 
T cells were comparable in patients and controls.
The humoral and cellular immune responses upon influenza vaccination were 
comparable in CFS patients and healthy controls. Putative aberrations in immune 
responses in CFS patients were not evident for immunity towards influenza. Standard 
seasonal influenza vaccination is thus justified and, when indicated, should be 
recommended for patients suffering from CFS.
Background
Chronic fatigue syndrome (CFS) is a clinical condition characterized by severe and 
disabling fatigue that is medically unexplained and lasts longer than six months.1 The 
estimated worldwide prevalence of CFS is 0.4-1%.2 The existing evidence suggests 
that cognitive behavior therapy (CBT), specifically designed for CFS, is an effective 
treatment option.3-10 However, although it is possible to effectively treat CFS, the 
nature of the underlying pathophysiology remains unclear. 
 Hypotheses explaining the pathophysiological mechanism of CFS include 
morphological and metabolic alterations in the brain,11-17 diminished central activation 
of muscles,18 altered central nervous system functioning,2 a neuroendocrine 
disturbance,2 or cognitive impairment.2 Furthermore, the presence of an underlying 
immunological problem has been suggested as an explanation for CFS.2 Cytokine 
dysregulation, decreased natural killer cell functioning, the presence of autoantibodies, 
and a reduced response of T cells to mitogens and other specific antigens have been 
reported in CFS.2, 19, 20 If immunity is disturbed in CFS patients, they might have an 
altered response to vaccination. Vaccines, accompanying adjuvants, and silicone 
breast implants could act in concert in the development of CFS.2, 19-21 Therefore, the 
aim of this study was to compare the humoral and cellular immune responses upon 
vaccination, using seasonal influenza vaccination as a model of a vaccination, in CFS 
patients and healthy controls.
Methods
Participants
The study population consisted of a group of CFS patients (n=20) and a group of 
healthy controls (n=20). CFS patients fulfilled the Centre for Disease Control and 
prevention criteria for CFS1 and were referred for CBT to the Expert Centre for Chronic 
Fatigue of the Radboud University Nijmegen Medical Centre (RUNMC). CFS patients 
were asked to bring a gender- and age-matched non-fatigued friend as a control. 
Fatigue severity was measured by the fatigue severity subscale of the Checklist 
Individual Strength (CIS-fatigue).22, 23 A cutoff score of ≥35 points on this subscale 
indicates severe fatigue and a score of <27 points signifies normal fatigue feelings. 
All participants were between 18 and 60 years old. The local ethics committee of the 
RUNMC approved the study and all participants provided written informed consent.
Vaccination and blood collection
Between September 2010 and January 2011, all participants were intramuscularly 
vaccinated with a single dose of the inactivated trivalent split influenza vaccine 
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Statistics
Statistical analyses were performed using PASW for Windows®, version 18.0.2 
(Armonk, New York, USA). Independent samples t tests were performed to assess 
differences in numerical variables at day 1, 8, and 22. Paired t tests were used to 
assess changes in numerical variables from pre- to post-vaccination. Chi-square 
tests were performed to compare groups on categorical variables. Differences were 
considered statistically significant at p<0.05.
Results
Baseline characteristics
Baseline characteristics of the participants are presented in Table 1. 
(VaxigripR, Sanofi Pasteur MSD, Hoofddorp, the Netherlands), which contained 
inactivated, split virion of the three influenza strains (A/H3N2/Perth/16/2009, A/H1N1/
California/7/2009, and B/Brisbane/60/2008). 
 Peripheral blood mononuclear cells (PBMC) were collected at baseline (day 1) 
and 7 days after vaccination (day 8), and serum was collected at baseline and 21 
days after vaccination (day 22).24 
Humoral immune response
The humoral immune responses on influenza vaccination were measured in serum 
by the hemagglutination-inhibition (HI) antibody test as described previously.25 The 
virus antibody responses were measured at day 1 and day 22 for the three different 
influenza strains of the vaccine (A/H3N2/Perth/16/2009, A/H1N1/California/01/2010, 
and B/Florida/004/2006). Seroprotection was defined as an antibody titer of at least 
1:40.25, 26 Post-vaccination seroresponse was defined as at least a four-fold increase 
in titers.26 
Cellular immune response
The cellular immune responses were measured by T lymphocyte proliferation and 
cytokine secretion of PBMC collected at day 1 and 8, and the presence of regulatory 
T lymphocytes (Treg) at day 1. 
 For analysis of lymphocyte proliferation and cytokine secretion, 1.5x105 PBMC 
were added per well of a 96-wells plate in culture medium (RPMI 1640 supplemented 
with 4% human serum albumin). In the proliferation assay, PBMC were incubated with 
1μg/ml phytohemagglutinin (PHA) and with a 1:10 dilution of the separate virus-strains 
(A/H3N2/Perth/25/11/2008, A/H1N1/California/01/2010, and B/Florida/05/11/2008). 
After 48 hours of culture, supernatant was harvested to analyze cytokine production. 
The Th1/Th2 11plex kit (eBioscience, San Diego, CA) was used according to the 
manufacturer’s protocol in order to measure interleukin-10 (IL-10) at day 1 and 
interferon gamma (IFN-γ), interleukin-4 (IL-4), and interleukin-5 (IL-5) at day 8. After 
four days of culture, 1 μCi 3[H]-thymidine (MP Biomedicals, Santa Ana, California, 
USA) was added to each well for overnight incubation to measure T lymphocyte 
proliferation. 
 Multi-color flow cytometric analysis was performed on unstimulated PBMC 
collected at day 1 according to the manufacturer’s protocol. Cells were stained for 
anti-CD4/FITC (Beckman Coulter), anti-CD25/PE-Cy7 (BD Biosciences, Breda, the 
Netherlands), anti-CD127/PE (BD Bioscience), and anti-FOXP3/APC (clone PCH101, 
eBioscience). Treg were defined as CD4+CD25++CD127-FOXP3+ and were 
expressed as a percentage of CD4+CD25++CD127- cells. 
Table 1   Baseline characteristics
Chronic 
fatigue 
syndrome 
patients 
(n=20)
Healthy 
controls 
(n=20)
p-value
Gender
  Male
  Female  
7 (35)
13 (65)
7 (35)
13 (65)
1.000
Age (years)
  Mean  
 
35.0±10.0 34.4±9.2 0.857
CIS-fatigue 48.15±5.48 15.80±3.62 <0.001
Hemoglobin (mmol/l) 8.6±0.6 8.4±0.7 0.235
Mean absolute leukocyte count (*109/l) 7.2±1.9 6.9±1.9 0.654
Mean neutrophil count (% of total) 60.2±8.7 59.9±8.7 0.928
Mean lymphocyte count (% of total) 29.8±7.6 29.2±7.1 0.797
Mean monocyte count (% of total) 5.7±1.5 5.2±1.4 0.332
Influenza vaccination prior to 2010
  Yes
  No
5 (25)
15 (75)
5 (25)
15 (75)
1.000
Data are presented as mean ± standard deviation or as absolute numbers with percentages in brackets.
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Humoral immune response 
Vaccination induced a significant increase in HI antibody titers for influenza strain 
H3N2 and H1N1 in the CFS group as well as in the healthy control group (Figure 1A 
and 1B). For influenza strain B, vaccination induced no significant increase in HI 
antibody titers, neither in the CFS, nor in the healthy control group (Figure 1A and 1B). 
No significant differences in HI antibody titers between both groups were observed 
prior to vaccination or at day 22. Compared to the healthy controls, CFS patients 
demonstrated similar seroprotection rates (both pre- and post-vaccination) and 
seroresponse rates against all three virus-strains (Table 2). 
Figure 1   Hemagglutination inhibition (HI) antibody responses before (day 1) 
and after (day 22) influenza vaccination, and cellular proliferation 
before (day 1) and after (day 8) influenza vaccination. Both immune 
responses are presented for the three influenza strains of the vaccine 
(H3N2, H1N1, and B), in chronic fatigue syndrome patients (A and C) 
and healthy controls (B and D)
Antibody titers are presented as mean ± standard error of the mean, the dotted line indicates the protective 
titer cut-off value. Proliferation counts are presented as absolute numbers and mean (horizontal line) on a 
logarithmic scale. Abbreviation: CFS: chronic fatigue syndrome.
Table 2   Humoral and cellular immune responses
Chronic 
fatigue 
syndrome 
patients
(n=20)
Healthy 
controls 
(n=20)
p-value
Seroprotection rate pre-vaccination 
(day 1)
  H3N2
  H1N1
  B
  H3N2, H1N1, and B 
Seroprotection rate post-vaccination 
(day 22)
  H3N2
  H1N1
  B
  H3N2, H1N1, and B 
Seroresponse rate post-vaccination 
(day 1 to 22)
  H3N2
  H1N1
  B
  H3N2, H1N1, and B
13 (65)
4 (20)
16 (80)
2 (10) 
18 (90)
18 (90)
18 (90)
15 (75) 
10 (50)
13 (65)
2 (10)
1 (5)
12 (60)
5 (25)
17 (85)
4 (20) 
20 (100)
18 (90)
20 (100)
18 (90) 
12 (60)
12 (60)
3 (15)
2 (10)
0.744
0.705
0.677
0.376
0.147
1.000
0.147
0.212
0.525
0.744
0.633
0.548
 IL-10 production at baseline 
(day 1, pg/ml)
  H3N2
  H1N1
  B  
Treg at baseline (day 1, %)
  Unstimulated
4.5±10.9
65.6±127.4
19.3±56.0
2.8±1.2
2.5±5.0
35.3±47.2
10.5±20.2
2.7±1.5
0.457
0.329
0.514
0.733
IFN-γ production post-vaccination 
(day 8, pg/ml)
  H3N2
  H1N1
  B
IL-4 production post-vaccination 
(day 8, pg/ml)
  H3N2
  H1N1
  B 
162.1±220.5
578.3±828.8
316.4±520.7
0.0±0.0
0.0±0.0
2.9±8.8
116.0±180.8
382.5±446.1
418.1±528.9
4.3±13.5
7.7±20.2
0.0±0.0
0.474
0.360
0.544
0.169
0.105
0.163
IL-5 production post-vaccination 
(day 8, pg/ml)
  H3N2
  H1N1
  B
1.4±4.3
1.2±3.4
0.8±3.4
1.7±4.7
1.5±4.5
3.4±6.4
0.811
0.788
0.114
Data are presented as absolute numbers with percentages in brackets or as mean ± standard error of 
the mean.
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known to suppress immunity. First, the immunosuppressive cytokine IL-10, which is 
able to inhibit T cell proliferation, was assessed.28 However, production at baseline of 
IL-10 was similar in patients and controls. Secondly, Treg are known to negatively 
modulate T cell responses.29 Nevertheless, the percentage of Treg in CFS patients at 
baseline did not differ from the controls. Another possible explanation for the 
decreased number of proliferating T lymphocytes in CFS patients is elevated numbers 
of co-inhibitory molecules, like programmed death-1,30, 31 cytotoxic T lymphocyte 
antigen-4,30 or B and T lymphocyte attenuator.32 Whether inhibitory mechanisms play 
a role in CFS patients need to be explored in more detail.
 From pre- to post-vaccination, CFS patients showed a significant increase in 
cellular proliferation in two out of three virus-strains and a trend in the same direction 
for the third virus-strain, whereas healthy controls did not show a significant change 
in proliferation from day 1 to day 8. In absolute counts, CFS patients showed post-
vaccination more proliferating T cells for all three virus-strains, compared to controls. 
This non-significant elevation in cellular immune responses could not be explained 
by an increase in the levels of cytokines IFN-γ, IL-4, and IL-5, cytokines involved in the 
type 1 and type 2 helper T cell responses, suggesting a type 0 helper T cell response 
in CFS patients after vaccination.
Limitations of the study
Given the exploratory nature of this study, group sizes were relatively small and not 
based on power calculations. Consequently, subtle differences between CFS patients 
and healthy controls may have gone unnoticed. However, the sample size of our 
study was sufficiently high to show that CFS patients are able to mount a significant 
protective antibody response and a sufficient cellular immune response upon a 
single shot of influenza vaccine.  
In conclusion, putative aberrations in immune responses in CFS patients were not 
evident for immunity towards influenza. We show that CFS patients are able to mount 
a protective antibody response and a sufficient cellular immune response upon a 
single shot of influenza vaccine, which is comparable with healthy controls. Therefore, 
standard seasonal influenza vaccination is thus justified and, when indicated, should 
be recommended for patients suffering from CFS.
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Cellular immune response
Prior to vaccination, T cells proliferated upon PHA and virus stimulation in both CFS 
patients and healthy controls (respectively 14,883±4,265 counts and 22,997±3,902 
counts), indicating that these T cells are functional (Figure 1C and 1D). Cellular 
proliferation showed no significant differences between CFS patients and healthy 
controls at baseline (Table 2). Of note, in absolute counts, CFS patients showed at 
baseline a lower T cell proliferation upon stimulation in comparison with controls. 
IL-10 production and the number of Treg were not significantly different between CFS 
patients and healthy controls at baseline (Table 2).
 Vaccination induced a significant increase in cellular proliferation in CFS patients 
after stimulation with influenza strain H3N2 and B, and a trend in the same direction 
for strain H1N1, whereas in healthy controls vaccination induced no significant 
change in cellular proliferation after stimulation with any of the three virus-strains 
(Figure 1C and 1D and Table 2). 
 Post-vaccination, T cell proliferation showed no significant differences between 
CFS patients and controls, neither for the three different virus strains (Figure 1C and 
1D), nor for PHA (respectively 34,964±4433 counts and 15,406±2719 counts). Of 
note, in absolute counts, CFS patients showed post-vaccination more proliferating T 
cells upon stimulation with all three virus-strains, compared to controls. IFN-γ, IL-4, 
and IL-5 production post-vaccination were not significantly different between CFS 
patients and healthy controls (Table 2).
Discussion
To the best of our knowledge, we are the first to explore both the humoral and cellular 
immune responses after influenza vaccination in CFS patients. The hypothesized immuno- 
logical aberrancy claimed to be operative in CFS could not be confirmed by our data. 
Both CFS patients and healthy controls showed a significant increase in humoral 
immune responses from pre- to post-vaccination for virus-strains H3N2 and H1N1. 
Virus-strain B did not show such an increase from day 1 to day 22, but for this 
virus-strain the HI titer was already high prior to vaccination. 
 In a previous study, only the effect of influenza vaccination on the antibody response 
of CFS patients was determined in 40 CFS patients and 21 matched healthy volunteers.27 
In accordance with our study, influenza vaccination provided protective antibody levels. 
Our study gives additional information on cellular immune responses in CFS patients. 
 We observed that, although not statistically significant, the incorporation of tritium 
thymidine by proliferating T cells at baseline was numerically lower in patients suffering 
from CFS in comparison to healthy controls. To investigate whether it is worthwhile to 
examine this trend in more detail, we studied immunological mechanisms commonly 
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General discussion
In this chapter, the results of the studies presented in this thesis will be discussed and 
put in a broader perspective. In particular, we will try to explain why we did not identify 
(neuro)physiological factors of postcancer fatigue.
Why we could not identify (neuro)physiological factors of 
postcancer fatigue
At the start of this research project, the literature about (neuro)physiological factors of 
postcancer fatigue was very limited. In view of the observed similarities as clinical 
syndromes between postcancer fatigue and chronic fatigue syndrome (CFS), we 
expected a common (neuro)physiological ground for fatigue. However, our 
hypotheses could not be confirmed. The results of the present thesis point to 
differences in the underlying physiological mechanism of postcancer fatigue and 
other fatigue syndromes. Physical fitness was not significantly different between CFS 
patients and healthy controls,1 whereas we demonstrated that maximal exercise 
performance was inferior in fatigued cancer survivors compared to non-fatigued 
controls. Several studies observed a significantly reduced gray matter volume in CFS 
patients compared to controls.2, 3 Also, altered levels of specific metabolites have 
been reported in the brains of CFS patients.4, 5 Opposite to these findings, we 
observed no relation between postcancer fatigue and the studied volumetric and 
metabolic markers. Low peripheral muscle fatigue and high central muscle fatigue 
appeared to be a shared neurophysiological feature of fatigue in patients with CFS 
and neuromuscular diseases.6, 7 In contrast, we showed that postcancer fatigue is 
neither characterized by abnormally high central muscle fatigue, nor by low peripheral 
muscle fatigue. Finally, we observed no significant immunological differences 
between CFS patients and healthy controls, while on the other hand, fatigued cancer 
survivors showed several significant differences in baseline immunological reactivity. 
 Possible explanations for the fact that we could not confirm our hypotheses and 
did not identify biomarkers for postcancer fatigue can be the following a) we did not 
study the right parameters and/or we did not use the right methods to measure the 
different parameters b) the sample size was too small c) the underlying physiology of 
postcancer fatigue is really different from CFS. This will be further discussed in the 
next paragraphs.
Parameters and Methods
In Chapter 2.1 and Chapter 2.2, the primary outcome parameter was maximal 
oxygen consumption in cycle ergometry as a measure for physical fitness. Although 
direct measurements of peak oxygen consumption are expensive in terms of 
equipment and staff and results in patient burden,8 peak oxygen consumption is 
regarded as the golden standard for measuring cardiopulmonary fitness and is 
capable of assessing cardiopulmonary limitations during exercise.9 However, in a 
review discussing the physiological differences between cycling and running, it was 
concluded that maximal oxygen consumption is dependent on the specific exercise 
modality.10 The majority of the reviewed studies indicated that runners achieve a 
higher maximal oxygen consumption on treadmill compared to cycling, whereas 
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addressed by resting-state fMRI. Functional connectivity is defined as the temporal 
dependency of neuronal activation patterns of anatomically separated brain regions.19 
After the performance of a fatigue task, repetitive unilateral handgrip contractions, the 
interhemispheric signal correlation in the primary motor cortices decreased 
significantly. These results suggest that resting state interhemispheric motor cortex 
functional connectivity may be used as an index of recovery from fatigue. It would be 
interesting to repeat this study in fatigued and non-fatigued cancer survivors and it 
would be even more interesting to combine this measurement with MRS of the muscle 
itself, which will be further discussed in the paragraph concerning Chapter 4. 
 We observed no differences in brain morphology or metabolism between 
fatigued and non-fatigued cancer survivors or between patients in the therapy and 
the waiting list condition, despite an extensive set of parameters and accurate 
analyses. The reproducibility of the measurements in the RCT portion of the study is 
high. It would be valuable to address the parameters that could not be included in this 
study due to time restraints, to repeat the measurements that may need more 
statistical power, and to study potential biomarkers of postcancer fatigue using 
functional MRI.
In Chapter 4, we examined peripheral and central muscle fatigue. As described by 
Schillings et al,20 the presence of peripheral fatigue during a contraction has mostly 
been studied by electromyography (EMG). The decline in muscle fiber conduction 
velocity, which can be measured by surface EMG, reflects the accumulation of 
metabolic byproducts and can be used as an indicator of peripheral muscle fatigue.20 
Another measure of peripheral muscle fatigue is the decrease in muscular force 
response to electrical stimulation pre- versus post-exercise. Both measures were 
applied in the present study, but only the decrease in rest twitch force showed a 
significant difference between fatigued and non-fatigued cancer survivors. 
Metabolism of the muscle can also be studied during exercise using MRS.21, 22 
Because there was no possibility to further expand our MR protocol in terms of time, 
and because this measurement would ask for a totally different set-up, we did not 
study peripheral muscle fatigue by using MRS, but it would be useful to do so in 
future MR experiments.
 Only a small number of methods have been developed to study central muscle 
fatigue. One of the methods showing central muscle fatigue during maximal voluntary 
contraction is transcranial magnetic stimulation.23 However, the non-specificity of this 
measurement technique complicates quantification.20 Usually, central muscle fatigue, 
or central activation failure, has been determined by a twitch-interpolation technique.24 
In case additional force production was observed following electrical stimulation of 
motor nerves or endplates, this indicated that voluntary activation was suboptimal.20 
In the present study, the motor endplate of the biceps brachii muscle was electrically 
cyclists can achieve a maximal oxygen consumption in cycle ergometry similar to 
that in treadmill running. Based on these results, running ergometry would be the 
preferred way to measure maximal oxygen consumption. To confirm our current 
outcomes and to make sure that the type of ergometry did not affect our results, it 
would be useful to measure maximal oxygen consumption in postcancer fatigue 
patients on a treadmill rather than a cycle ergometer.
In Chapter 3, we investigated volumetric and metabolic markers of the brain. The 
voxel-based morphometry (VBM) method is an extensively validated and fully 
automated technique to calculate differences in global volumes of gray and white 
matter.11, 12 The VBM method is able to detect subtle differences between study 
groups, as has been shown before.2, 3, 13 The analysis method used to calculate 
subcortical brain volumes also was shown to have the potential to detect small 
differences, however, in larger groups of subjects.14, 15 
 Magnetic resonance spectroscopy (MRS) provides a noninvasive window on a 
biochemical profile of the brain, without the need of a biopsy. We performed our MR 
measurements on a 3 Tesla system, using semi-LASER sequences, resulting in high 
signal-to-noise ratios. Further increasing the signal-to-noise ratio is possible by 
increasing the field strength. Two regions of interest for brain MRS in postcancer 
fatigue, which have not been described in the present thesis, are the basal ganglia 
and the lateral ventricles. In an MRS study of the basal ganglia, a significant increase 
in the signal from choline-containing compounds was observed in CFS patients 
compared to matched healthy controls.16 Unfortunately, we were not able to perform 
MRS in the basal ganglia due to time restraints. In another previous study, CFS was 
associated with significantly raised concentrations of ventricular lactate.17 The data of 
one of our pilot studies suggested that ventricular lactate levels were not significantly 
different between fatigued and non-fatigued cancer survivors. However, due to 
partial volume effects, these results were not fully reliable and therefore not included 
in the present thesis.
 Although we found no relation between postcancer fatigue and the studied 
volumetric and metabolic markers, these results do not imply that alterations in the 
pathophysiology of the brain can be excluded as underlying mechanism of postcancer 
fatigue. In particular, alterations in the dynamics of brain physiology, which are not 
reflected in the static levels of brain metabolites or in brain volumes as investigated in 
this study, may be involved. To address whether these aspects of brain physiology 
contribute to the experience of fatigue, the performance of additional MR studies, 
such as resting state functional MRI (fMRI), is required. In a previous study, it has 
been hypothesized that fatigue involving voluntary muscle activities creates a 
temporary ‘disrupted state’ in the motor cortical regions.18 This distortion would 
decrease interhemispheric motor cortical functional connectivity, which could be 
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Sample size
One of the limitations of the studies reported in the present thesis is the relatively 
small sample size. However, the samples sizes of our studies comparing fatigued 
and non-fatigued cancer survivors are similar to, or sometimes even higher than, the 
sample sizes of the studies reported in literature comparing CFS patients and healthy 
controls (Table 1). For these CFS studies, the sample size was sufficiently high to 
demonstrate significant differences between CFS patients and healthy controls. 
 In the clinical trial described in the present dissertation, the measurements 
addressing physical fitness, global brain volumes, and metabolite (tissue) concentrations 
comply with the sample sizes reported in literature. Subcortical brain volumes in CFS 
patients and healthy controls have not been studied yet, but results are available from 
a large reproducibility study addressing the volumes of the four major nuclei of the 
basal ganglia.15 In that study, volume differences in the range of 3% were detected in 
the basal ganglia. Although this percentage could be different for the other subcortical 
brain structures addressed in our study, since not every subcortical brain structure is as 
easily segmented, we were probably not able to detect subcortical brain volume 
changes smaller than 3%. Unfortunately, the sample size of our study investigating 
central and peripheral muscle fatigue was relatively low, perhaps too low. However, in 
general, the power of the studies describing the randomized controlled trial was 
sufficiently high to demonstrate a significantly larger decrease in fatigue levels in 
patients in the therapy group compared to patients in the waiting list group. 
 Possibly, the samples sizes of both influenza studies were too small to detect 
subtle differences between fatigued and non-fatigued cancer survivors and/or between 
CFS patients and healthy controls. However, the sample sizes were adequately high 
to show that both patients suffering postcancer fatigue and CFS patients are able to 
mount protective antibody responses and sufficient cellular immune responses upon 
a single shot of influenza vaccine. In addition, compared to non-fatigued cancer 
survivors, fatigued cancer survivors showed several significant differences in 
immunological reactivity at baseline. 
 When we have a closer look at the p values obtained in our studies, the majority 
of the non-significant p values do not even approach levels of significance. In other 
words, the inclusion of more subjects would probably not have resulted in significant 
differences in (neuro)physiological parameters between fatigued and non-fatigued 
cancer survivors. 
Thus, unfortunately, the sample size of the study was smaller than desired and might be 
responsible for the fact that we could not identify biomarkers for postcancer fatigue. Yet, 
the numbers of patients included were higher than in most previous studies addressing 
physiological and neurophysiological determinants. The findings of the present thesis 
should be verified in a larger cohort of patients in future investigations. 
stimulated. This relatively short stimulation of the endplate using surface electrodes 
does not result in activation of the total muscle, which is the case when the nerve is 
stimulated for a longer period of time. However, motor nerve stimulation is much 
more uncomfortable for the patient than motor endplate stimulation. Being aware of 
the total amount of patient burden in this whole study, it is reasonable to only stimulate 
the motor endplate, which still results in effective measurements of central muscle 
fatigue.
In Chapter 5.1 and Chapter 5.2, we measured the humoral and cellular immune 
responses upon influenza vaccination in respectively patients suffering from 
postcancer fatigue and CFS patients. The humoral immune responses on influenza 
vaccination were measured in serum by the hemagglutination-inhibition antibody 
test, as described previously.25 Analytic assays to measure the full range of T-cell 
responses against influenza virus have been extensively documented.26 In accordance 
with a previous influenza study, which has been successfully executed by our 
department, we addressed these outcome parameters and followed similar 
protocols.27 Since postcancer fatigue patients showed several significant differences 
in immunological reactivity at baseline, it might be favorable to further explore immune 
activation and potential immune suppressive mechanisms. A possible approach 
could be to analyze influenza reactive T cells, using tetramers.28-30 This way, it is 
possible to study differences in functionality on this specific T cell population instead 
of on the total pool of peripheral blood mononuclear cells. The work presented in this 
thesis already provides an essential basis on the immunological reactivity in 
postcancer fatigue and future research could elucidate this even further.
In general, we extensively explored various aspects of both postcancer fatigue and 
chronic fatigue syndromes using different robust methods, including maximal 
exercise tests, MR scans, EMG measurements, and immunological assays. 
According to the knowledge we had at the beginning of the project, we selected the 
parameters that were most likely involved in the underlying mechanism of postcancer 
fatigue. For these parameters we applied the best readout methods available, 
considering patient burden and time restraints. However, we were unable to identify 
a biomarker for postcancer fatigue. Therefore, more research is required to learn 
more about the pathophysiology of (postcancer) fatigue. 
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Postcancer fatigue versus CFS 
Although postcancer fatigue and CFS show strong similarities as a clinical syndrome, 
there seem to be differences between severely fatigued cancer survivors and patients 
suffering from CFS. In this section, the similarities and differences between postcancer 
fatigue and CFS are discussed and tabulated (Table 2 and 3).
In postcancer fatigue, a distinction can be made between precipitating and 
perpetuating factors. The assumption is that the fatigue is provoked by the cancer 
itself and/or by the cancer treatment, i.e. by the precipitating factors. A distortion in 
the human system can lead to tumor growth, resulting in further disturbance of the 
normally balanced processes in the human body, which will be aggravated by the 
subsequent tumor therapy. Over time, after curative cancer treatment, other factors 
are responsible for the maintenance of the fatigue, i.e. the perpetuating factors.31 
Cognitive behavior therapy (CBT) for postcancer fatigue addresses these perpetuating 
factors, including poor coping with cancer and cancer treatment, excessive fear of 
disease recurrence, dysfunctional cognitions, dysregulatory sleep-wake cycle, 
dysregulatory activities, and low social support and negative interactions.31 CBT is 
also a proven effective treatment option for patients suffering from CFS,32 focusing on 
partly the same perpetuating factors as in CBT for postcancer fatigue. Poor coping 
with cancer and cancer treatment and excessive fear of disease recurrence are 
specific for postcancer fatigue and are not present in CFS. In contrast to postcancer 
fatigue, in which a clear precipitating moment can be identified that initiated fatigue, 
a precipitating factor cannot always be identified in CFS. Thus, postcancer fatigue 
and CFS might already differ at the starting point of the fatigue complaints. 
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Table 2   Similarities and differences between postcancer fatigue and chronic 
fatigue syndrome
PCF versus CFS33
Precipitating factors Clearer
Perpetuating factors Partly the same, partly different
Fatigue severity Lower
Functional impairment Lower
Physical activity Higher
Pain Lower
Self-efficacy regarding fatigue Higher
Abbreviations: CFS: chronic fatigue syndrome; PCF: postcancer fatigue.
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Comparing patients suffering from postcancer fatigue and CFS patients, Servaes et 
al33 showed that CFS patients score more problematic with regard to the level of 
fatigue, functional impairment, physical activity, pain, and self-efficacy. 
Although in the present thesis postcancer fatigue and CFS can only be compared directly 
in the influenza study, indirect comparisons can be made between our (neuro)physiological 
studies in postcancer fatigue and studies in CFS reported in literature. Physical activity is 
reduced in both fatigue syndromes, even more in CFS than in postcancer fatigue. 
Surprisingly, physical fitness is not significantly reduced in CFS patients compared to 
healthy controls, as demonstrated by Bazelmans et al1, but severely fatigued cancer 
survivors did show an inferior physical fitness compared to non-fatigued controls. 
 A significant reduced gray matter volume in CFS compared to healthy controls 
has been reported by two independent research groups,2, 3 and, in addition, one of 
the groups demonstrated that this difference in gray matter volume can be partly 
reversed by CBT for CFS.13 This volumetric trait found in CFS, which we expected to 
be a reflection of fatigue in general, could not be demonstrated in postcancer fatigue. 
White matter volumes were neither affected in postcancer fatigue, nor in CFS. In 
addition, alterations in metabolite (tissue) concentrations were observed on different 
locations in CFS,4, 5, 16, 17 but could not be replicated in postcancer fatigue.
 High central and low peripheral muscle fatigue appeared to be a shared neuro-
physiological feature, not only in CFS,7 but also in neuromuscular diseases.6 
Unexpectedly, postcancer fatigue patients neither showed central muscle fatigue, 
nor did these patients show low peripheral muscle fatigue.
 The presence of an immunological distortion has been suggested as an 
explanation for both postcancer fatigue and CFS.34, 35 Therefore, we hypothesized 
that these patients might have an altered immune response to vaccination. Upon a 
single shot of influenza vaccination, both fatigued patient groups mounted a 
protective antibody response and a sufficient cellular immune response. However, 
postcancer fatigue showed several significant differences in immunological reactivity 
at baseline, including reduced T cell proliferation and increased levels of regulatory T 
cells, which could not be observed in CFS patients.
Despite the fact that postcancer fatigue and CFS show strong resemblances as 
clinical syndromes and that the present work confirms some parallels between both 
fatigue syndromes, the main part of this thesis suggests differences between 
postcancer fatigue and CFS. 
Altogether, the extensive explorations described in this thesis indicate that differences 
in the underlying (neuro)physiological mechanism of postcancer fatigue versus 
chronic fatigue syndrome may exist.
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Summary
Fatigue during -but also long after- curative treatment of cancer is a frequently 
occurring, severe, and invalidating problem, impairing quality of life. Cognitive 
behavior therapy (CBT), especially designed for postcancer fatigue, is an effective 
treatment option. Although it is now possible to effectively treat postcancer fatigue, 
the nature of the underlying physiology of postcancer fatigue remains unclear. 
This dissertation approaches (neuro)physiological aspects of postcancer fatigue, 
including two studies on physical deconditioning, two studies on central and 
peripheral fatigue, and two studies on the disbalance of the immune system. 
The study protocol is described in Chapter 1. A randomized controlled trial (RCT) 
with 6 months follow-up was conducted to identify and measure (neuro)physiological 
factors of fatigue in severely fatigued disease-free cancer survivors and to determine 
the role of these factors in the maintaining of fatigue. At baseline, fatigued and 
matched non-fatigued patients underwent measurements for physical activity and 
fitness, brain morphology and metabolism, and peripheral and central muscle 
fatigue. Both patient groups were curatively treated for cancer and finished treatment 
at least one year before study inclusion. Fatigued patients were randomly (3:1) 
assigned to either the intervention group, who will immediately start CBT, or the 
control group, who will start CBT after six months. After six months follow-up, the 
measurements will be repeated in both groups of fatigued patients. 
 Next to the RCT, a case-control study was performed to compare humoral and 
cellular immune responses upon influenza vaccination in severely fatigued 
disease-free cancer survivors and in patients with chronic fatigue syndrome (CFS). 
Humoral immune responses were measured at baseline and three weeks post-vac-
cination. Cellular immune responses were measured at baseline and one week post-
vaccination.
 
We hypothesized that compared to non-fatigued cancer survivors, postcancer 
fatigue patients have an impaired physical fitness due to decreased physical activity 
after cancer diagnosis and treatment. In Chapter 2.1, we evaluated whether physical 
fitness of severely fatigued and non-fatigued cancer survivors, as measured by 
maximal exercise performance, is different between both groups and, if so, whether 
this difference can be explained by differences in physical activity, self-efficacy 
regarding the exercise test, and/or social support. Twenty fatigued and 20 non-fatigued 
cancer survivors performed an incremental cycling exercise test. Physical activity 
was assessed via actigraphy. Self-efficacy regarding the test and social support were 
assessed via questionnaires. Maximal oxygen consumption, a measure for physical 
fitness, was significantly lower in fatigued compared to non-fatigued patients. Actual 
physical activity, self-efficacy regarding the test, and negative interactions of social 
support were significantly different between both groups. However, also after 
inclusion of these three variables in linear regression analyses, the difference in 
physical fitness between fatigued and non-fatigued cancer survivors persisted. Other 
currently still unknown factors, such as a disturbance in the cardiopulmonary circuit, 
may play a role.
 As we learned from Chapter 2.1, patients suffering from postcancer fatigue have 
an inferior physical activity and physical fitness compared to cancer survivors who 
experience normal feelings of fatigue. However, the role of physical activity and 
physical fitness in fatigue reduction is unclear. In Chapter 2.2, we examined the 
effect of CBT on physical activity and physical fitness of severely fatigued cancer 
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diseases. We hypothesized that postcancer fatigue is also characterized by low 
peripheral muscle fatigue and high central muscle fatigue. In Chapter 4, we examined 
whether central and peripheral muscle fatigue were different between severely 
fatigued and non-fatigued cancer survivors. In addition, we examined the effect of 
CBT on peripheral and central muscle fatigue of severely fatigued cancer survivors. 
Sixteen patients in the intervention (CBT) and 8 patients in the waiting list condition 
were successfully assessed both at baseline and at six months follow-up. Baseline 
measurements of 20 fatigued cancer survivors were compared with 20 matched 
non-fatigued cancer survivors. To measure primary outcome measures central 
activation failure (an indicator of central muscle fatigue) and muscle fiber conduction 
velocity (an indicator of peripheral muscle fatigue), a twitch interpolation technique 
and surface electromyography were applied, respectively, during a sustained 
maximal voluntary contraction of the biceps brachii muscle. CBT resulted in a 
significantly larger decrease in fatigue severity compared to a period of waiting for 
therapy. However, the change scores of peripheral and central muscle fatigue from 
baseline to follow-up were not significantly different between the therapy and the 
waiting list condition. Thus, postcancer fatigue was neither characterized by 
abnormally high central muscle fatigue nor by low peripheral muscle fatigue. These 
findings suggest a difference in the underlying physiological mechanism of 
postcancer fatigue and other fatigue syndromes. 
The presence of an immunological distortion has also been suggested as an 
explanation for postcancer fatigue. If so, postcancer fatigue patients might have an 
altered response to vaccination. In Chapter 5.1, we aimed to compare the humoral 
and cellular immune responses upon vaccination, using seasonal influenza 
vaccination as a representative vaccination, in severely fatigued and non-fatigued 
cancer survivors. Fifteen fatigued and twelve matched non-fatigued cancer survivors 
were vaccinated against seasonal influenza. Humoral immune responses were 
measured at baseline and three weeks post-vaccination by a hemagglutination 
inhibition assay. Cellular immune responses were measured at baseline and 1 week 
post-vaccination by lymphocyte proliferation and activation assays. We demonstrated 
that fatigued cancer survivors mount a protective antibody response and a sufficient 
cellular immune response upon a single shot of influenza vaccine, which is 
comparable to non-fatigued cancer survivors. However, compared to non-fatigued 
cancer survivors, fatigued cancer survivors showed several significant differences in 
immunological reactivity at baseline, which warrant further investigation. 
 CFS is a clinical condition characterized by severe and disabling fatigue that is 
medically unexplained and lasts longer than 6 months. Although it is possible to 
effectively treat CFS, the nature of the underlying physiology remains unclear. The 
presence of an underlying immunological problem has also been suggested as an 
survivors. Moreover, we examined whether the effect of CBT on postcancer fatigue 
was mediated by a change in physical activity and/or physical fitness. Twenty-three 
patients in the intervention condition and fourteen patients in the waiting list condition 
were assessed both at baseline and at six months follow-up. The primary outcome 
measures were physical activity, assessed via actigraphy, and maximal oxygen 
consumption, a measure for physical fitness, assessed by a maximal exercise test. A 
non-parametric bootstrap approach was used to test statistical significance of the 
mediation effects. As has been shown before, CBT was effective in reducing 
postcancer fatigue. CBT resulted in a significantly larger decrease in fatigue severity 
compared to a period of waiting for therapy, increased physical activity significantly, 
but did not change physical fitness. A bootstrap analysis showed that the positive 
effect of CBT on postcancer fatigue was neither mediated by a change in physical 
activity, nor by a change in physical fitness. Thus, change in physical activity and 
physical fitness are not the factors, or at least not the only factors, that contributed to 
reduction of fatigue.
For non-cancer patients with CFS, certain characteristics of brain morphology and 
metabolism have been identified in previous studies. We hypothesized that the 
volumetric and metabolic traits found in CFS patients are a reflection of fatigue in 
general and may also be of importance for patients suffering from postcancer fatigue. 
In Chapter 3, we investigated whether these volumetric and metabolic parameters 
are different between severely fatigued and non-fatigued cancer survivors. 
Furthermore, we assessed the effect of CBT on these volumetric and metabolic 
parameters in severely fatigued cancer survivors. Twenty-five patients in the 
intervention condition (CBT) and fourteen patients in the waiting list condition were 
assessed at baseline and six months later. Baseline measurements of 20 fatigued 
patients were compared with 20 non-fatigued controls. Global brain volumes, 
subcortical brain volumes, metabolite tissue concentrations, and metabolite ratios 
were primary outcome measures. Patients in the therapy group reported a significant 
larger decrease in fatigue scores than patients in the waiting list group, but no relation 
was found between postcancer fatigue and the studied volumetric and metabolic 
markers. The volumetric and metabolic parameters were not significantly different 
between fatigued and non-fatigued patients and the change scores of the volumetric 
and metabolic parameters from baseline to follow-up were not significantly different 
between patients in the therapy group and patients in the waiting list group. These 
results may suggest that, although postcancer fatigue and CFS show strong 
resemblances as a clinical syndrome, the underlying physiology is different. 
Low peripheral muscle fatigue and high central muscle fatigue appear to be a shared 
neurophysiological feature of fatigue in patients with CFS and neuromuscular 
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explanation for CFS. Like in Chapter 5.1, we compared in Chapter 5.2 the humoral 
and cellular immune responses upon vaccination, using seasonal influenza 
vaccination as a model of a vaccination, but the study population consisted of a 
group of 20 CFS patients and a group of 20 matched healthy controls. Humoral 
immune responses were measured at baseline and three weeks post-vaccination by 
a hemagglutination inhibition assay. Cellular immune responses were measured at 
baseline and 1 week post-vaccination by lymphocyte proliferation and activation 
assays. Both the humoral and cellular immune responses upon influenza vaccination 
were similar in CFS patients and healthy controls. Putative aberrations in immune 
responses in CFS patients were not evident for immunity towards influenza. Standard 
seasonal influenza vaccination is thus justified and, when indicated, should be 
recommended for patients suffering from CFS. 
The results of the studies presented in this manuscript were discussed and put in a 
broader perspective in Chapter 6.1. Possible explanations for the fact that we could 
not confirm our hypotheses and did not identify biomarkers for postcancer fatigue 
were discussed. Altogether, the extensive explorations described in this thesis 
resulted in interesting new insights and indicate that differences in the underlying 
(neuro)physiological mechanism of postcancer fatigue versus chronic fatigue 
syndrome exist.
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Vermoeidheid tijdens -maar ook lang na- de behandeling van kanker is een veel-
voorkomend, ernstig en invaliderend probleem dat de kwaliteit van leven aantast. 
Cognitieve gedragstherapie* (CGT), speciaal ontwikkeld voor patiënten met vermoeidheid 
na kanker, is een effectieve behandeloptie. Hoewel het tegenwoordig dus mogelijk is 
om vermoeidheid na kanker effectief te behandelen, blijft het onduidelijk wat de 
onderliggende oorzaak van vermoeidheid na kanker is.
Dit proefschrift gaat in op (neuro)fysiologische aspecten die ten grondslag zouden 
kunnen liggen aan vermoeidheid na kanker. Er zijn twee studies opgenomen die 
gericht zijn op lichamelijke activiteit en lichamelijke conditie (Hoofdstuk 2.1 en 
Hoofdstuk 2.2), twee studies die zich richten op centrale* en perifere vermoeidheid* 
(Hoofdstuk 3 en Hoofdstuk 4), en één studie naar de mogelijke disbalans in het 
immuunsysteem (Hoofdstuk 5.1). Tevens is er een studie opgenomen naar de 
mogelijke disbalans in het immuunsysteem bij patiënten met het chronisch vermoeid-
heidssyndroom (CVS, Hoofdstuk 5.2).
Het studieprotocol is beschreven in Hoofdstuk 1. We hebben een gerandomiseerde, 
gecontroleerde studie opgezet en uitgevoerd om (neuro)fysiologische factoren van 
vermoeidheid in ernstig vermoeide, ziektevrije kankerpatiënten te identificeren en 
meten. Bovendien wilden we de rol van deze factoren bepalen bij het in stand houden 
van vermoeidheid na de behandeling van kanker. Aan het begin van deze studie zijn 
zowel bij vermoeide als bij niet-vermoeide ziektevrije kankerpatiënten metingen 
gedaan gericht op lichamelijke activiteit en lichamelijke conditie, hersenvolume* en 
hersenmetabolisme*, en perifere en centrale spiervermoeidheid. Beide patiëntgroepen 
waren behandeld met als doel te genezen van kanker en hadden de behandeling op 
het moment van deelname aan de studie minimaal één jaar eerder met succes 
afgerond. De vermoeide patiënten werden vervolgens op basis van loting toegewezen 
aan de interventiegroep, waarin meteen met CGT gestart werd, of aan de controlegroep, 
die na zes maanden met CGT startte. Na zes maanden therapie of wachten op therapie 
werden bij beide groepen de metingen herhaald. 
 Naast de gerandomiseerde, gecontroleerde studie hebben we ook een patiënt-
controle-onderzoek uitgevoerd om de immuunrespons na griepvaccinatie te onder- 
zoeken bij zowel ernstig vermoeide ziektevrije kankerpatiënten als bij patiënten met 
CVS. De humorale immuunrespons* werd bij de start van de studie bepaald alsook 
drie weken na vaccinatie. De cellulaire immuunrespons* werd gemeten aan het begin 
van de studie en één week na vaccinatie. 
Aangezien lichamelijke activiteit meestal afneemt na diagnose en behandeling van 
kanker, hebben patiënten met vermoeidheid na kanker mogelijk een slechtere 
lichamelijke conditie (fitheid) in vergelijking met niet-vermoeide controles. In 
Hoofdstuk 2.1 hebben we bestudeerd of de lichamelijke conditie van ernstig 
vermoeide en niet-vermoeide ziektevrije kankerpatiënten, gemeten door middel van 
een maximale inspanningstest, inderdaad verschillend is tussen deze twee groepen 
en, als dat zo is, of dit verschil verklaard kan worden door verschillen in lichamelijke 
activiteit, in het geloof in eigen kunnen ten aanzien van de inspanningstest 
(self-efficacy ten aanzien van de taak) en/of in sociale steun. Twintig vermoeide en 20 
niet-vermoeide patiënten voerden een maximale fietstest uit. Lichamelijke activiteit 
werd gemeten door middel van een actometer*. Het geloof in eigen kunnen en 
sociale steun werden gemeten door middel van vragenlijsten. Maximale zuurstof-
opname, een maat voor lichamelijke conditie, was duidelijk lager in vermoeide in 
vergelijking met niet-vermoeide ziektevrije kankerpatiënten. Lichamelijke activiteit, 
het geloof in eigen kunnen ten aanzien van de inspanningstest en sociale steun 
waren ook lager in de vermoeide dan in de niet-vermoeide groep. Echter, na correctie 
voor deze drie variabelen bleef het verschil in lichamelijke conditie tussen vermoeide 
en niet-vermoeide patiënten bestaan. Ziektevrije vermoeide kankerpatiënten hebben 
dus een slechtere lichamelijke conditie, waarbij mogelijk tot nu toe onbekende 
Begrippen aangeduid met een asterisk (*) worden verder uitgelegd in de begrippenlijst 
aan het einde van dit hoofdstuk.
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groep rapporteerden een veel grotere afname in de ernst van de vermoeidheid dan 
patiënten in de wachtlijstgroep, maar er werd geen relatie gevonden tussen 
vermoeidheid en de bestudeerde volumetrische en metabole markers. Deze markers 
verschilden niet tussen de vermoeide en de niet-vermoeide patiënten. Ook de grootte 
van de veranderingen in de genoemde markers tussen baseline en follow-up 
verschilden niet tussen patiënten in de therapiegroep en patiënten in de wachtlijst-
groep. Hoewel vermoeidheid na kanker en CVS veel op elkaar lijken als klinisch 
syndroom, suggereren deze resultaten dat de onderliggende fysiologie verschillend is. 
Lage perifere spiervermoeidheid en hoge centrale spiervermoeidheid blijken 
kenmerkend te zijn voor zowel patiënten met CVS als voor patiënten met neuromus-
culaire ziekten. Mogelijk wordt vermoeidheid na kanker ook gekenmerkt door lage 
perifere en hoge centrale spiervermoeidheid. In Hoofdstuk 4 zijn we nagegaan of 
centrale en perifere spiervermoeidheid inderdaad anders is bij vermoeide ziektevrije 
kankerpatiënten vergeleken met niet-vermoeide patiënten. We hebben ook het effect 
van CGT op perifere en centrale spiervermoeidheid onderzocht bij patiënten met 
vermoeidheid na kanker. Zestien patiënten in de therapiegroep en acht patiënten in 
de wachtlijstgroep werden zowel aan het begin van de studie als zes maanden later 
onderzocht. De uitgangsmetingen van 20 vermoeide patiënten werden vergeleken 
met 20 niet-vermoeide patiënten. De belangrijkste uitkomstmaten waren centrale 
activatiefout (central activation failure), een indicator voor centrale spiervermoeid-
heid, en spiervezelgeleidingssnelheid, een indicator voor perifere spiervermoeidheid. 
Voor het meten van deze uitkomstmaten werden een twitch interpolatietechniek* en 
oppervlakte-elektromyografie* toegepast tijdens een 2 minuten durende, maximale 
vrijwillige contractie van de bovenarmspier (biceps brachii). CGT resulteerde in een 
significant grotere afname in vermoeidheidsscore dan een periode van wachten op 
therapie. Echter, de veranderingen in perifere en centrale spiervermoeidheid tussen 
de start en het einde van de studie (zes maanden later) waren niet verschillend tussen 
beide condities. Een abnormaal hoge centrale en een verlaagde perifere spier-
vermoeidheid zijn dus geen kenmerken van vermoeidheid na kanker. Deze bevindingen 
suggereren dat het onderliggende fysiologische mechanisme dat ten grondslag ligt 
aan vermoeidheid na kanker anders is dan bij andere vermoeidheidssyndromen. 
Een andere mogelijke verklaring voor vermoeidheid na de behandeling van kanker is 
de aanwezigheid van een verstoring in het immuunsysteem. Als dat klopt, dan 
hebben patiënten met vermoeidheid na kanker mogelijk een andere respons op 
vaccinatie. In Hoofdstuk 5.1 hebben we de humorale en de cellulaire immuunrespons 
op vaccinatie bij vermoeide en niet-vermoeide ziektevrije kankerpatiënten met elkaar 
vergeleken, gebruikmakend van de jaarlijkse griepvaccinatie als onderzoeksmodel. 
Vijftien patiënten met vermoeidheid na kanker en twaalf niet-vermoeide controles 
factoren, bijvoorbeeld een verstoring in het cardiopulmonaire circuit, een rol spelen. 
 Hoewel we in Hoofdstuk 2.1 vonden dat patiënten met vermoeidheid na kanker 
zowel een geringere lichamelijke activiteit als een slechtere lichamelijke conditie 
hebben dan niet-vermoeide ziektevrije kankerpatiënten, is de rol van lichamelijke 
activiteit en lichamelijke conditie in het verminderen van vermoeidheid nog niet 
duidelijk. In Hoofdstuk 2.2 hebben we het effect van CGT op lichamelijke activiteit en 
lichamelijke conditie bij ernstig vermoeide kankerpatiënten onderzocht. Daarnaast 
hebben we bekeken of het effect van CGT op vermoeidheid werd gemedieerd door 
een verandering in lichamelijke activiteit en/of lichamelijke conditie. Drieëntwintig 
patiënten in de interventiegroep en veertien patiënten in de wachtlijstgroep kregen 
metingen zowel bij start van de studie als zes maanden later. Lichamelijke activiteit 
werd gemeten door middel van een actometer en maximale zuurstofopname werd 
bepaald door middel van een maximale fietstest. Een niet-parametrische bootstrap 
methode werd gebruikt voor het testen van de statistische significantie van de 
mediatie effecten. Zoals ook beschreven in voorgaande studies is CGT effectief in het 
verminderen van vermoeidheid na de behandeling van kanker. CGT resulteerde in 
een veel grotere afname in vermoeidheidsscore in vergelijking met een periode van 
wachten op therapie. CGT leidde wel tot een toename in lichamelijke activiteit, maar 
veranderde de lichamelijke conditie niet. De bootstrap analyse liet zien dat het 
positieve effect van CGT op vermoeidheid na kanker echter niet wordt gemedieerd 
door een verandering in lichamelijke activiteit en ook niet door een verandering in 
lichamelijke conditie. Lichamelijke activiteit en lichamelijke conditie zijn dus niet de 
factoren, of althans niet de enige factoren, die bijdragen aan de vermindering van 
vermoeidheid na kanker door middel van CGT.
In eerdere studies bij patiënten met CVS zijn er bepaalde afwijkingen in de volumes 
en het metabolisme van de hersenen vastgesteld in vergelijking met gezonde 
controles. Mogelijk zijn deze volumetrische en metabole karakteristieken die bij CVS 
gevonden zijn een weerspiegeling van vermoeidheid in het algemeen en dus mogelijk 
ook van belang bij patiënten met vermoeidheid na kanker. In Hoofdstuk 3 hebben 
we bestudeerd of deze volumetrische en metabole parameters daadwerkelijk 
verschillend zijn tussen vermoeide en niet-vermoeide ziektevrije kankerpatiënten. 
Tevens hebben we gekeken naar het effect van CGT op deze volumetrische en 
metabole parameters bij patiënten met vermoeidheid na kanker. Vijfentwintig 
patiënten in de interventiegroep en veertien patiënten in de controlegroep kregen 
zowel bij de start van de studie als zes maanden later een MR scan van de hersenen. 
De baseline metingen van 20 vermoeide patiënten werden vergeleken met 20 
niet-vermoeide controles. De belangrijkste uitkomstmaten waren grijze en witte stof 
volumes, volumes van subcorticale structuren* en concentraties en ratio’s van 
metabolieten in de hippocampus* en de occipitaalcortex*. Patiënten in de therapie- 
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Begrippenlijst
Begrip Omschrijving
Actometer Een instrument ter grootte van een luciferdoosje, dat met een bandje 
om de enkel wordt gedragen en waarmee het activiteitenniveau van de 
patiënt in kaart kan worden gebracht.
Cellulaire 
immuunrespons
De reactie van het afweersysteem op een stimulus, zoals vaccinatie, kan 
worden onderverdeeld in een humorale en een cellulaire immuunrespons. 
De cellulaire immuunrespons wordt verzorgd door cellen van het 
afweersysteem, zoals de witte bloedcellen, die ziekteverwekkers 
kunnen uitschakelen en afbreken.
Centrale 
spiervermoeidheid
Spiervermoeidheid is opgebouwd uit perifere en centrale vermoeidheid. 
Met centrale spiervermoeidheid wordt verminderde aansturing van de 
spieren vanuit de hersenen bedoeld.
Cognitieve 
gedragstherapie
Een vorm van psychotherapie waarbij de nadruk ligt op het veranderen 
van gedachten en gedragingen die aan de klachten verbonden zijn. 
Bij vermoeidheid na kanker kan er onderscheid gemaakt worden 
tussen uitlokkende en instandhoudende factoren. De diagnose en de 
behandeling van kanker zijn uitlokkende factoren. Na een jaar is de 
invloed van de uitlokkende factoren verdwenen en zijn er andere factoren 
die de vermoeidheid in stand houden. Cognitieve gedragstherapie 
richt zich op de volgende zes instandhoudende factoren: onvolledige 
verwerking van het feit dat men kanker heeft gehad, angst voor het 
terugkeren van de ziekte, verkeerde opvattingen rondom vermoeidheid, 
verstoord slaap- waakritme, verstoord activiteitenpatroon en laag 
ervaren sociale steun en interacties. 
Hemagglutinatie-
remmingsreactie
De gouden standaard voor het bepalen van de hoeveelheid antilichamen 
in het bloed na vaccinatie. 
Hersenmetabolisme Stofwisseling in de hersenen die gemeten kan worden door middel van 
magnetic resonance spectroscopy (MRS), een techniek geassocieerd 
met magnetic resonance imaging (MRI). Met behulp van MRS kunnen 
de concentraties van verschillende stoffen, oftewel metabolieten, op 
verschillende plaatsen in de hersenen worden bepaald. 
Hersenvolume Het berekenen van de volumes grijze stof (aan de buitenkant van de 
hersenen) en witte stof (aan de binnenkant van de hersenen) gebeurt 
op basis van beelden van de gehele hersenen, gemaakt door middel 
van magnetic resonance imaging (MRI), oftewel door middel van een 
MRI-scan. Bij MRI hoeft het lichaam niet te worden geopend om het 
volume van de hersenen te bepalen. Ook komt er geen straling aan te 
pas; er wordt gebruik gemaakt van magneetvelden.
Hippocampus Een structuur in de hersenen die een rol speelt bij het werkgeheugen en 
bij de opslag en het ophalen van informatie.
Humorale 
immuunrespons
De reactie van het afweersysteem op een stimulus, zoals vaccinatie, kan 
worden onderverdeeld in een humorale en een cellulaire immuunrespons. 
Bij de humorale immuunrespons zijn bepaalde eiwitten betrokken, 
antilichamen genoemd, die zich in lichaamsvloeistoffen bevinden, zoals 
het bloed. Antilichamen remmen zelf de ziekteverwekker of activeren 
andere eiwitten of cellen om de ziekteverwekker uit te schakelen. 
deden mee aan dit onderzoek. De humorale respons werd zowel bij de start van de 
studie als drie weken na vaccinatie gemeten door middel van een hemagglutinatie-
remmingsreactie*. De cellulaire respons werd eveneens aan het begin van de studie 
en vervolgens één week na vaccinatie gemeten door middel van een lymfocyten 
proliferatietest* en een activatietest*. We hebben laten zien dat patiënten met 
vermoeidheid na kanker na één enkele injectie met het griepvaccin een beschermende 
antistofrespons en voldoende cellulaire respons opbouwen, vergelijkbaar met de 
respons van niet-vermoeide patiënten. Echter, vermoeide patiënten laten in 
vergelijking met niet-vermoeide patiënten wel verscheidene significante verschillen 
zien in immunologische reactiviteit bij baseline, waarnaar meer onderzoek nodig is.
 CVS wordt gekenmerkt door lichamelijk onverklaarde, ernstige en invaliderende 
vermoeidheid die tenminste zes maanden duurt. Hoewel het nu mogelijk is om CVS 
effectief te behandelen, blijft de onderliggende fysiologie onduidelijk. De aanwezigheid 
van een verstoring in het immuunsysteem wordt ook naar voren gebracht als een 
mogelijke verklaring voor CVS. Net zoals in Hoofdstuk 5.1, hebben we in Hoofdstuk 5.2 
de humorale en de cellulaire respons op griepvaccinatie vergeleken, gebruikmakend 
van de jaarlijkse griepvaccinatie als onderzoeksmodel, maar de studiepopulatie 
bestond uit een groep van 20 CVS patiënten en een groep van 20 gezonde controles. 
De humorale respons werd zowel bij de start van de studie als drie weken na 
vaccinatie gemeten door middel van een hemagglutinatie-remmingsreactie. De 
cellulaire respons werd eveneens aan het begin van de studie en vervolgens één 
week na vaccinatie gemeten door middel van een lymfocyten proliferatietest en een 
activatietest. Er werden geen verschillen in de humorale en de cellulaire immuun- 
respons op griepvaccinatie gevonden tussen CVS patiënten en gezonde controles. 
De verwachtte afwijking in immuunrespons na griepvaccinatie blijkt niet te bestaan 
bij CVS patiënten. Standaard griepvaccinatie is dus gerechtvaardigd en zou bij 
indicatie aanbevolen moeten worden voor patiënten met CVS. 
In Hoofdstuk 6.1 worden de resultaten van de studies beschreven in dit manuscript 
bediscussieerd en in een breder perspectief geplaatst. Mogelijke verklaringen 
worden besproken voor het feit dat we onze hypotheses niet konden bevestigen en 
dat we geen biomarkers voor vermoeidheid na kanker hebben kunnen identificeren. 
De diverse uitgebreide studies beschreven in dit proefschrift hebben geresulteerd in 
interessante, nieuwe inzichten en vormen een aanwijzing dat de (neuro)fysiologische 
mechanismen die ten grondslag liggen aan vermoeidheid na kanker en CVS 
verschillend zijn.
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Lymfocyten 
activatietest
Een test waarmee het aantal geactiveerde lymfocyten (een bepaald 
type witte bloedcellen) als respons op een stimulus, zoals vaccinatie, 
gemeten kan worden.
Lymfocyten 
proliferatietest
Een test waarmee het vermogen van lymfocyten (een bepaald type 
witte bloedcellen) om zich te delen als reactie op een stimulus, zoals 
vaccinatie, gemeten kan worden. 
Occipitaalcortex De grijze stof (cortex betekent hersenschors) aan de achterzijde van de 
hersenen (oftewel occipitaal).
Oppervlakte-
elektromyografie
Een methode waarmee spiervezelgeleidingssnelheid, de snelheid 
waarmee elektrische pulsen door een spiervezel worden geleid, kan 
worden gemeten. Spiervezelgeleidingssnelheid is een indicator voor 
perifere spiervermoeidheid. Door middel van het plaatsen van een rij 
elektroden op de huid boven de te registreren spier, parallel aan de 
richting van de spiervezel, wordt de elektrische activiteit van de spier 
gemeten. 
Perifere 
spiervermoeidheid
Spiervermoeidheid is opgebouwd uit perifere en centrale vermoeidheid. 
Perifere spiervermoeidheid is vermoeidheid in de spier zelf.
Subcorticale 
structuren
Structuren gelegen in het binnenste deel van de hersenen (subcorticaal 
betekent onder de hersenschors). 
Twitch interpolatie 
techniek
Een techniek waarmee de centrale activatiefout, een indicator voor 
centrale spiervermoeidheid, kan worden gemeten. Als (elektrische) 
stimulatie van een spier tijdens maximale, vrijwillige aanspanning leidt 
tot extra krachtproductie, dan is er sprake van een centrale activatiefout. 
Mensen met een centrale activatiefout zijn niet goed in staat om hun 
spieren tot maximale inspanning aan te zetten.
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voor wat afleiding. Ik denk dat er bij ons op de kamer significant het meest gelachen werd!
Thiele Kobus, we begonnen ongeveer tegelijk aan ons promotietraject en zijn daarna 
allebei naar de Verenigde Staten gegaan voor werk. Daar tussenin hebben we veel 
samen beleefd, zowel de ups als de downs van het promoveren.  Wat hebben we 
veel plezier gehad, in binnen- en buitenland, op het werk en daarbuiten. Hopelijk 
zetten we dit voort in Amerika!
Overige (ex-)spec-groepers en collega-onderzoekers van de Radiologie: Houshang 
AmiriDoumari, Bart van de Bank, Fernando Bonetto, Vincent Breukels, Devashish 
Das, Rianne Engels, Cindy Frentz, Marinette van der Graaf, Bob Hamans, Frits van 
Heijster, Martijn Hoogenboom, Barbara Janssen, Marc Jupin, Miriam Lagemaat, 
Graag wil ik van deze gelegenheid gebruik maken om iedereen te bedanken die 
direct of indirect heeft geholpen bij het uitvoeren van mijn onderzoek en bij het tot 
stand komen van dit proefschrift. 
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Artsen op de afdeling Medische Oncologie, dank voor het uitdelen van het 
eindeloze aantal vragenlijsten en voor het motiveren van patiënten voor onze studie. 
Uw bijdrage aan dit proefschrift was essentieel.
Linda Heijmen, bedankt dat jij me in het tweede deel van de studie als arts hebt 
geholpen bij de fietstesten. Fijn dat we de beslommeringen rondom het afronden van 
onze promoties met elkaar konden bespreken. Succes met je opleiding!
Marlies Peters, we zitten allebei in het vermoeidheidsonderzoek, jij palliatief, ik 
curatief. Bedankt voor de praatjes in de wandelgangen en voor de gezellige lunches. 
Succes met het afronden van je eigen onderzoek!
Maria Hopman, dank voor de gastvrijheid voor het uitvoeren van de fietstesten op de 
afdeling Inspanningsfysiologie en voor het brainstormen over de inhoud van onze 
artikelen. 
Piet Vis, bedankt voor alle keren dat je spontaan achterwacht wilde zijn als dat 
onverwacht nodig was. 
Bregina Hijmans-Kersten en Linda Pardoel, bedankt voor alle technische 
ondersteuning. Jullie hadden altijd een oplossing als er een hartslagband niet werkte, 
als het ECG-apparaat het niet deed of als het mondkapje te groot was. 
Thijs Eijsvogels, wij hebben elkaar eigenlijk pas leren kennen na mijn werk bij jullie 
op de afdeling. Toevallig kwamen we allebei voor een langere periode in Connecticut 
terecht voor werk. Bedankt voor de leuke uitstapjes die we al gemaakt hebben, 
succes tijdens je periode in Nijmegen en ik kijk alweer uit naar het volgende tripje als 
je straks weer terug bent in de States!
Machiel Zwarts, bedankt voor de prettige samenwerking op de afdeling Klinische 
Neurofysiologie, ook nadat je verhuisde naar Kempenhaeghe.
Henny Janssen, jij hebt me geleerd om het EMG-onderzoek uit te voeren. Dank daarvoor 
en voor alle keren dat ik tegen problemen aanliep en jij me uit de brand hebt geholpen. 
Hans van Dijk, bedankt voor de technische ondersteuning, samen met Mark Massa, 
en voor alle hulp bij het uitwerken en interpreteren van de data. 
Sumientra Rampersad, niet alleen collega bij de KNF, maar ook flatgenootje en 
dansmaatje. We hebben heel wat af gedanst, gelachen, gegeten, gedronken en 
vooral heel veel gekletst. Succes met het afronden van je eigen promotie!
Jolanda de Vries, bedankt voor de samenwerking op de afdeling Tumorimmunolo-
gie bij het verwerken van het FICS bloed en tijdens de griepstudies. Het opwerken 
van de enorme hoeveelheden bloed en de mega-experimenten die onmogelijk leken, 
kwamen bij jou op de afdeling altijd tot een goed einde. 
Mijn grote dank voor alle denkbare hulp op het lab aan: Annemiek de Boer, Eric van 
Dinther, Tjitske Duiveman-de Boer, Stanleyson Hato, Hans Jacobs, Michel 
Marnix Maas, Christine Nabuurs, Patricia Nunes, Marcel Oei, Tom Scheenen, 
Isabell Steinseifer, Mark van Uden, Andor Veltien, Kim van de Ven, Eline Vos, 
Jannie Wijnen, Alan Wright, and Valerio Zerbi. I’m really thankful that I worked with 
you at the same department. Thanks for all the great cake-breaks, lunches, dinners, 
(Aescu)laafjes, parties, conferences and vacations. I hope we can stay in touch!
Mark Rijpkema, bedankt voor je hulp bij het berekenen van de hersenvolumes en bij 
de interpretatie ervan. Het is prettig met je samenwerken: je hebt kennis van zaken en 
weet de moeilijkste dingen voor mij begrijpelijk te maken.
Solange Estourgie en Leonie Vos, ladies van het secretariaat Radiologie, ook al 
was ik een ‘gastarbeider’ vanuit de Medische Oncologie, jullie maakten geen verschil, 
voor jullie hoorde ik er altijd bij, bedankt!
Secretariaat en psychologisch medewerkers van het NKCV; Tiny Fasotti-Dumont, 
Ellis Gielink-Kersten, Carel Kruip, Judith de Natris, Liesbeth Nieboer, Thea de 
Valk-Jacobs en speciaal: Lianne Vermeeren. Bedankt voor jullie eindeloze geduld 
en inzet voor FICS. Niets was jullie te gek: het plannen van onmogelijke afspraak-
combinaties, het keer op keer verzetten van afspraken, nat geworden aktometers, 
uitpuilende Excel-bestanden, jullie waren er altijd voor de patiënten en voor mij. 
Lianne, bedankt voor de prettige samenwerking: ik waardeer je snelheid, nauwkeurig -
heid en organisatie. Ook bedankt voor de gezellige etentjes en jazzdance uurtjes. 
Cognitieve gedragstherapeuten; Thea Berends, José de la Fonteijne, Hans Knoop, 
Dennis Marcelissen, en Hein Voskamp. Bedankt voor de goede zorgen voor de 
FICSers. Het succespercentage van cognitieve gedragstherapie bij FICS ligt ver 
boven het gemiddelde! Dames, overleg met jullie was altijd een feest. Dank dat ik een 
aantal van jullie sessies bij heb mogen wonen.
Collega-onderzoekers van het NKCV; Martine Goedendorp, Marianne Heins, 
Marcia Tummers en Jan Wiborg. We zaten allemaal in ongeveer hetzelfde schuitje 
en zijn nu allemaal zo ongeveer klaar met promoveren. Dank voor de hulp en de 
gezelligheid op het NKCV!
Secretariaat Medische Oncologie, bij jullie heb ik heel wat uurtjes doorgebracht 
met het doorspitten van statussen, op zoek naar geschikte kandidaten voor onze 
studie. Natascha Dix, bedankt voor alle praktische hulp en voor de gezellige praatjes 
tussendoor.
Dames van Post Rood, bedankt voor het inplannen van alle polibezoekjes (Toosje 
Messelink-Dodemont!), voor het prikken van de enorme hoeveelheid buisjes bloed, 
voor het maken van alle ECGs, voor het verzamelen van tig potjes urine en voor het 
zetten van alle griepprikken. Jullie maakten altijd tijd voor FICS en voor de griepstudie, 
ook al was die tijd er eigenlijk niet.
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maakte thuis alvast de opdrachten, zodat je op school tijd had om mij te helpen. 
Daarna hebben we elkaar nooit meer uit het oog verloren en volgden vele gezellige 
etentjes, stapavondjes, dagjes uit, vakanties, en wat al niet meer. In hectische tijden 
kom ik bij jou altijd helemaal tot rust. Ik kan altijd op je rekenen. Dank!
Marieke Brugmans, mentorzusje en studiemaatje in Nijmegen, inmiddels verhuisd 
naar Valkenswaard. Ik denk met heel veel plezier terug aan onze studietijd samen. Wij 
begrijpen elkaar met een half woord. Bedankt voor alle borrels en gezelligheid, maakt 
niet uit waar: op het terras, op de schaatsbaan, in de kroeg, of gewoon thuis, met jou 
is het altijd een feest. Succes met het afronden van je eigen onderzoek!
Christine Cramer-van der Welle, lieve meis, bedankt voor de gezelligheid in 
Nijmegen buiten het onderzoek om. We zien elkaar niet meer zo vaak, maar je bent 
altijd geïnteresseerd in mijn wel en wee. 
Thatjana Gardeitchik, lieve Thats, lief (mentor)zusje, wat moet ik toch zonder jou? Jij 
weet altijd precies wat ik nodig heb. Dank je wel. Veel geluk straks met z’n drietjes! 
Willemijn Hobo, lief vriendinnetje, jij bent mijn voorbeeld op het gebied van onder - 
zoek doen. Wat fijn dat we alles kunnen delen, zowel op het werk als privé. Jij bent 
mijn steun en toeverlaat. Wat hebben we samen al veel gelachen en gehuild. Hopelijk 
gaan we samen nog heel veel meemaken. Bedankt dat je mijn paranimf wilt zijn!
Wandana Nanhoe-Mahabier, lieve meis, wij kunnen elkaars gedachten lezen. Één 
blik is genoeg. Als het nodig is, zijn we serieus, als het niet nodig is, liever niet. Wat 
kunnen we samen toch genieten van lekker eten! Onze vriendschap is heel speciaal. 
Bedankt voor al je warmte. Ik ben er trots op dat je mijn paranimf wilt zijn!
Ooms, tantes, neven, nichten, neefjes en nichtjes, lieve familie, bedankt voor de 
steun vanuit Brabant: Valkenswaard, Dommelen en Bergeijk. Ome Harry en tante 
Toos, jullie hebben een speciaal plekje in mijn hart. Ik ben er trots op jullie petekind 
te mogen zijn.
Koen Prinsen, grote broer, wat fijn om jouw zusje te mogen zijn. Je lieve vriendinnetje 
Mariëlle Donkers en jij zijn altijd op de hoogte van waar ik mee bezig ben. Bedankt 
dat jullie er altijd voor me zijn als ik jullie nodig heb. Ik kan niet wachten om jullie mijn 
leven in Amerika te laten zien! 
Papa en Mama, bedankt voor jullie onvoorwaardelijke liefde. Jullie steunen me door 
dik en dun, in goede en in slechte tijden, naar welke stad of naar welk land ik ook ga, 
jullie staan altijd voor me klaar. Bedankt voor alle fijne weekendjes en vakanties in 
thuishaven Valkenswaard of samen in Nijmegen. Qua afstand zijn we nu ver uit elkaar, 
maar qua gevoel nog even dichtbij. Ik hou van jullie!
oldeNordkamp, Mandy van de Rakt, Nicole Scharenborg, Gerty Schreibelt, 
Jurjen Tel, en speciaal: Jeanette Pots. Zonder jullie was het nooit gelukt. Jeanette, 
jij hebt niet alleen geholpen met de enorme organisatie van de griepstudies, maar 
ook bij het uitwerken van de data. Bedankt ook voor de gezellige uitjes naast het 
werk. 
Ruurd Torensma, jij bent wat later bijgesprongen, maar van grote waarde geweest. 
Als jij meedenkt, dan komt er actie in de tent. Dank voor je hulp en je snelheid.
Professor Leer, dank voor de prettige en zinvolle samenwerking. Zonder 
medewerking van u en uw collega’s op de afdeling Radiotherapie hadden we nooit 
genoeg patiënten gehad voor onze studies. Fantastisch hoe er bij u op de afdeling 
wordt meegewerkt aan onderzoeken van andere afdelingen. 
Dames van het secretariaat Radiotherapie, bedankt voor de gezelligheid tijdens 
het screenen van de statussen.
Foekje Stelma, dank voor de hulp bij het bepalen van de antistoftiters voor de 
griepstudies vanuit de afdeling Medische Microbiologie en bij het interpreteren van 
de resultaten. 
Lammy Elving, dank voor de hulp vanuit de afdeling Algemene Interne Geneeskunde 
bij de inclusie van patiënten met het chronisch vermoeidheidssyndroom in het kader 
van de griepstudie. 
Dokter van Spronsen, dank voor het meedenken bij de inclusie van patiënten vanuit 
het Canisius-Wilhelmina Ziekenhuis. 
Dokter Smilde, dank voor de hulp bij het includeren van patiënten vanuit het Jeroen 
Bosch ziekenhuis. 
Dokter Kamm, helaas verhuisd naar Maasziekenhuis Pantein, maar vanuit daar ook 
geholpen bij het includeren van patiënten, waarvoor dank.
Christoph Juchem, thank you for giving me the great opportunity to work with you at 
Diagnostic Radiology at Yale, a department with a huge amount of knowledge and 
facilities, and to collaborate with the department of Neurology. Together we are 
exploring the field of magnetic resonance spectroscopy in multiple sclerosis, in which 
I hope we will make good contributions.  
Moniek Overes en Ronald Brugmans, wat fijn dat we zulke goede vrienden zijn, al 
vanaf de middelbare school. Bedankt voor jullie interesse in mijn onderzoek en voor 
de gezelligheid tijdens de weekendjes Valkenswaard. Succes met jullie avontuur in 
Waalre!
Ilse van Gorp, onze vriendschap ontstond bij wiskunde op de middelbare school. Jij 
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Hetty Prinsen werd geboren op 21 augustus 1985 te Valkenswaard. In 2003 behaalde 
zij haar VWO-diploma aan de Scholengemeenschap WereDi in Valkenswaard. Vervolgens 
studeerde ze Biomedische Wetenschappen aan de Radboud Universiteit Nijmegen. 
In 2006 behaalde zij haar Bachelor of Science diploma waarvoor zij een onderzoeks-
stage uitvoerde bij de afdeling Matrix Biochemie van het UMC St Radboud in Nijmegen. 
Voor haar Master koos ze het hoofdvak Pathobiologie en het bijvak Geneesmiddelen-
onderzoek waarvoor ze nog drie onderzoeksstages uitvoerde: één bij de afdeling 
Kwaliteit van Leven van TNO in Zeist, één bij de afdeling Biomaterialen van het UMC 
St Radboud en één bij de afdeling Farmacologie van Organon N.V. in Oss. Na het 
behalen van haar Master of Science diploma in 2008 startte zij haar promotie-
onderzoek bij de afdeling Medische Oncologie van het UMC St Radboud. Onder 
begeleiding van dr. Hanneke van Laarhoven, prof. dr. Gijs Bleijenberg en prof. dr. 
Arend Heerschap voerde zij onderzoek uit naar (neuro)fysiologische aspecten die ten 
grondslag zouden kunnen liggen aan vermoeidheid na de behandeling van kanker. 
Sinds januari 2013 is ze werkzaam als postdoc op de afdeling Diagnostische Radiologie 
van Yale School of Medicine in New Haven, Verenigde Staten. Onder begeleiding van 
dr. Christoph Juchem onderzoekt zij het hersenmetabolisme van patiënten met 
multipele sclerose met behulp van magnetische resonantie spectroscopie.

